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Abstract 
Organisms belonging to Acinetobacter genus constitute a remarkable example of 
bacterial evolution, evolving from traditionally harmless organisms towards to important 
nosocomial pathogens, probably in consequence of the introduction of new powerful 
antibiotics. In the last decades we have assisted to increasing reports of drug-resistant 
hospital related, and more recently, community acquired infections, with Acinetobacter 
baumannii being the most prevalent species of this genus in the hospital setting. In 
addition, the prevalence of non-baumannii Acinetobacter species involved in 
nosocomial infections has increased in the last years, probably due to the exchange of 
resistance determinants among Acinetobacter species. Carbapenem resistance is of 
particular concern, since this class of antibiotics constitutes the first line therapy for 
Acinetobacter infections; however, its use has become limited by the increasing 
prevalence of resistant strains. The recognition of the main carbapenem-resistant A. 
baumannii lineages responsible for nosocomial infections as well as the complete 
understanding of the factors that are driving their dissemination and persistence is 
essential to create strategies to control these organisms. 
This study focused on the characterization of the population structure of carbapenem-
resistant A. baumannii (CRAB) clinical isolates from Portugal, Brazil and Czech 
Republic. The mechanisms underlying carbapenem resistance, not only in A. 
baumannii but also in other Acinetobacter species (A. haemolyticus and A. lwoffii), the 
role of mobile genetic elements in the inter- and intra-species dissemination of 
carbapenem resistance, and the comparison of adhesion and biofilm abilities among 
the main Portuguese CRAB lineages were explored. 
All the typing methods used to characterize A. baumannii clinical isolates revealed that 
very few lineages are associated with carbapenem-resistance, belonging most of them 
to European clone II.  Using Bartual MLST scheme, which provided a higher 
discrimination, was possible to identify three main lineages in Portugal: ST92 carrying 
blaOXA-23, ST98 carrying blaOXA-24/40, both belonging to the same clonal complex (CC) 92, 
and ST103 carrying blaOXA-58, a lineage with no apparent relationship with CC92. The 
use of this MLST scheme also allowed the detection of a progressive switching, with 
ST98 carrying blaOXA-24/40 being gradually replaced by ST92 carrying blaOXA-23, a lineage 
that also included a pandrug resistant isolate. Carbapenem resistance in Czech 
Republic’s isolates seems to be associated with impaired CarO porin expression, but 
they also belonged to ST92, confirming the worldwide dissemination of this lineage. On 
the other hand, Brazilian blaOXA-23-carrying A. baumannii clinical isolates were 
distributed among four new STs: ST131, ST132, ST133 and ST134, suggesting a local 
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diversity hotspot. This finding, together with the chromosomal location of blaOXA-23 
embedded in Tn2006 observed in all blaOXA-23-carrying isolates, both from Portugal and 
Brazil, raises the question about when or where the diversification from a common 
ancestral and blaOXA-23 acquisition might have occurred. The CHDL genes blaOXA-24/40 
and blaOXA-58 were found both in the chromosome and plasmids. The blaOXA-58 gene was 
flanked by ISAba3-like and ISAba3 elements upstream and downstream, respectively. 
Plasmidic blaOXA-24/40 gene was found to be flanked by XerC/XerD-like binding sites 
which might be responsible for their mobilization by a mechanism of recombination. 
Only two types of blaOXA-24/40 carrying plasmids were detected: 30-kb repA_AB 
(belonging to homology group GR12) identified both in A. baumannii and A. 
haemolyticus, and 10-kb repAci2 (belonging to homology group GR2) identified only in 
A. baumannii. These findings are in accordance to what was observed in other 
countries, although associated with isolates belonging to different STs, stressing the 
plasmid contribution in the dissemination of carbapenem resistance and highlight 
interspecies plasmid transfer. Moreover, analysis of different plasmid scaffolds 
suggests frequent recombinatorial events on these plasmids.  
The detection of an environmental A. lwoffii isolate harboring the metallo-β-lactamase 
IMP-5 raises concerns about the potential of environmental non-baumannii 
Acinetobacter species to acquire resistance determinants and/or act as reservoirs of 
resistance genes, particularly because blaIMP-5 was embedded in a Tn402-like 
transposon, a structure previously identified in A. baumannii.  
Strong adherence properties and ability to form biofilms in abiotic surfaces were 
observed in most isolates from the different lineages recovered in Portuguese 
hospitals, a trait that together with antibiotic resistance might explain their persistence. 
In summary, this work illustrates the dynamics of epidemic clones and the role of 
carbapenem resistance determinants in the current dominance of particular A. 
baumannii lineages, both in Portugal and at a global level. It is of note the stability of 
specific acquired CHDL within each lineage, although the plasmid contribution on the 
dissemination of blaOXA-24/40 was also demonstrated. The occurrence of an 
environmental blaIMP-5-carrying A. lwoffii and blaOXA-24/40-carrying A. haemolyticus 
stresses the possible contribution of non-baumannii Acinetobacter species in the 
dissemination of resistance genes. This study highlights the importance of monitoring 
the national and international spread of epidemic, multidrug-resistant, and virulent 
clones, aiming the development of more effective guidelines in the treatment and 
infection control procedures.  
Keywords: Acinetobacter, carbapenem, resistance, MLST, plasmid.  
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Resumo 
Os microrganismos pertencentes ao género Acinetobacter constituem um exemplo 
notável de evolução bacteriana, tendo passado de tradicionalmente inofensivos para 
importantes patogénicos nosocomiais, provavelmente em consequência da introdução 
de novos antibióticos. Nas últimas décadas assistiu-se a crescentes relatos de estirpes 
hospitalares multi-resistentes e, mais recentemente, de infeções adquiridas na 
comunidade, sendo a espécie Acinetobacter baumannii a mais frequente em ambiente 
hospitalar. Além disso, a prevalência de espécies de Acinetobacter não-baumannii 
envolvidas em infeções nosocomiais tem aumentado nos últimos anos, provavelmente 
devido à transferência inter-espécies de determinantes de resistência. A resistência 
aos carbapenemos é particularmente preocupante, uma vez que esta classe de 
antibióticos constitui a primeira linha terapêutica para infeções por Acinetobacter, 
estando o seu uso limitado pela crescente prevalência de estirpes resistentes. O 
reconhecimento das principais linhagens de A. baumannii resistentes aos 
carbapenemos e responsáveis por infeções hospitalares, bem como a compreensão 
dos fatores que influenciam a sua difusão e persistência, são essenciais para o 
desenvolvimento de estratégias para o controlo destes microrganismos. 
Este estudo incidiu sobre a caracterização da estrutura populacional de isolados 
clínicos de A. baumannii resistentes aos carbapenemos (CRAB) de Portugal, Brasil e 
República Checa. Foram estudados os mecanismos subjacentes à resistência aos 
carbapenemos, não só em A. baumannii, mas também noutras espécies de 
Acinetobacter (A. haemolyticus e A. lwoffii), o papel de elementos genéticos móveis na 
disseminação inter e intra-espécies de resistência aos carbapenemos, e a comparação 
das capacidades de adesão e formação de biofilme entre as principais linhagens 
CRAB portuguesas. Todos os métodos de tipagem utilizados para caracterizar os 
isolados clínicos de A. baumannii revelaram que muito poucas linhagens estão 
associadas à resistência aos carbapenemos, sendo a maioria pertencente ao Clone 
Europeu II. Usando o esquema de MLST desenvolvido por Bartual, o que proporcionou 
uma maior discriminação, foi possível identificar três linhagens principais em Portugal: 
ST92 produtora de OXA-23, ST98 produtora de OXA-24/40, ambas pertencentes ao 
mesmo complexo clonal (CC)92, e ST103 produtora de OXA-58, uma linhagem sem 
relação aparente com CC92. A utilização deste esquema de MLST também permitiu a 
deteção de uma substituição progressiva da ST98 pela ST92, uma linhagem que 
também inclui um isolado resistente a todos os antibióticos correntemente disponíveis. 
Embora a linhagem ST92 se encontre também disseminada na República Checa, 
confirmando a disseminação mundial desta linhagem, a resistência aos carbapenemos 
parece estar associada a alterações na expressão da porina CarO. Por outro lado, os 
isolados clínicos brasileiros de A. baumannii e produtores de OXA-23 distribuíram-se 
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por quatro novos STs (ST131, ST132, ST133 e ST134), sugerindo diversidade local. 
Esta constatação, juntamente com a localização cromossómica do gene blaOXA-23 
incorporado no Tn2006 em todos os isolados portadores de blaOXA-23 (Portugal e 
Brasil), levanta a questão sobre quando e onde a diversificação a partir de um 
ancestral comum e a aquisição de blaOXA-23 terão ocorrido. Os genes blaOXA-24/40 e 
blaOXA-58 foram encontrados tanto no cromossoma como em plasmídeos. O gene 
blaOXA-58 encontrava-se flanqueado por elementos ISAba3-like e ISAba3 a montante e 
a jusante, respetivamente. O gene plasmídico blaOXA-24/40 foi encontrado flanqueado por 
sítios de ligação XerC/XerD que poderão ser responsáveis pela sua mobilização por 
um mecanismo de recombinação. Foram apenas detetados dois tipos de plasmídeos a 
codificar a OXA-24/40: repA_AB com 30-kb (pertencente ao grupo de homologia 
GR12) identificado em A. baumannii e A. haemolyticus e repAci2 com 10-kb 
(pertencente ao grupo de homologia GR2) identificado apenas em A. baumannii. Estes 
resultados estão de acordo com o que foi observado noutros países, embora 
associados a isolados pertencentes a diferentes STs, salientando o contributo de 
determinados plasmídeos na disseminação da resistência aos carbapenemos, e 
envolvendo diferentes espécies. Além disso, a análise de diferentes estruturas 
plasmídicas sugere frequentes eventos de recombinação. A detecção de um isolado 
de A. lwoffii ambiental produtor de IMP-5 levanta preocupações sobre o potencial de 
espécies de Acinetobacter não-baumannii ambientais em adquirir resistência e/ou 
atuar como reservatórios de genes de resistência, principalmente porque blaIMP-5 
encontra-se num transposão Tn402-like, previamente identificado em A. baumannii. 
Salienta-se ainda que a maioria dos isolados portugueses apresentou forte aderência 
e capacidade de formar biofilmes em superfícies abióticas, características que, 
juntamente com a resistência aos antibióticos podem explicar a sua persistência. 
Em resumo, este trabalho ilustra a dinâmica de clones epidémicos e o papel dos 
determinantes resistência aos carbapenemos na prevalência de determinadas 
linhagens de A. baumannii, tanto em Portugal como a nível global. É digno de nota a 
estabilidade de determinadas carbapenemases em linhagens específicas, apesar da 
capacidade de disseminação de blaOXA-24/40 ter sido também demonstrada. A 
ocorrência de um A. lwoffii ambiental e produtor de IMP-5 e de A. haemolyticus 
produtores de OXA-24/40 salienta a possível contribuição de espécies Acinetobacter 
não-baumannii na disseminação de genes de resistência. Este estudo ilustra a 
importância de estudar a diferentes níveis os fatores intervenientes na emergência da 
resistência, essencial para monitorizar a disseminação nacional e internacional de 
clones/plasmídeos epidémicos e de relevância para o desenvolvimento de orientações 
mais eficazes para o tratamento e o controlo de infeção.  
Palavras-chave: Acinetobacter, carbapenem, resistência, MLST, plasmídeo. 
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CHAPTER 1 – INTRODUCTION 
 
1.1 The genus Acinetobacter 
 1.1.1 Taxonomy and Historical Perspective 
The first description of an organism belonging to the genus Acinetobacter occurred in 
1911 when the Dutch microbiologist and botanist Martinus Beijerinck isolated Micrococcus 
calcoaceticus from the soil using a calcium acetate-containing minimal medium (13). 
Several taxonomic modifications occurred since then. In 1954 Brisou and Prévot proposed 
the current genus designation, Acinetobacter (from the Greek ακινετσ [akinetos], which 
means nonmotile) (27), and in 1971 the Subcommittee on the Taxonomy of Moraxella and 
Allied Bacteria recommended that the genus Acinetobacter should include only oxidase-
negative strains based on several studies of Paul Baumann (11, 12). The genus 
Acinetobacter is now included in the family Moraxellaceae; Order Pseudomonadales; 
Class Gammaproteobacteria; and Phylum Proteobacteria; comprising gram negative rods, 
with a DNA G/C content of 39 to 47 mol%, that are strictly aerobic, nonmotile, 
nonfastidious, nonfermentative, catalase positive, and oxidase negative (204).   
During the 1970’s Acinetobacter genus identification was established with the 
transformation assay of Juni (125), a  method based on the property of the mutant 
Acinetobacter strain BD413 trpE27, recently identified as A. baylyi (34), to be competent 
for genetic transformation. A species was identified as belonging to the genus 
Acinetobacter when its crude DNA was able to transform the mutant strain to the wild-type 
phenotype. A decade after, the division of Acinetobacter isolates into genomic species 
become based on DNA-DNA reassociation studies and comprehensive phenotypic 
analysis, allowing the description of few DNA (hybridization) groups or genomospecies 
(25) (26, 194, 245). Currently the genus comprises 42 genomospecies, 33 with formal 
names (Table 1) and taxonomic characterizations are performed using several molecular 
methods, namely, amplified fragment length polymorphism (AFLP) (67), amplified rDNA 
restriction analysis (ARDRA) (259) or tDNA intergenic length polymorphism analysis (75).  
However, some of them are only available in reference laboratories.  
The nucleotide sequence analysis of 16S rRNA and rpoB (RNA polymerase β-subunit) 
genes may be used as simple and accurate methods for Acinetobacter species 
identification, particularly the rpoB that exists in only one copy per cell, presents a high 
intraspecies similarity, and a small intragenic fragment of this gene (ca. 350 bp) displays a 
discriminatory power comparable to the one obtained with the complete 16S rRNA gene 
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sequence (136). In what concerns the most clinically relevant species belonging to 
Acinetobacter genus, Acinetobacter baumannii, identification has also been performed by 
the detection of the blaOXA-51-like gene which encodes for a species-specific 
carbapenemase. (29, 85, 86). However, the detection of non-baumannii Acinetobacter 
species harbouring blaOXA-51-like-carrying plasmids revealed a possible drawback when 
identification is accomplished exclusively by this method (142). The increasing use of 
matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) MS as a method for 
Acinetobacter spp. identification is now revealing promising results, including the 
discrimination among the species belonging to the so called Acinetobacter calcoaceticus-
Acinetobacter baumannii complex:  A. baumannii, Acinetobacter pittii (formerly 
Acinetobacter genomic species 3), Acinetobacter nosocomialis (formerly Acinetobacter 
genomic species 13TU) and Acinetobacter calcoaceticus (189). They are closely related 
and difficult to distinguish from each other by phenotypic properties, making unsuitable 
many manual and semi-automated systems currently used for identification in routine 
clinical laboratories. However, since these species display different characteristics 
regarding colonization of human skin, antimicrobial susceptibility and mortality rates, a 
precise identification will orientate the therapeutic and improve the clinical outcome (84).  
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Table 1. Delineation of Acinetobacter genomic species [adapted from Peleg et al, 2008 
(204)]. 
Species Genomic speciesa Type Strain References 
A. antiviralis  KNF2022T; KCTC0699BPT (139) 
A. baumannii 2 CIP 70.34; ATCC 19606T; DSM 30007 (25, 245) 
A. baylyi  B2; CIP 107474; DSM 14961T (34) 
A. beijerinckii  NIPH 838T; LUH 4759T; CCUG 51249T; CCM 7266T; 58aT (190) 
A. bereziniae 10 LMG 1003T; CIP 70.12T; ATCC 17924T (191) 
A. bouvetii  DSM 14964T (34) 
A. brisouii  5YN5-8T; KACC 11602T; DSM 18516T (5) 
A. calcoaceticus 1 ATCC 23055T (245) 
A. gerneri  DSM 14968T (34) 
A. grimontiib/ A. junii 5 DSM 14967T; ATCC 17908T (245) 
A. guillouiae 11 LMG 988T; CIP 63.46T; ATCC 11171T; CCUG 2491T (191) 
A. gyllenbergii  NIPH 2150T; RUH 422T; CCUG 51248T; CCM 7267T; 1271T (190) 
A. haemolyticus 4 ATCC 17906T (245) 
A. indicus  DSM 25388T; CCM 7832T (162) 
A. johnsonii 7 ATCC 17909T (245) 
A. kyonggiensis  KSL5401-037T; JCM 17071T; KEMC 5401-037T (138) 
A. lwoffii 8/9 ATCC 15309T; ATCC 9957 (245) 
A. marinus  SW-3T; KCTC 12259T; DSM 16312T (277) 
A. nosocomialis 13TU LMG 10619T; CCM 7791T (189) 
A. oleivorans  DR1T; KCTC 23045T; JCM 16667T (127) 
A. parvus  NIPH384T (186) 
A. pittii 3 LMG 1035T; CIP 70.29T (189) 
A. radioresistens 12 IAM 13186T (195) 
A. rhizosphaerae  BIHB723 (105) 
A. rudis  G30T; LMG 26107T; CCUG 57889T; DSM 24031T; CECT 
7818T 
(262) 
A. schindleri  NIPH1034T (185) 
A. seohaensis  SW 100T; KCTC 12260T; DSM 16313T (277) 
A. soli  B1T; KCTC 22184T; JCM 15062T (132, 205) 
A. tandoii  DSM 14970T (34) 
A. tjernbergiae  DSM 14971T (34) 
A. towneri  DSM 14962T (34) 
A. ursingii, A. septicusc  NIPH137T; CCUG 56015 (185)  
A. venetianusd  ATCC 31012 (260)  
 6 ATCC 17979 (245) 
 13BJ, 14TU ATCC 17905 (25) 
 14BJ CCUG 14816 (26) 
 15BJ SEIP23.78 (26) 
 15TU M151a (25) 
 16 ATCC 17988 (26) 
 17 SEIP Ac87.314 (26) 
 Between 1 and 3 10095 (99) 
 Close to 13TU 10090 (99) 
a The genomic species according to Bouvet and Grimont classification (25). BJ refers to species delineation of 
Bouvet and Jeanjean (26) and TU refers to Tjernberg and Ursing (245); b Acinetobacter grimontii was recently 
reclassified as a later synonym of Acinetobacter junii (258); c There is a lack of evidence that “Acinetobacter 
septicus” is a different species from Acinetobacter ursingii (192); d The name “Acinetobacter venetianus” has 
been previously used to designate three marine hydrocarbon-degrading Acinetobacter strains, of which strain 
RAG-1 (ATCC 31012) has industrial applications for the production of the bioemulsifier emulsan. However, A. 
venetianus remains as a provisional designation awaiting further investigation (260). 
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1.1.2 Clinical relevance of Acinetobacter spp. 
During many years, organisms belonging to the genus Acinetobacter were considered 
saprophytes of little clinical significance (77). This pattern started to change in the early 
1970s with the recognition of the genus Acinetobacter as a significant nosocomial 
pathogen and more recently with the increasing frequency of drug-resistant related 
community and hospital acquired infections. This was probably a consequence of the 
introduction of powerful new antibiotics and the use of invasive diagnostic and therapeutic 
procedures in the clinical practice. (77, 249) In 2007, in one day survey along 75 countries 
aiming to provide information regarding the extent and patterns of infection in intensive 
care units (ICUs) Acinetobacter species were involved in 9% of all infections, highlighting 
the challenge that these pathogens present today (266).  
In addition, community-acquired infection and infections acquired following war or natural 
disasters (e.g., earthquakes and tsunamis) have also been described. (64, 156, 197, 271) 
Nowadays we still have a debate regarding the clinical impact and mortality attributable to 
Acinetobacter spp.. The reasons for that discussion include the difficulty in distinguish 
between colonization and infection and in some studies the methods used for species 
identification were not appropriate according to current standards. (101, 204)   
A. baumannii is the main genomic species associated with outbreaks of nosocomial 
infection. However it is of note the fact that in recent years we have assisted to increasing 
reports of non-baumannii Acinetobacter species associated with colonization and infection 
(14), namely A. pittii, Acinetobacter lwoffii, Acinetobacter ursingii, Acinetobacter 
haemolyticus, A. calcoaceticus, A. nosocomialis, Acinetobacter johnsonnii and 
Acinetobacter junii (47). Other studies refer the possibility that species like A. ursingii, 
Acinetobacter schindleri or Acinetobacter bereziniae might be underestimated due to their 
absence in the databases of all commercial biochemical kits (135). There are two reports 
of Acinetobacter baylyi isolated from clinical samples, although only one refers the 
species as the agent of infection (40). The detection of these species might be explained 
by the use of more accurate methods to routinely perform species identification (256). 
1.1.2.1 Infections caused by A. baumannii  
Hospital acquired A. baumannii infections include ventilator-associated pneumonia (VAP), 
skin and soft tissue infections, wound infections, urinary tract infections, secondary 
meningitis, and bloodstream infections (68). In a 2006-2007 antimicrobial‐resistant 
pathogens associated with healthcare‐associated infections survey (United States of 
America-USA), A. baumannii was the third more frequent species associated with VAP, 
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and the ninth most frequent species implicated in central line-associated bloodstream 
infections, catheter-associated urinary tract infections and surgical site infection (113). 
The species’ ability to acquire antimicrobial resistance determinants and the capacity to 
survive for long periods on dry surfaces (267, 268) contribute for a long persistence in the 
hospital setting.  A. baumannii infections concern particularly ill patients in ICUs, mainly 
those requiring mechanical ventilation, and patients with wound or burn injuries (249). The 
factors facilitating colonization or infections include increased length of hospital stay 
(although in outbreak situations may occur an earlier acquisition of infection), previous 
antibiotic therapy, mechanical ventilation, use of catheters, sutures, dialysis, exposure to 
patients colonized or infected with A. baumannii, environmental contamination, 
understaffing and poor adherence of staff to hand hygiene (174, 249).   
A. baumannii infections in the community setting have been mainly reported from 
countries with tropical or subtropical climate, probably due to the preference of the genus 
for moisture (6). These infections usually affect patients with some form of comorbidity like 
chronic obstructive pulmonary disease, renal disease, and diabetes mellitus or associated 
with heavy smoking and excess alcohol consumption, which may facilitate aspiration of 
pharyngeal bacteria. The community-acquired infections might include pneumonia (in the 
majority of cases), meningitis, soft-tissue infection, ocular infection, urinary tract infection, 
and native valve endocarditis. (6, 87, 119, 238) 
In recent years A. baumannii was increasingly isolated from wounds of combat casualties 
from Iraq and Afghanistan, has already occurred during the Vietnam War, identified at that 
time as Mimeae-Herellea-Bacterium-Alcaligenes) (36, 64, 248). Although was raised the 
possibility that inoculation could occur at the time of injury, both from previously colonized 
skin or contaminated soil, posterior studies concluded that A. baumannii acquisition 
occurred at health care facilities (232).  
Finally, the association of A. baumannii infection with natural disasters was evidenced in 
Marmara earthquake, Turkey, 1999, where A. baumannii was the most frequently isolated 
species among the trauma victims, especially from wound infections (197). After the 
earthquake in Wenchuan, China in 2008 A. baumannii was also the most frequently found 
in wound and sputum, and the third pathogen recovered from blood among the victims. 
(271)  
  1.1.2.2 Infections caused by non-baumannii Acinetobacter species 
While A. baumannii, frequently associated with outbreaks, A. pittii and A. nosocomialis are 
the most common of the Acinetobacter species among clinical isolates, A. johnsonii, A 
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junii, A. lwoffii, Acinetobacter parvus, Acinetobacter radioresistens, A. schindleri and A. 
ursingii became more frequently associated with infection, particularly, catheter-related 
bloodstream infections (68, 253, 256). A. haemolyticus, rarely identified in clinical isolates, 
although associated in our country with carbapenem resistance (215), has been 
implicated in cerebrospinal meningitis (102) or prosthetic infective endocarditis (35). A. 
lwoffii, a human commensal frequently found colonizing the skin of healthy persons, has 
been increasingly associated with nosocomial infections (68). Additionally, has been 
linked to acute gastritis, very similar to the one caused by Helicobacter pylori (217) and to 
pneumonia, including in the community setting (176). 
1.1.3 Acinetobacter spp. ecology 
1.1.3.1 Ecology of A. baumannii 
Species belonging to Acinetobacter genus have been recovered from soil, water and 
animals (68, 249). A. baumannii seems to be a rare colonizer of human skin in temperate 
climates (234), although common in tropical environments (49). This species has been 
identified in vegetables (16), with isolates presenting high rates of resistance to 
ciprofloxacin and gentamicin, findings that raised the question of being the food one of this 
species sources in the hospital setting. A. baumannii was also identified in aquacultures of 
fish and shrimp farms although was not determined if it constituted an environmental 
niche or was due to human contact (121). A. baumannii detection in hospitalized dogs, 
cats and horses raises concerns about the possibility of spread between humans and 
animals (82, 94, 284). The presence of this species in 22% sampled body lice of 
homeless persons raises the possibility that louse might constitute an A. baumannii 
reservoir and vector of transmission, although was speculated that this detection could 
also be due to undiagnosed transient A. baumannii bacteremia or even contamination 
(137).  
With the increasing reports of A. baumannii outside the hospital setting the discussion 
concerning the origin of the organism revived. However, the existing data is not sufficient 
to accurately define A. baumannii natural habitat, but it appears to be neither commensal 
nor a typical environmental organism (204).    
 1.1.3.2 Ecology of non-baumannii Acinetobacter species 
Several Acinetobacter species are normal colonizers of human skin, particularly A. lwoffii, 
A. johnsonii, A. junii, A. pitti, A. radioresistens, and A. haemolyticus, although their 
frequency may vary according to the season, region, and may increase in hospitalized 
patients (15, 202, 234). A. calcoaceticus, A. pittii, A. johnsonii, A. lwoffii and Acinetobacter 
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genomic species 11 have also been found in water, soil and vegetables (119),  and A. 
johnsonii was also associated with the human and fish intestinal tract (69, 104). In 
addition, A. haemolyticus and A. lwoffii have been detected in aquacultures environment 
and associated with fish intestinal content (104). Besides these species, which may be 
considered as opportunistic pathogens, other species have utility for biotechnology 
applications (242). 
1.1.4 Treatment  
Until 1970s, treatment of Acinetobacter infections included several therapeutic options, 
such as aminoglycosides, β-lactams and tetracyclines (14). Since then, Acinetobacter, 
and in particular, A. baumannii´s remarkable ability to accumulate a myriad of resistance 
mechanisms has limited the therapeutic options (201).  
Carbapenems are β-lactam antimicrobial agents introduced in therapeutics in 1985 and 
presenting an exceptionally broad spectrum of activity. Carbapenems are stable to most 
β-lactamases including AmpC β-lactamases and extended-spectrum β-lactamases 
(ESBLs) and have long been regarded as the agents of choice for the treatment of 
infections caused by Acinetobacter spp., but resistance rates have risen substantially in 
some areas, with susceptibility to the carbapenems ranging from 90% to as low as 32%, 
depending on the geographic region and the carbapenem tested (91, 281).  
β-Lactamase inhibitors, particularly sulbactam, revealed intrinsic activity against many 
Acinetobacter strains, with a bacteriostatic or bactericidal mechanism of activity, 
depending on the strain examined, and mediated via penicillin binding proteins (PBPs). 
Sulbactam was used, particularly in combination with rifampin, colistin or fosfomycin, 
during the last decade for the treatment of carbapenem-resistant Acinetobacter spp. (130, 
163, 198). However, the high level of resistance occurring nowadays to sulbactam 
hampers its use against MDR A. baumannii (223). Polymyxins are cationic polypeptides 
discovered in 1947 from different species of Bacillus polymyxa (122). Their mode of 
activity is the interaction with the lipopolysaccharide layer of Gram-negative bacteria. In 
the early 1980s polymyxins were withdrawn from clinical use due to toxicity reports, 
namely neurotoxicity and nefrotoxicity, being used only for the treatment of cystic fibrosis. 
However, the emergence of Gram negative bacteria resistant to almost all classes of 
available antibiotics except polymyxins contributed for their revival. This class of 
antibiotics consists of five chemically different compounds, polymyxin A, B, C, D, and E 
(colistin) but only two are currently available for clinical use - namely, polymyxin B and 
colistin (polymyxin E). Polymyxins show bactericidal activity against A. baumannii, and 
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resistance rates against these agents have remained low, even in multidrug-resistant and 
carbapenem-resistant isolates(223). However, there are recent reports of heteroresistance 
among A. baumannii isolates, resulting from the existence of subpopulations of resistant 
A. baumannii within colistin-susceptible clinical isolates, particularly in patients with prior 
colistin therapy (110). These findings raise the concern about the use of colistin, 
especially in monotherapy, as a therapeutic option in the treatment of MDR A. baumannii. 
Aminoglycosides constitute one of the oldest classes of antimicrobials, presenting activity 
by binding to 16S rRNA in the 30S ribosomal subunits and inhibiting protein synthesis 
(Magnet and Blanchard, 2005). Regardless the nephro- and ototoxicity, aminoglycosides, 
in particular amikacin and tobramycin, retain good activity against MDR Acinetobacter 
spp. (199). However, resistance to these agents is also increasing, being recommended 
their use in combination with other antimicrobials. Inhaled tobramycin has shown good 
activity in association with an intravenous β-lactam in the treatment of VAP (107) and 
intrathecal amikacin in combination with colistin has been effective in the treatment of 
meningitis (96).  
Fluoroquinolones are broad-spectrum bactericidal agents used to treat diverse bacterial 
infections and levofloxacin, moxifloxacin and ciprofloxacin previously presented good 
activity against Acinetobacter spp. (111, 153). New derivatives are now under pre-clinical 
studies, in order to overcome the increasing resistance observed among this genus, and 
in particular A. baumannii (153). 
Glycylcyclines are a novel class of antimicrobial agents related to the tetracyclines 
presenting a similar mechanism of action. They are represented by tigecycline, a 
semisynthetic derivative of minocycline, which was licensed for the treatment of 
complicated skin and soft tissue infections (261), and intra-abdominal infections (196) and 
has shown a good in vitro activity against A. baumannii. However, several studies indicate 
that tigecycline may not be consistently active against the multidrug-resistant isolates 
(184, 200) and the reports of resistance development in the course of the treatment (118) 
suggest that should only be used in combined regimens with other antimicrobials, such as 
levofloxacin, amikacin, imipenem, and colistin (213). 
Rifampicin has demonstrated in vitro and in vivo bactericidal activities against multi-drug 
resistant (MDR) A. baumannii, including severe infections caused by imipenem-resistant 
strains (143). However, the easily development of resistance, due to RNA polymerase 
mutations, emphasizes the need to be associated with other antibiotics, generally colistin 
(10). 
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Azithromycin has been tested in the treatment of Acinetobacter spp. infections, generally 
in combination with other antimicrobials like colistin, meropenem and colistin, showing 
synergistic effects (244). 
Tetracyclines constitute another option for Acinetobacter spp. infections treatment.  From 
a recent work concerning ventilator acquired pneumonia (VAP) due to carbapenem-
resistant A. baumannii was concluded that VAP could be effectively treated with 
minocycline or minocycline/ doxycycline (37, 272). 
Although clinical data are lacking, combination therapy seems to be the better option for 
the treatment of patients with multidrug-resistant A baumannii with in vitro and animal 
studies suggesting the use of colistin plus rifampin or azithromycin, imipenem or 
azithromycin plus rifampicin and the triple combination of imipenem, rifampicin and colistin 
(134, 145). 
1.1.5 Antimicrobial Resistance  
Acinetobacter spp. exhibit a natural reduced susceptibility to antibiotics explained by the 
low permeability of the outer membrane, the constitutive expression of some efflux pumps 
or the interplay between the two processes. In addition, several species present intrinsic 
β-lactamases (263). The increasing antimicrobial resistance displayed by these 
organisms, and in particular A. baumannii, has largely contributed for their persistence in 
the hospital setting limiting the therapeutic options. In addition, the recent reports of A. 
baumannii strains resistant to all available antibiotics, whether called pandrug, extreme or 
extensively drug resistant, according with the currently accepted terminology (Table 2), 
raise concerns about returning to the pre-antibiotic era (73, 157, 200).  
Table 2 - Definitions regarding antimicrobial resistance, proposed by Magiorakos et al, 
2012 (157) 
MDR  
Multidrug Resistant 
Acquired non-susceptibility to at least one agent in three or 
more antimicrobial categories. 
XDR 
Extreme Drug Resistant 
Non-susceptibility to at least one agent in all but two or fewer 
antimicrobial categories. 
PDR 
Pandrug-Resistant 
Non-susceptibility to all agents in all antimicrobial categories. 
 
1.1.5.1 Resistance to β –lactams 
β -lactams constitute the most flexible antibiotic class, with a great versatility and diversity 
in what concerns chemical properties, antibacterial spectra and administration plans. 
Resistance to β-lactams in Acinetobacter spp. can occur due to enzymatic (β-lactamases) 
Chapter 1 - Introdução 
12 
 
or nonenzymatic mechanisms (loss of or decrease in the expression of porines; increased 
expression of efflux pumps or penicillin binding proteins – PBPs - alterations).  
1.1.5.1.1 β –lactamases 
 
The β-lactamases are divided into A-D four classes based on a molecular classification 
(4). Classes A, C and D belong to serine type enzymes with a serine moiety at the active 
site, whereas class B enzymes require divalent metal cations as cofactors (eg. Zn2+) being 
designated metallo-β-lactamases (MBL) (269). 
A. baumannii possesses two intrinsic β-lactamases: a class C chromosomally encoded 
cephalosporinase (ADC, for Acinetobacter derived cephalosporinase) and a class D 
oxacillinase (OXA-51-like)(225, 255). Other Acinetobacter species like A. haemolyticus, A. 
lwoffii, A. johnsonii, A. radioresistens and A. calcoaceticus also present naturally occurring 
CHDLS, OXA-214-like, OXA-134-like, OXA-211-like, OXA-23-like and OXA-213-like, 
respectively (89).   
ADCs are normally expressed at low levels and are not inducible (23, 120). However, both 
ADCs and OXA-51 expression levels might be augmented by the presence of insertion 
sequences (224, 254, 255, 263). The role of OXA-51 will be discussed later on, since it 
has become an important tool for epidemiological studies and genetic marker for 
identification of A. baumannii species. 
The acquired class A β-lactamases reported in Acinetobacter spp. include at least nine 
families: TEMs (83), SHVs (182), CARBs (212), CTX-Ms type (183), SCO (207), 
PERs(181), GES (235), VEBs (181) and KPCs (220) (Table 3). However, the β-
lactamases that confer resistance or reduced susceptibility to carbapenems 
(carbapenemases), belonging to classes D, B and A (in order of frequency), are the ones 
that truly constitute a sentinel event for antimicrobial resistance and will be detailed in the 
next section. 
1.1.5.1.1.1 Carbapenemases 
Historically, carbapenems have been considered the best therapeutic response in 
infections caused by MDR Acinetobacter spp. and detection of carbapenemase-producing 
isolates always constitutes a concerning event.  
The most disseminated carbapenemases belong to class D β-lactamases group 
(carbapenem-hydrolyzing class D β-lactamases - CHDLs). 
The first report of an acquired class D β -lactamase with carbapenemase activity occurred 
in 1993 (206). The enzyme OXA-23, initially designated as ARI-1 (for Acinetobacter 
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resistant to imipenem), was detected in a multidrug-resistant A. baumannii clinical isolate 
collected in Scotland in 1985 (203). Few years later was demonstrated its plasmid location 
(231), although a chromosomal location is also common (177).
 
In the following years were 
described closely related derivatives for this enzyme, constituting together the OXA-23 
group which comprises today fifteen variants (Table 3). OXA-23 cluster displays 48% of 
amino acid homology with the OXA-58 cluster, 60% homology with OXA-40 cluster and 
63% homology with OXA-143 cluster. 
A second group of CHDLs corresponds to the OXA-24/OXA-40 group, which includes 
seven variants. The blaOXA-24/40 gene was originally identified as chromosomally encoded 
in carbapenem-resistant A. baumannii isolates recovered in Spain and France (24, 112) 
but was later demonstrated its presence in plasmids of A. baumannii and A. haemolyticus 
clinical isolates from Portugal (215) and subsequently in Italy (169) and Spain (227) were 
OXA-24/40 was also found in A. calcoaceticus species. OXA-40 cluster displays 60% 
homology with OXA-23 cluster, 47% homology with OXA-58 cluster and 88% homology 
with OXA-143 cluster (115, 204). 
A third group of CHDLs is represented by OXA-58 (208), including at this moment four 
variants (Table 3). The blaOXA-58 gene was found to be either plasmid and/or chromosome 
encoded. OXA-58 cluster presents 48%, 47% and 52% of aminoacidic identity with OXA-
23 cluster, OXA-40 cluster and OXA-143 cluster respectively (115, 204) 
 Finally, OXA-143, first identified in Brazil, encoded in a plasmid, represents a fourth group 
of acquired CHDLS, revealing 88% amino acid sequence identity with OXA-40, 63% 
identity with OXA-23, and 52% identity with OXA-58 (115).  
CHDLs present hydrolytic activity against penicillins, extended-spectrum cephalosporins, 
methicillin, aztreonam and carbapenems(230). They are resistant to inhibition by 
clavulanate and tazobactam but most are susceptible to NaCl inhibition, which provides a 
means of their laboratory identification. The level of carbapenem-hydrolysis by CHDLs is 
considerably low, with imipenem being the preferred substrate over meropenem (214).  
Class B β-lactamases or metallo-β-lactamases (MBLs) are able to hydrolyze 
carbapenems, cephalosporins and penicillins but lack the ability to hydrolyze aztreonam 
and are resistant to the clinically available β-lactamase inhibitors. Although MBLs are 
much more potent in carbapenem-hydrolyzing activity (100 to 1000-fold higher) than 
CHDLs (204), they are described with less frequency in A. baumannii. MBLs families 
described until now in A. baumannii include the IMP, VIM, SIM, and more recently SPM 
and NDM (Table 4). IMP-type MBLs were initially described in Pseudomonas aeruginosa 
isolates from Japan in 1990 (209). Until now, were identified thirty three IMP variants, from 
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which eight were detected in A. baumannii (Table 3)  VIM-type MBLs, whose five variants 
were identified in A. baumannii (Table 3), were initially described in Italy and generally 
present a higher affinity toward carbapenems in comparison to IMP enzymes (71). SIM-1 
was identified in a Korean isolate, and that remains the only description of SIM enzymes 
in A. baumannii (140). SPM has also a low frequency in A. baumannii, with only one 
description (SPM-1) from Iranian clinical isolates (235). Finally, the novel class B MBL 
enzyme, NDM, initially reported in Klebsiella pneumoniae and Escherichia coli clinical 
isolates, has increasingly been reported in Acinetobacter spp, particularly in A. baumannii 
and A. lwoffii, with two variants described until now (NDM-1 and NDM-2) (Table 3) (20, 
100). 
 
In what concerns CHDLs global distribution, OXA-23 is the most widespread, being 
frequently detected in isolates from Asian countries, (eg. China, Korea)(276, 282), but 
also reported in South America in countries such as Brazil, Colombia (62, 265) and 
particularly in Europe (58, 128, 177) (Figure 1). The OXA-58 is frequently found in Europe 
(8, 168). OXA-24/OXA-40
 
is not so disseminated as OXA-23 but has been identified in 
different areas, especially in Portugal, Spain, France and United States (24, 57, 61, 150, 
152, 169, 215)(Figure 1). In Asia, an OXA-24/OXA-40
 
derivative, the OXA-72
 
was also 
detected with some frequency (154), and more recently in isolates from Croatia and USA 
(243, 273, 280) (Figure 1). OXA-143 has only been described in Brazil (115, 274).  
In comparison with acquired CHDLs, which have been mostly identified in A. baumannii, 
MBLs have been identified in a wide variety of Gram-negative species, but less frequently 
in A. baumannii (52, 209) (Figure 2). Only the recently described NDM (variants NDM-1
 
and NDM-2) seem to have a more wide dissemination among Acinetobacter species (39, 
41, 42, 100, 126, 129, 133, 144).  
In Portugal, the prevalence of carbapenem-resistant A. baumannii has increased since 
1998 (59, 61, 215). Previous studies identified an OXA-40 producing clone as endemic in 
our country, constituting a sub-cluster of EUII (59). Besides this dominant clone, two other 
clones defined by ApaI-pulsed-field gel electrophoresis (PFGE) typing, were identified 
among the carbapenem resistant A. baumannii population but occurring with a less 
frequency (215). Additionally, the description of OXA-40 in a different Acinetobacter 
species, A. haemolyticus, raised the possibility that horizontal dissemination of the blaOXA-
40 gene could contribute for its occurrence among different species (215). 
Finally, in Portugal the only MBL described in A. baumannii was IMP-5, an enzyme also 
identified in Pseudomonas aeruginosa isolates (28, 60). This enzyme genetic vicinity was 
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recently characterized being detected its association with a Tn402-like transposon (278). 
These findings raise the possibility of dissemination, not only among A. baumannii, but 
also between different species. 
Figures 1 and 2 present the main occurrences of CHDL enzymes and MBL enzymes, 
respectively, in Acinetobacter spp. clinical isolates at a global level. 
 
 
Figure 1. Global distribution of CHDLs enzymes reported in Acinetobacter spp. 
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Figure 2. Global distribution of MBLs enzymes reported in Acinetobacter spp. 
 
Class A carbapenemases are relatively rare in Acinetobacter spp., being described in A. 
baumannii some members of the families GES (GES-14) detected in France and Belgium 
(19), and KPC (KPC-2, -3, -4 and -10) in Puerto Rico (220, 221)(Table 3), being able to 
hydrolyze a broad variety of β-lactams, including carbapenems, penicillins, cephalosporins 
and aztreonam (in the case of KPC), but can be inhibited by clinically available β-
lactamase inhibitors such as clavulanate and tazobactam (19, 214, 220, 221, 235).   
 
1.1.5.1.2 Alterations on membrane permeability 
Non-enzymatic mechanisms such as alterations on membrane permeability (decrease or 
absence of porines, and overexpression of efflux pumps) and PBPs alterations, might also 
contribute for β-lactam resistance, including to carbapenems. When these alterations 
occur simultaneously with the production of β-lactamases usually are detected high 
carbapenem MICs (263).  
1.1.5.1.2 .1 Porins 
Porins (outer membrane proteins – OMPs) form channels that allow the transport of 
molecules across lipid bilayer membranes. A. baumannii reveals a decrease in outer 
membrane permeability (less than 5%) when compared with other Gram-negative 
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organisms which might be explain by the small number and size of porins (263).  
Additionally, changes in membrane permeability due to the loss of OMPs are usually 
implicated in resistance to β-lactams. The major OMP in A. baumannii is OmpA which 
plays an important role in bacterial pathogenesis, quorum sensing and biofilm formation, 
regulating adhesion to surfaces. It seems that is also implicated in the entry of β-lactams 
and saccharides up to approximately 800 Da and, therefore, the lack of this porin could 
contribute to high levels of resistance (263). Other Omps whose reduced expression has 
been associated with carbapenem resistance include the 33- to 36-kDa Omp, 47-, 44-, 37-
kDa Omp and 43 KDa Omp (protein homologous to the OprD of Pseudomonas 
aeruginosa) (50, 79) (Table 3). Other studies have shown that the loss of a heat-
modifiable 29-kDa OMP, designated CarO, was also responsible for imipenem resistance 
(146, 179, 180)(Table 3).  
1.1.5.1.2 .2 Efflux systems 
The main function of efflux systems is to remove chemicals that could be toxic for the 
bacterial cell. However, in the last years it has become patent that efflux pumps have a 
potent ability to actively eliminate several classes of antibiotics, including β-lactams. Until 
now were described six families of pumps: ATP-binding cassette (ABC) transporters, the 
small multidrug resistance (SMR) and multidrug and toxic compound extrusion (MATE) 
families, the major facilitator superfamily (MFS), the bacterial integral membrane proteins 
(BIMP), and the resistance-nodulation-cell division (RND) (263). RND systems are the 
most prevalent in A. baumannii, including the AdeABC, AdeIJK and AdeFGH efflux 
systems (where Ade stands for Acinetobacter drug efflux) (Figure 3). Among non-
baumannii Acinetobacter species, AdeDE pump has been identified in A. pittii and A. 
nosocomialis (38, 48) and more recently was detected an AdeABC-like efflux system in A. 
nosocomialis (222). This family of efflux pumps expels the antimicrobial by utilizing the 
proton motive force as the driving force for efflux, exhibiting a wide substrate range that 
can include antibiotics, dyes, biocides, detergents, and antiseptics. Among the systems 
belonging to this family, overexpression of AdeABC constitutes a major mechanism of 
multiresistance in A. baumannii, including to β-lactams (164). The adeABC operon 
encodes the AdeA major fusion protein (MFP), the multidrug transporter AdeB (inner 
membrane protein – pump), and the AdeC outer membrane factor (OMF). Overexpression 
of this system (identified in ca. 80% A. baumannii strains) results from mutations in a two-
component regulatory system encoded by the genes adeR (regulator gene) and adeS 
(sensor kinase) (164) (Figure 3).  Although several studies indicate the propensity of A. 
baumannii to achieve multidrug resistance by overexpression of the efflux pump when 
exposed to its substrates, the signal recognized by AdeS, the mechanism of regulation of 
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AdeABC by AdeRS and the DNA-binding site of AdeR remain to be elucidated (116). 
AdeIJK is intrinsic of A. baumannii species and is responsible for resistance to various 
drug classes including β-lactams, such as ticarcillin, cephalosporins and aztreonam (155). 
Overexpression of this system above a certain level results in toxicity for the bacterial cell. 
Therefore, its transcription is tightly regulated by a TetR regulator encoded by the adeN 
gene (155). Figure 3 shows a schematic representation of the main RND efflux systems 
present in A. baumannii and responsible for antibiotic resistance.  
 
 
Figure 3 - Schematic representation of operons for the main efflux systems belonging to 
RND family in A. baumannii. Arrows represent coding sequences and indicate direction of 
transcription. adeS, adeR, adeN and adeL encode transcriptional regulators. [Adapted 
from Coyne et al, 2011 (55)]. 
1.1.5.1.3 Alterations of penicillin binding proteins (PBPs) 
Resistance to β-lactams might also occur by changes in the affinity or expression levels of 
PBPs, although information regarding this mechanism is still limited (Table 3). However, in 
order to result in carbapenem resistance, these mechanisms usually occur associated 
with β-lactamases, overexpression of efflux pumps or decreased expression of OMPs 
(279).  Until now were identified seven PBPs (PBP1, PBP1b, PBP2, PBP3, PBP5/6, 
PBP6b, PBP7/8) that might contribute to carbapenem resistant phenotype in A. baumannii 
(51). However, carbapenem resistance has only been associated with decreased 
expression of the PBP2 (88). 
 
1.1.5.2 Resistance to aminoglycosides 
Aminoglycosides have been used for a long time being an important alternative for 
therapy of infections caused by MDR strains. Resistance to aminoglycosides by 
aminoglycoside-modifying enzymes (AMEs) is also an important feature in the multidrug-
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resistant phenotype of Acinetobacter spp. AMEs include acetyltransferases (74, 226), 
nucleotidyltransferases and phosphotransferases, with some A. baumannii strains often 
containing multiple enzymes of these classes (101). High level resistance to 
aminoglycosides occurs in the presence of another group of enzymes, the 16S rRNA 
methyltransferases, with the armA gene being relatively widespread in A. baumannii (43, 
72, 283) (Table 3). 
Overexpression of efflux pumps such as AdeABC and AbeM (MATE family) also 
contributes for aminoglycoside resistance (263) (Table 3). 
1.1.5.3 Resistance to tetracyclines and glycylcyclines 
 
Resistance to tetracyclines and glycycyclines (tigecycline) may occur by overexpression 
of RND efflux systems (AdeABC, AdeFGH and AdeIJK) (56, 63, 117, 147, 155). 
Resistance to tetracyclines may also implicate efflux systems of the MFS family (TetA, 
TetB) and might also involve the tetM gene, associated with tetracycline ribosomal 
protection (3, 55). 
 
1.1.5.4 Resistance to colistin 
 
Resistance to colistin is associated with mutations in the first three genes of the lipid A 
biosynthesis pathway, lpxA, lpxC, and lpxD, which results in the complete loss of LPS 
production. This results in the escape to the first step of colistin action which is the 
electrostatic interaction between the positively charged antibiotic molecule and the 
negatively charged lipid A (component of lipopolysaccharide - LPS) (172, 173, 239). 
Additionally, mutations in pmrA and pmrB may be linked to colistin resistance being 
responsible by the removal of an initial charge-based interaction between the bacterial 
outer membrane lipid bilayer and colistin (2).  
1.1.5.5 Other resistance mechanisms 
Mechanisms of fluoroquinolone resistance in A. baumannii include mutations in gyrA and 
parC encoding for DNA gyrase and DNA topoisomerase IV, respectively (148). Finally, 
trimethoprim resistance seems to involve mutations in a putative dihydrofolate reductase 
gene (folA) (161).  
 
Table 3 summarizes the major mechanisms of resistance that have been identified for the 
different classes of antibiotics in Acinetobacter spp. 
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Table 3. Major antimicrobial resistance mechanisms in Acinetobacter spp. 
 
Antimicrobial 
Class 
Resistance 
Mechanism Class/family Variants Reference 
β -lactams β-lactamases 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OMP alterations 
 
 
 
 
 
Efflux pump 
 
Altered PBP 
expression 
Class C  
Intrinsic 
cephalosporinases  
 
 
Class A  
 
 
 
 
 
 
 
 
 
 
 
 
Carbapenemases 
Class A 
 
 
Class B – MBLs 
 
 
 
 
 
 
 
Class D – CHDLs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CarO 
OmpA 
33-36 KDa protein 
43 KDa protein 
 
 
RND 
AmpC (ADC-1 to -4, -6, -
7, -10, -11, -25, -26, -29 to 
-33,-38, -39, -50 to -54, -
56) 
 
TEM-1, -2 
TEM-type ESBLs: TEM-
92, -116, -128, -150  
SHV-1b,-2, -5, 12, -18, -
56, -71, -96 
CARB-2, -4, -5, -8, -10 
VEB-1, -1a, -3 
PER-1, -2, -7 
CTX-M-2, -5, -15, -43 
SCO-1 
GES-1, -11, -12 
 
 
 
KPC-2, -3, -4, 10 
GES-14 
 
IMP-1, -2, -4, -5, -6, -8, -
11, -14, -19 
VIM-1, -2, -3, -4, -11 
SIM-1 
SPM-1 
NDM-1, -2 
 
 
OXA-23 group (OXA-23, -
27, -49, -102, -103, -105, -
133, -146, -165 to -171) 
OXA-24/40 group (OXA-
24/40; -25, -26, -72, -139, 
-160, -182) 
OXA-58 group (-96, -97, -
164) 
OXA-143  
aOXA-51 group; OXA-
214-like, OXA-134 group, 
OXA-211group, OXA-213-
group 
 
 
 
 
 
 
 
 
 
AdeABC 
 
 
PBP2 downregulation 
 
(120) 
 
(19, 21, 83, 
182, 183, 
212, 240) 
 
(19, 220) 
 
(20, 126, 
209, 235) 
 
(89, 115, 
209) 
 
(50, 103, 
146) 
 
(98, 158) 
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Table 3. Major antimicrobial resistance mechanisms in Acinetobacter spp. (cont.) 
Antimicrobial 
Class 
Resistance 
Mechanism Class/family Variants Reference 
 
Tetracyclines 
 
Efflux pump 
 
 
 
Ribosomal protection 
 
MFS 
RND 
 
TetA, TetB 
AdeABC, AdeFGH, 
AdeIJK 
 
TetM 
 
(263) 
 
 
 
(218) 
Glycylcyclines Efflux pump RND AdeABC, AdeFGH, 
AdeIJK 
(229) 
Aminoglycosides Enzymatic 
degradation 
 
 
 
 
Efflux pumps 
 
 
 
16S rDNA 
methytransferases 
Acetyltransferases 
Nucleotidyl-
transferases 
Phospho-
transferases 
 
RND 
MATE 
AacC1/2, AadA, AAdB 
 
Ant1 
 
AphA1, AphA6 
 
AdeABC 
AdeM 
 
 
ArmA 
 
 
(187) 
 
 
 
(263) 
 
 
 
(72) 
 
Quinolones 
 
DNA gyrase 
mutations 
Topoisomerase 
mutations 
 
Efflux pumps 
 
GyrA 
 
ParC 
 
 
RND 
MATE 
BIMP 
 
 
 
 
 
 
AdeABC 
AdeM 
AbeS 
 
 
 
(108) 
 
 
 
 
(263) 
 
Chloramphenicol 
 
 
 
Efflux pumps 
 
RND 
 
MFS 
 
BIMP 
 
AdeABC 
AdeIJK 
CmlA 
CraA 
AbeS 
 
 
(263) 
Trimethoprim/ 
sulfamethoxazole 
Efflux pump 
 
 
Dihydropteroate 
synthase 
 
Dihydrofolate 
reductase 
RND AdeABC, AdeIJUK 
 
 
 
SulI/II 
 
 
FolA 
(263) 
 
 
 
(101) 
 
 
(161) 
 
Macrolides 
 
Efflux pumps 
 
MATE 
BIMP 
 
AbeM 
AbeS 
 
(263) 
Polymyxins PmrAB two 
component mutation 
signalling proteins 
 
Loss of the lipid A 
component of 
lipopolysaccharide  
  
PmrA and PmrB 
 
 
 
LpxA, LpxC, LpxD 
 
(2) 
 
 
 
(173) 
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1.2 Resistance mobilization 
 1.2.1 Mobile Genetic Elements   
Acinetobacter spp. display a remarkable capacity to acquire and disseminate resistance 
mechanisms, a feature associated with specific genetic elements such as insertion 
sequences, transposons, integrons (not mobile by themselves), plasmids and resistance 
islands (223). 
  1.2.1.1 Insertion sequences and composite transposons 
Insertion sequences (IS) are defined as short mobile DNA elements, up to 2 kbp, and are 
the most abundant transposable elements (206). IS are constituted by one or two ORF 
encoding a transposase, the enzyme that catalyzes the transposition of the IS element. 
The transposase is usually surrounded by short terminal repeats and insertion occurs by 
duplication of a direct repeat, a short sequence of the target DNA flanking the IS (159, 
160). Miniature inverted-repeat transposable elements (MITEs) are nonautonomous ISs 
deleted for part or all of the transposase ORF but retaining both ends (223, 237). It is 
important to note that besides acquisition of accessory functions ISs are also involved in 
other events, such as chromosome rearrangements and plasmid integration (159, 160)  
Many IS elements present promoter hexamers located in the terminal IRs (−35) that when 
are placed (by transposition) at the correct distance from a resident −10 hexamer, new 
promoters are able to activate the expression of neighboring genes. Probably this is the 
reason why CHDLs genes are usually associated with ISs, since they present a poor 
catalytic activity against carbapenems and need expression enhancers. Among the ISs 
that have been reported in Acinetobacter spp (more than 30 different types) (237). ISAbaI 
and ISAba125 seem to be the most common. ISAba1 is frequently found adjacent to 
ampCs and blaOXAs as well as adjacent to sulII (178). Curiously, was identified in 
Acinetobacter spp., but not in Enterobacteriacea and Pseudomonas aeruginosa, being 
suggested that this IS is customized for Acinetobacter (233). 
Additionally, ISAbaI, ISAba2, ISAba3, ISAba4, ISAba10, ISAba16, ISAba125, ISAba825, 
and IS18 were found upstream from blaOXA-23 and blaOXA-58 (17, 53, 151, 209, 210, 216).  
blaOXA-58 usually appears associated with ISAba1, ISAba2, ISAba3-like and, and IS18 
(210). The blaOXA-23 gene may be mobilized through different genetic structures, such as 
the composite transposon Tn2006, formed by two ISAba1 elements. ISAba4 was also 
found upstream of the blaOXA-23 gene but in a single copy, constituting the Tn2007 (178). 
Finally, ISAba9 has been described upstream from both blaOXA-51 and the gene encoding 
CARB-10 (90, 212). 
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IS elements may also be associated with resistance by disrupting coding sequences of 
certain genes. For instance, the disruption of carO gene resulting in carbapenem 
resistance, or the lpxA or lpxC genes disruption leading to colistin resistance (141, 172). 
Composite (or compound) transposons are structures in which a DNA segment is flanked 
by two copies of a given IS that act in concert, contributing for the mobilization of that 
region (159). An example of this structure is the already mentioned Tn2006, composed by 
two copies of ISAba1 and usually associated with blaOXA-23 (177). Another example is the 
In76 encoding for the MBL IMP-5 which was found to be embedded in aTn402-like 
transposon. In this structure In76 was flanked by MITE-like structures suggesting that a 
MITE-facilitated transposition-like mechanism is responsible for the mobilization of the 
integron (278). In Figure 4 we can find the schematic representation of a typical IS (A), the 
structure of Tn2006 implicated in blaOXA-23 mobilization (B) and the structure of the Tn402-
like transposon harboring the blaIMP-5 (C). 
 
Figure 4. Schematic representation of insertion sequences (IS) and transposons. A) 
Typical IS. IRL, left inverted repeat; IRR, right inverted repeat; transposase is represented 
by the textured rectangle, extending within IRR and constituting the only ORF of the 
system; XYZ represent the short direct repeats (DR) sequences generated in the target 
DNA;  P, transposase promotor, partialy located within IRL. (Adapted from Mahillon, 1998) 
B) Tn2006 structure. The orf 1 and orf2 genes of unknown function are indicated; 
ATPase, gene encoding the putative AAA ATPase; DEAD, gene encoding the putative 
DEAD (Asp-Glu-Ala-Asp) helicase; DNAmethyl, DNA methylase.  C) Schematic 
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representation of the MITEs structures flanking regions the integron In76. [Adapted from 
(159, 177, 278)] 
1.2.1. 2 Integrons 
While IS are common vehicles for acquisition of CHDLs genes, MBLs genes such as 
blaIMP, blaVIM or blaSIM, but not blaNDM, are usually embedded in integron structures (223). 
Integrons are genetic elements responsible for the acquisition and rearrangement of open 
reading frames (ORFs), embedded in gene cassette units, guaranteeing genes correct 
expression. Integrons are not mobile by themselves (but gene cassettes can readily be 
exchanged to other integrons), but they can spread to different chromosomal locations, 
plasmids or even other microorganisms by IS-mediated transposition or homologous 
recombination (165). Acquisition of genetic determinants is usually linked to the so called 
“mobile integrons” due to their association with mobile DNA elements (transposons), 
which in turn can be carried by plasmids (32). According to the integrases sequences 
were identified five different classes of mobile integrons, with class 1 integrons being the 
most widespread and clinically relevant. Integrons are organized in three regions: the 5′ 
conserved region, the 3′conserved region, and a variable region. The 5′ region consists of 
the integrase gene (intl), its adjacent recombination site (attI), and a promoter, constituting 
the integron functional platform. The 3′ conserved region often consists of a partially 
deleted qac gene (qacE∆1) fused to a sul gene conferring resistance to quartenary 
ammonium compound and sulfonamide, respectively (270). Figure 5 gives a schematic 
representation of class1 integrons. 
 
Figure 5. Schematic representation of a class 1 integron. intI, integrase gene; Pc cassette 
promoter;  P2, second promoter;  Pint, promoter for the integrase; attI, integration site; 
attC, sequence in the gene cassette recognized by the integrase; qacE∆1, partially 
deleted gene that encodes resistance to a quartenary ammonium compound; sulI, gene 
for sulfonamide resistance; orf, open reading frame. [Adapted from (22)]  
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1.2.1.3 Genomic Islands 
Genomic islands constitute clusters of genes involved in horizontal gene transfer (HGT) 
being generally associated with microbial adaptations of medical or environmental interest 
(70, 106). They are usually identified due to differences in G+C content from the rest of 
the genome and by the presence of direct repeats at their ends, the association of 
pathogenicity islands with transfer RNA genes, the presence of integrase determinants 
and other mobility loci (106).  
The genome sequencing of several A. baumannii strains, particularly those belonging to 
the main epidemic lineages, revealed a high genomic plasticity and the presence of hot-
spots for acquisition of genomic islands that might contain resistance markers - resistance 
islands (131). The best studied of these RIs is AbaR1, described in A. baumannii AYE 
strain and constituting the largest described to date (93).  It is an 86 kb region with a G+C 
content of 52.8% while the G+C typical of A. baumannii chromosome is 38.8%. AbaR1 is 
constituted by 88 predicted ORFs, much of them probably acquired from other species 
belonging to Pseudomonas, Salmonella and Escherichia genera. AYE strain harbored 52 
antibiotic resistance genes with 45 being located in AbaRI. Additionally, this region also 
includes genetic determinants for resistance to arsenic, mercury and quaternary 
ammonium compounds (93, 219). Since then several other resistance islands were 
described among A. baumannii isolates being noticed that different clonal lineages seem 
to display differences in resistance gene content and organization of AbaRs, although 
most of them are preferentially incorporated into a specific location within the comM gene 
(193, 211).  The blaOXA-23 is one of the resistance genes found associated with an 
antibiotic resistance island, Tn6167, in an ST92 isolate from Australia (193)   
Figure 6 represents the common backbones described for European clone I (ECI) and 
ECII AbaRs.  
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Figure 6. AbaR-type transposons backbones. EC I share a 16.3-kb backbone transposon, 
Tn6019, constituted by two ORFs and the universal stress protein gene (uspA) 
disdisrupted by a second cadmium and zinc resistance transposon (Tn6018) which is 
flanking a multiple antibiotic resistance region (MARR). However is observed higher 
diversity among AbaRs from EC II isolates. [Adapted from (223)] 
1.2.1.4 Plasmids 
Plasmids are extra-chromosomal pieces of DNA, which are capable of replicating 
independently of the genome (241). They play an important role in bacterial adaptation 
being involved in many accessory functions and constituting the so called “accessory 
genome”. In general, a plasmid is constituted by one or more genes implicated in 
replicative functions, and genes coding for different accessory metabolic processes. 
Plasmid architecture is more flexible than the chromosomal due to the presence of 
transposable elements giving origin to recombinatory events (92).  Most of the plasmids 
confer positively selectable phenotypes (33) since they are directly   implicated in the 
acquisition of resistance to many antibiotics (241). Additionally, plasmids may cross many 
species and genus barriers, contributing for a successful dissemination (33, 241).  
The development of a classification scheme based on replicons identification revealed 
that Acinetobacter plasmid replicons differ from all those described previously for other 
prokaryotic species, being identified 27 replicases grouped into 19 homology groups 
(18).This scheme contributed to better understand the diffusion of plasmids conferring 
antimicrobial resistance among Acinetobacter spp., especially those involved in CHDLs 
dissemination (18, 250) CHDLs genes were found to be particularly associated with 
repAci6 and repAci1 (blaOXA-23), repAci6, repAci1, repAci3, repAci4, and repAciX (blaOXA-58) 
and repAci6, repAci2, and p2ABSDF0001 (blaOXA-40) (250). Curiously, plasmid encoded 
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blaOXA-40 gene was always found to be flanked by conserved inverted repeats homologous 
to binding sites acting as targets for the XerC and XerD recombinases (57, 169), probably 
constituting a novel mechanism of mobilization (169). 
Thus, Acinetobacter spp. successful evolution greatly results from the genomic plasticity 
provided by the combination of variety of genetic elements. 
1.2.2 Horizontal Gene Transfer 
Horizontal gene transfer (HGT), in opposition to the transmission of traits from parents to 
offspring, known as vertical inheritance, corresponds to the transfer of genetic material to 
the surrounding bacteria, constituting an important source of bacterial adaptation and 
evolution (81, 251). This event is particularly important in the resistance evolution to 
antibacterial agents, constituting probably one of the most important means by which the 
spread of antimicrobial resistance in a hospital environment occurs.  
Transformation is considered a major horizontal gene transfer mechanism contributing to 
genetic adaptation and evolution of prokaryotes (65). Acinetobacter spp. belongs to a 
group of naturally transformable organisms by not discriminating between their own and 
foreign DNA (78).Conjugation, on the other hand, does not seem to be the most frequent 
mechanism of acquisition of foreign DNA among this genus, since the most frequent 
plasmids associated with resistance genes are non-self-transferable (250). The lack of 
mobilization and transfer functions which is in accordance with the observation that most 
intrinsic Acinetobacter plasmids seem to be non-self-transferable in the laboratory, might 
be overcome by the almost ubiquitous presence of plasmids belonging to GR6 (repAci6) 
that could confer an intrinsic system for plasmid mobilization (18, 250). In addition, was 
recently demonstrated in vitro a new mechanism of carbapenem resistance genes 
dissemination in A. baumannii, via delivery of plasmids harboring blaOXA-24 gene included 
in outer membrane vesicles (OMVs) to the surrounding bacteria (227).  
1.3 Pathogenesis and virulence factors of A. baumannii  
There are several factors responsible by the high prevalence of A. baumannii strains in 
the hospital in epidemic and endemic situations but the precise mechanisms that 
contribute for the establishment and progression of infection are only now being defined.  
The most studied mechanism of A. baumannii pathogenicity is the biofilm formation, an 
important requirement for chronic colonization of human tissues and persistence in 
implanted medical devices (149). Other pathogenic determinants that have been reported 
in Acinetobacter  include the production of siderophores such as acinetobactin, with the 
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ferric-siderophore complex being transported inside bacterial cells with the aid of 
membrane receptors (TonB-dependent receptors) or hydrolytic enzymes such as 
phospholipase C and phospholipase D (7, 76, 123). OmpA has also an important role in 
the pathogenicity as binds to eukaryotic cells, translocates to the nucleus and induces 
apoptosis (45).  Moreover, participates in the biogenesis of A. baumannii outer membrane 
vesicles (OMVs) that interacted with lipid rafts in the plasma membranes and deliver 
virulence factors, such as tissue-degrading enzymes (124, 175). In addition, Acinetobacter 
growth and resistance to salt stress seems to be enhanced by low concentrations of 
ethanol which also stimulates the expression of genes encoding proteins involved in 
siderophore synthesis and siderophore receptors (31).  
1.3.1 Biofilm formation 
Biofilms are highly structured communities of bacteria attached to a surface and represent 
the prevalent microbial mode of existence in nature, being suggested that more than 90% 
of bacteria exist within biofilms (54). Biofilms are associated with multiple drug resistance, 
being the microorganisms contained in these structures more resistant to desiccation, 
environmental stress (nutritional or oxidative stress), UV light exposure and phagocytosis. 
(236) The ability of A. baumannii to form biofilms is multifactorial including nutrient 
availability (eg. iron limitation), bacterial appendages (pili), bacterial surface components 
(outer membrane proteins, adhesins) quorum sensing and macromolecular secretions 
(polysaccharides, nucleic acids). The response to a variety of environmental signals and 
sensing molecules results in differential expression of biofilm associated genes, 
depending also on the type of surface implicated (97). Table 4 summarizes the main steps 
involved in biofilm formation. 
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Table 4. Description of the main mechanisms involved in the development of mature 
biofilm structures in A. baumannii 
Stage Description Genes/Proteins  References 
1 - Adherence 
Adhesion to both biotic and 
abiotic surfaces assisted by 
type I pili. 
CsuA/BABCDE 
chaperone-usher complex 
(expression regulated by 
bfmR and bfmS genes);  
Outer membrane proteins 
( Omp38 and OmpA) 
(45, 46, 246, 247) 
  
2 - Irreversible 
attachment 
Cell-to-cell contact: 
increased production of (c-di-
GMP)a results in cell-to-cell 
contact, quorum sensing and 
reduction in surface 
associated swarming 
behavior. 
Biofilm-associated protein 
(Bap) 
(149) 
3 - Microcolonies 
Structured sessile microbial 
community embedded in an 
extracellular polymeric 
substance (EPS) composed 
of PNAGb; eDNAc, lipids, and 
proteins. This highly hydrated 
layer might be responsible 
for resistance to desiccation. 
pgaABCD locus (44) 
4 – Cell dispersal 
Cell dispersal occurs for 
daughter cells and when 
nutrients become limited, 
being advantageous for 
bacteria to dissemble and 
revert to initial planktonic 
existence. Detachment from 
surfaces occurs via twitching 
motility, mediated by type-IV 
pili. 
pilA, pilB, pilC, pilF, pilM, 
pilN, pilO, pilP, pilQ, pilR, 
pilS, pilT, pilU,  pilZ, pilW 
(30, 223)  
  
aintracellular messenger signalling molecule bis-(3´-5´)-cyclic di-GMP; b poly-β- (1-6)-N-acetylglucosamine; c 
extracellular DNA 
1.4 Population structure of carbapenem-resistant A. baumannii  
Several typing methods with different discriminatory power have been applied to gain 
insights into A. baumannii population dynamics: Pulsed-Field Gel Electrophoresis (PFGE) 
– more suitable for short-term outbreak investigations–, amplified fragment length 
polymorphism (AFLP) analysis, other PCR fingerprinting methods and multiple-locus 
variable tandem repeat number analysis (MVLA) (9). The development of multilocus 
sequence typing schemes allowed the generation of objective and comparable data that 
might be exchanged between laboratories and the establishment of important databases. 
Presently, there are three MLST schemes in use. The first MLST scheme was developed 
by Bartual et al in 2005 (9), and is hosted in the Oxford database 
(http://pubmlst.org/abaumannii/). The second MLST scheme, which shares three loci with 
the original scheme, was developed by Nemec et al. at the Pasteur Institute 
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(http://www.pasteur.fr/recherche/genopole/PF8/mlst/Abaumannii.html) (188). The third 
one includes PCR coupled with electrospray ionization mass spectrometry (PCR/ESI-MS) 
(80).   
Dissemination of carbapenem-resistant A. baumannii seems to be due to the spread of 
highly similar strains, usually harboring acquired CHDLs.  Additionally, inter-hospital 
transfer of colonized patients might also account for A. baumannii outbreaks emphasizing 
the importance of infection control programs to prevent this dissemination. 
In Europe, hospital outbreaks of A. baumannii infections have been investigated since the 
early 1980s (264) Using the AFLP method were identified the European clones (EU) I, II 
and III that constituted at that time the major genotypes circulating in European hospitals 
and associated with carbapenem resistance (67, 257) The development of a PCR-based 
sequence group typing method focused on the allelic variation within three genes likely to 
be under selective pressure, ompA, csuE and blaOXA-51-like, created an easier method for 
the definition of these lineages previously delineated by AFLP (252). More recently, the 
use of repetitive-sequence-based PCR (rep-PCR) typing with the DiversiLab system has 
expanded the structure of carbapenem-resistant A. baumannii population from three to 
eight clonal lineages disseminated worldwide (WW1 to -8) (Higgins, 2010). In the 
particular case of Portugal a blaOXA-40 carbapenem-resistant clone endemic in at least 
three tertiary-care hospitals (61, 215), formed a sub-cluster of EUII, emphasizing the role 
of this lineage in carbapenem-resistance dissemination (59). 
The use of the MLST scheme developed by Nemec et al. at the Pasteur Institute led to the 
identification of three main clonal complexes (CC1-CC3), each one corresponding to 
European clones I to III, and ST15, and all associated with the majority of multidrug 
resistant A. baumannii isolates (66). 
The MLST Bartual scheme allowed the recognition of the worldwide disseminated clonal 
complex (CC) 92 which comprises today the majority of carbapenem-resistant A. 
baumannii isolates (9, 96, 110, 115, 179, 202). Among the more than fifty STs included in 
this CC, ST92 is the most disseminated (Figure 7) being frequently associated with OXA-
23 producing A. baumannii. In a survey among hospitals from sixteen cities in China was 
observed the dominance of ST92 among the carbapenem-resistant isolates, with blaOXA-23 
being the only CHDL identified in those isolates. Curiously, in that same study, ST92 also 
achieved a dominant position among the carbapenem-susceptible isolates, raising the 
possibility that ST92 presents additional features, besides antibiotic resistance, which 
allow its survival under selective pressures (96). Additionally, in South Korea, ST92-OXA-
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23 producing A. baumannii clinical isolates were also associated with pan-drug resistance 
phenotype (203). In Australia, in a study conducted among isolates obtained during eight 
years was also observed the dominance of ST92 associated with the carriage of blaOXA-23 
(231). Curiously, in order to avoid a bias, the inclusion of sporadic and susceptible strains 
in this type of epidemiological studies revealed that the majority of clinical isolates also 
belong to ST92, reinforcing that its success might be due to an effective adaptation to the 
hospital environment, as well as a great ability to further acquire antibiotic resistance 
(231). In a recent survey (2008-2009) from USA hospitals was observed that sequence 
types (STs) belonging clustering in CC92 and the pan-European clonal lineage II (EUII) 
were also predominant. The most common were ST122 and ST208, but not ST92, 
suggesting that carbapenem-resistant A. baumannii isolates found in USA hospitals 
constitute part of the global epidemic driven by CC92, probably sharing the same 
ancestral, but evolving independently from the European isolates (1).  
Several studies confirm the correspondence between CC2 and CC92, with some pointing  
for the better  discrimination obtained with the MLST scheme developed by Bartual et al, 
2005 (1, 66, 179, 190).  This higher discriminatory power seems to be conferred by the 
use of gyrB and gpi loci included in this scheme. However, a report suggesting that 
horizontal gene transfer has occurred at the gyrB and gpi loci with some frequency 
opened the discussion about their utility in phylogeny studies (110). 
 
Figure 7. Worldwide dissemination of A. baumannii belonging to ST 92. 
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1.5 Future perspectives in the control and prevention of A. baumannii infections 
The extensive antibiotic resistance presented by A. baumannii, which has surpassed 
human capacity to create new antimicrobials, is leading us toward a concerning era of 
hospital-acquired infections, highlighting the urgent need for novel therapeutic 
approaches. We will refer just a few strategies that are now being developed, some of 
them with good efficacy perspectives.  
For instance, a renewed interest in phage therapy has led to the characterization of the 
virulent AB1 bacteriophage which has been shown to be effective against A. baumannii 
(279). Another possible therapeutic option might include the development of vaccines. 
Several molecules are candidate to be used has antigen: i) inactivated whole cell vaccine 
seems to elicit a robust antibody response (168); ii) a vaccine consisting on multiple 
surface antigens from A. baumannii  outer membrane elicited humoral and cellular 
responses reducing post infection bacterial loads, and post infection proinflammatory 
cytokine levels in serum (169); iii) immunization with outer membrane vesicles was also 
able  to elicit protective immunity, particularly in a short period of time (168); and iv) 
recombinant OmpA using aluminium hydroxide as adjuvant also induced high titers of 
protective anti-OmpA antibodies (157). However, the use of vaccine against A. 
baumannii raises the question of which population should be immunized. It is proposed 
that persons presenting risk factors for the development of A. baumannii infection, such 
has long-term hospitalization in intensive care units, mechanical ventilation, and previous 
antibiotherapy, should be considered as potential targets for vaccination. Other 
therapeutic options might include the use of radioimmunotherapy, photodynamic or 
nanoparticle technology (172, 173).  
Not all of these approaches will be available in the near future. Prevention and infection 
control, assisted by good surveillance programs, with an accurately and early recognition 
of antimicrobial resistance mechanisms, will be the best allied to combat Acinetobacter 
spp. infections. 
 
  
 
  
 
  
“Savoir s'étonner à propos est le premier pas fait sur la route de la découverte.” 
Louis Pasteur  
(1822-1895) 
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CHAPTER 2 - OBJECTIVES  
2.1 Objectives of the study 
In the last decades, Acinetobacter species have emerged as important and threatening 
pathogens, representing a significant and difficult challenge for healthcare institutions 
all over the world. Acinetobacter baumannii, the most prevalent Acinetobacter species 
within the clinical setting, shows a prodigious ability to become resistant to several 
antimicrobial agents and to persist in the hospital environment. With the boost of 
multidrug resistant strains, carbapenems emerged as last therapeutic options for 
serious A. baumannii-causing infections. Unfortunately, their usefulness rapidly 
became limited as an increasing number of carbapenem-resistant strains sprouted 
worldwide. 
The emergence and spread of carbapenem-resistant A. baumannii within the hospital 
setting derives mainly from clonal expansion and horizontal gene transfer. These 
factors together with adhesion and biofilm formation capabilities strongly contributed to 
the successfully adaptation and evolution of this species. Moreover, the possibility of 
interspecies transfer of resistance traits could account for carbapenem resistance in 
Acinetobacter species other than A. baumannii, which might constitute important 
source/reservoir of relevant resistance genes. 
 
The goal of this thesis was to gain insights on the population diversity of carbapenem-
resistant A. baumannii clinical isolates, the influence of mobile genetic elements in the 
intra- and inter-species exchange of carbapenem resistance mechanisms, and the role 
of adhesion and biofilm production in the dissemination and persistence of particular A. 
baumannii lineages. The recognition of the main carbapenem-resistant A. baumannii 
lineages responsible for nosocomial infections as well as the complete understanding 
of the factors that are driving their dissemination and persistence is essential to create 
and promote effective strategies to control these organisms within the hospital setting. 
 
With this purpose in mind, the dynamics of A. baumannii populations existing in several 
Portuguese hospitals (1995-2008) was characterized and the role of particular lineages 
in the dissemination of carbapenem resistance in hospitals from Brazil (2006-2007) and 
Czech Republic (2008) was determined. Additionally, the role of mobile genetic 
elements in carbapenem resistance dissemination, not only among A. baumannii 
isolates, but also among different Acinetobacter species was also clarified. 
Chapter 2 - Objectives 
38 
 
This study focuses on the following specific aims: 
 
1. To characterize the population structure of carbapenem-resistant Acinetobacter 
baumannii clinical isolates collected in the hospital setting in Portugal (1995-
2008), Brazil (2006-2007) and Czech Republic (2008). 
2. To characterize the carbapenem resistance mechanisms and the mobile 
genetic elements responsible for the spread of carbapenem resistance 
determinants among Acinetobacter species. 
3. To explore the mechanisms that might drive the antimicrobial resistance 
evolution in A. baumannii. 
4. To explore the role of environmental Acinetobacter species in the acquisition 
and dissemination of carbapenem resistance mechanisms. 
5. To characterize the adhesion ability and biofilm formation displayed by the main 
A. baumannii lineages disseminated in Portuguese hospitals. 
6. To integrate the results emerging from the objectives 1, 2, 3, 4 and 5 for a 
better understanding of the role of specific lineages, particular mobile genetic 
elements and virulence factors in the dynamics of the emergence phenomenon 
of carbapenem resistance in Acinetobacter spp. 
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2.2 Organization of the thesis 
The results gathered during this study were partially published (4 publications in peer 
review journals, 1 under editorial revision and 2 manuscripts in preparation) and were 
organized according to the following structure: 
I. Population structure analysis of carbapenem-resistant Acinetobacter 
baumannii clinical isolates 
This chapter includes results obtained from the characterization process of a large 
collection of A. baumannii isolates collected in the hospital setting in Portugal, Brazil 
and Czech Republic (1995-2008), as well as the description of in vivo evolution of a 
multidrug-resistant A. baumannii isolate towards resistance to all available antibiotics 
(extreme drug resistance).  
 Grosso F, Quinteira S, Peixe L. 2011. Understanding the dynamics of 
imipenem-resistant Acinetobacter baumannii lineages within Portugal. Clinical 
Microbiology and Infection. 17(8):1275-1279.  
 Grosso F, Carvalho KR, Quinteira S, Ramos A, Carvalho-Assef AP, Asensi MD, 
Peixe L. 2011. OXA-23-producing Acinetobacter baumannii: a new hotspot of 
diversity in Rio de Janeiro? J Antimicrob Chemother. 66(1):62-5. 
 Grosso F, Quinteira S, Pinheiro M, Bergerová T, Hrabák J, Peixe L. Clonal 
outbreak of Multidrug-Resistant ST92 Acinetobacter baumannii in the University 
Hospital of Pilsen, Czech Republic. (in preparation) 
 Grosso F, Quinteira S, Peixe L. 2010. Emergence of an extreme-drug-resistant 
(XDR) Acinetobacter baumannii carrying blaOXA-23 in a patient with acute 
necrohaemorrhagic pancreatitis. Journal of Hospital Infection. 75(1):82-83.  
 
II. Contribution of mobile genetic elements for the dissemination of carbapenem 
resistance among Acinetobacter spp. 
The characterization of blaOXA-24/40-carrying plasmids and blaIMP-5 genetic environments, 
exploring the role of horizontal gene transfer in the dissemination of carbapenem 
resistance, was conducted and the collected data is presented and discussed within 
this chapter. 
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 Grosso F, Quinteira S, Poirel L, Novais A, Peixe L. 2012. The role of common 
blaOXA-24/40-carrying platforms and plasmids in the spread of OXA-24/40 among 
Acinetobacter spp. clinical isolates.  Antimicrobial Agents and Chemotherapy. 
56(7):3969-3972.  
 Grosso F, Ramos H, Quinteira S, Peixe L. IMP-5-producing multidrug-resistant 
Acinetobacter lwoffii from a newborn incubator. (submitted)  
III. Contribution of adhesion and biofilm production for the persistence of 
carbapenem-resistant A. baumannii lineages 
In this study the biofilm formation ability of spread carbapenem resistant A. baumannii 
lineages was investigated. The possible role of blaOXA-24/40-carrying plasmids as a 
genetic platform for the anchorage of biofilm formation capabilities, as well as its 
contribution for the endemicity of some lineages in Portugal, is also discussed. 
 
 Vuotto C, Grosso F, Costa ML, Ferreira H, Quinteira S, Donelli G, Peixe L. 
Contribution of adhesion and biofilm production in the persistence of 
carbapenem-resistant A. baumannii lineages: exploring the role of blaOXA-24/40-
carrying plasmids. (in preparation)  
 
 
 
 
 
 
 
 
  
 
  
“In the fields of observation chance favors only the prepared mind.” 
Louis Pasteur  
(1822-1895) 
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I. Population structure analysis of carbapenem-resistant Acinetobacter 
baumannii clinical isolates 
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Abstract
A recent collection of 213 imipenem-resistant Acinetobacter bau-
mannii (IRAB) clinical isolates was characterized for the presence
of acquired carbapenem-hydrolysing class D b-lactamases
(CHDLs) and clonality. A population structure analysis of IRAB
was also conducted, with five molecular typing methods. Three
main clusters, each one associated with a specific CHDL, were
observed with multilocus sequence typing. Overall, our results sug-
gest a switch in the dominant clone, with sequence type (ST) 92,
carrying blaOXA-23 (63.4%), replacing the closely related ST98,
carrying blaOXA-24/40 (22%). In addition, ST103, an independent
lineage, was associated with blaOXA-58-carrying isolates (14.6%).
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During the last decade, an ongoing rise in Acinetobacter
baumannii carbapenem resistance has been observed
worldwide, with recent reports of resistance to all available an-
timicrobials [1,2]. The production of acquired carbapenem-hy-
drolysing class D b-lactamases (CHDLs) belonging to the
OXA-23, OXA-24/40 and OXA-58 groups is the main
reported carbapenem resistance mechanism [1–7]. Despite the
description of two particular isolates producing IMP-5 [8] and,
more recently, OXA-23 [2], the imipenem resistance observed
in Portuguese A. baumannii clinical isolates has been mainly
associated with the production of OXA-24/40 and linked to
the spread of a particular multidrug-resistant clone [3,6].
Several sequence-based typing methods have been proposed
for A. baumannii population structure analyses [9–12], with
multilocus sequence typing (MLST) being increasingly applied as
a standard method [4,5,10,11,13]. Nevertheless, studies evalu-
ating the robustness of each particular method are still scarce.
In this work, we have characterized the antimicrobial sus-
ceptibility, acquired CHDLs and clonality of 213 previously
undescribed imipenem-resistant A. baumannii (IRAB) isolates,
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collected from 2004 to 2008, from five hospitals and two clini-
cal analysis laboratories located in the north and central
regions of Portugal. Isolates were identified with the Vitek 2
system and 16S rRNA gene sequencing. Susceptibility to b-
lactams, colistin and tigecycline was determined according to
CLSI guidelines [14]. The blaOXA genes were detected with a
multiplex PCR [7] and confirmed by sequencing. The genetic
location of acquired CHDL genes was assessed by hybridiza-
tion of I-CeuI-digested genomic DNA with specific probes for
blaOXA-23, blaOXA-24/40, blaOXA-58 and 16S rRNA [6]. The vicin-
ity of each CHDL gene was established by PCR and sequenc-
ing [15–18]. Pulsed-field gel electrophoresis (PFGE) typing
was performed with the ApaI restriction enzyme [3], and
pattern analysis was conducted with InfoQuestTM FP v5.4
(BioRad Laboratories, Hercules, CA, USA). Isolates clustering
together with >85% similarity levels [19] were considered to
belong to the same PFGE type. In order to better understand
the population structure of CHDL-producing IRAB Portugal,
we also used four distinct sequence-based typing methods
(Table 1). To this end, we selected nine representative iso-
lates (from the 213 IRAB isolates described above), together
with four additional isolates from a previously characterized
collection [3,6]. This selection process was aimed at simulta-
neously gathering isolates with different acquired CHDL con-
tent and of distinct PFGE types, collected from different
hospitals over the course of several years. Identification of
PCR-based sequence groups (SGs) and sequence-based typing
of blaOXA-51-like genes were performed as described else-
where [9,12]. MLST analysis was conducted according to two
distinct schemes that will be referred to from now on as
MLST1 (developed by Bartual et al. [10]) and MLST2 (pub-
lished by Nemec et al. [11]). Clonal complexes (CCs) for
MLST1 were determined with the eBURST software program
(http://eburst.mlst.net/) [20]. It is important to point out the
renumbering of alleles, sequence types (STs) and CCs that
occurred on the MLST1 database in February 2010. CCs relat-
ing to MLST2 were deduced with a minimum spanning tree
analysis [13].
The majority of isolates (77.5%) were obtained from inpa-
tients attending a general hospital (hospital A), with an ende-
mic situation for IRAB, continuously observed since 2001
and epidemiologically monitored by our group [3,6]. The
remaining isolates were provided by four hospitals in which
IRAB had started to spread more recently (Table 1). Two
isolates collected from distinct outpatients, with no previous
hospitalization history, were obtained from two clinical
analysis laboratories. A predominance of blaOXA-23 has
been observed since 2006, being detected in 135 isolates
(63.4%) from four hospitals and from two outpatients; this
represents, to our knowledge, the first description of T
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blaOXA-23-producing A. baumannii within the community.
Overall, besides resistance to all tested b-lactams, including
carbapenems, they had higher tigecycline MICs (Table 1),
findings that might explain their dominance. In fact, one iso-
late even showed an extreme drug resistance phenotype [2].
All OXA-23-producing isolates showed the association of
blaOXA-23 with Tn2006, with a chromosomal location. The
blaOXA-24/40 gene was detected in 47 isolates (22%) from
two hospitals. This acquired CHDL gene was encoded in
plasmids, flanked by XerC/XerD-like binding sites [18] and,
for some isolates, it was also observed on the chromosome
(Gross. F, Quinteila S, Peixe L, unpublished data). The
blaOXA-58 gene was detected in 31 isolates (14.6%) obtained
from hospital A. The higher susceptibility generally shown by
these isolates, namely to meropenem and tigecycline, might
explain their low prevalence. The blaOXA-58 gene was flanked
by ISAba3-like and ISAba3 elements upstream and down-
stream, respectively, and was found to be both chromosomal
and plasmid-carried. The insertion sequence ISAba1 was
observed upstream of blaOXA-51-like in all isolates. Only
three PFGE types were identified within this IRAB popula-
tion: PFGE type A for blaOXA-23-carrying and blaOXA-24/40-
carrying IRAB, and PFGE types B and C for blaOXA-58-carry-
ing IRAB (Table 1). Identification of SGs showed that both
blaOXA-23-carrying and blaOXA-24/40-carrying IRAB isolates
belonged to SG1 [9], which corresponds to international clo-
ne II [13]. These isolates also harboured the same blaOXA-51-
like gene, blaOXA-66, and belonged to ST2 (CC2) as revealed
by the MLST2 scheme [11], suggesting a close relationship
between these two groups of isolates. The blaOXA-58-carrying
IRAB isolate belonged to SG4 [19], harboured blaOXA-132 as
a blaOXA-51-like allele, and belonged to ST15 according to
the MLST2 scheme. When the MLST1 scheme [10] was
applied, it was possible to observe a distinction between
blaOXA-23-carrying and blaOXA-24/40-carrying IRAB on the
basis of gpi and gyrB allelic variants. Thus, ST92 (the former
ST22) was identified for blaOXA-23-carrying IRAB, and a novel
ST, ST98 (formerly designated ST33, and double-locus vari-
ant of ST92) was identified for blaOXA-24/40-carrying IRAB
(Table 1; Fig. 1). These STs were included together in the
CC92
(1, 3, 3, 2, 2, 7, 3)
(1, 12, 3, 2, 2, 3, 3)
(12,17,12, 1, 29, 39, 19)
FIG. 1. Clustering of Acinetobacter baumannii sequence types (STs) by eBurst, with 185 multilocus sequence typing profiles representing 304 iso-
lates from the database (http://pubmlst.org/abaumannii/, last accessed 30 July 2010). Each ST is represented as a node; the relative size of each
node is indicative of its prevalence among the isolates, and lines connect single-locus variants. Clonal complex (CC)92 is represented by a dashed
circle. STs and the corresponding allelic profiles for the 13 isolates included in the population structure study are indicated by arrows.
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worldwide predominant CC92, with 20 recognized STs,
ST92 being the most frequently reported and disseminated
[4,5] (http://pubmlst.org/abaumannii/). The available data indi-
cate that most of the bla-OXA-23-carrying IRAB isolates clus-
ter with ST92 [4,5], and are usually associated with
multidrug resistance patterns, including reports of extreme
drug resistance [1]. On the other hand, ST98 seems to be
associated only with blaOXA-24/40-carrying IRAB from Portugal
(http://pubmlst.org/abaumannii/). Moreover, with this MLST1
scheme, blaOXA-58-carrying IRAB isolates were associated
with ST103 (formerly designated ST38), a lineage with no
apparent relationship with CC92 (Table 1; Fig. 1).
In summary, our results show the current dominance of
the worldwide ST92 carrying blaOXA-23. It seems interesting
to highlight the progressive switching that occurred in our
country, as shown by the MLST1 scheme, where ST98 IRAB
carrying blaOXA-24/40 has been gradually replaced by ST92
IRAB carrying blaOXA-23. This lineage, which exhibits an
extensive multidrug resistance profile, is now emerging in
hospitals that have never before experienced the occurrence
of IRAB. It is well known that the association of CHDL
genes with mobile genetic elements favours transference
between different lineages. Curiously, we observed stability
of a specific acquired CHDL within each lineage. Although
both MLST schemes have been applied to differentiate
A. baumannii populations [4,5,10,11,13], our data point to the
higher resolution of the MLST1 scheme, which provided a
better association between epidemiological features, acquired
CHDL content and temporal distribution of the studied iso-
lates. It is reasonable to suggest that this MLST scheme
could emerge as a key epidemiological tool for future studies
of the regional and global epidemiology of A. baumannii.
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Abstract
The molecular epidemiology of 32 non-duplicate, CTX-M-15
extended-spectrum beta-lactamase (ESBL)-producing Escherichia
coli strains, isolated from clinical samples, was investigated. Mul-
tilocus sequence typing revealed multiple sequence type clonal
complexes: ST131 (12), ST405 (4), ST638 (3), ST38 (2), ST827
(2), ST224 (1), ST648 (1), ST46 (1) and two new sequence type
clonal complexes (1845 and 1848) in 22 pulsed field gel electro-
phoresis clusters. The blaCTX-M-15 gene was located on conjuga-
tive IncF plasmids. This is the first report of the worldwide
emerging clonal complex ST131 linked to blaCTX-M-15 in Tanzania
and demonstrates the need for constant surveillance in develop-
ing countries to prevent the spread of these multiresistant iso-
lates.
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Extended-spectrum beta-lactamases (ESBLs) are the predomi-
nant resistance enzymes among enterobacteriaceae and most
of the beta-lactamases described to date are plasmid-encoded
enzymes [1,2]. CTX-M is a recently described family of
ESBLs. These enzymes hydrolyze cefotaxime more effectively
than ceftazidime [3] and are also able to hydrolyze cefepime
with high efficiency. The blaCTX-M-15 allele is considered to be
the predominant allele worldwide [4,5]. Extensive studies
investigating the association of the multilocus sequence typing
(MLST) clonal complex ST131 and blaCTX-M-15 have been
reported from Canada, India, Kuwait, France, Switzerland,
Portugal, Spain, Korea and Japan; worldwide dissemination of
blaCTX-M-15 seems to be linked to this clonal complex, which
is situated in the phylogenetic group B2 [4,5].
Two studies revealed that CTX-M enzymes were present
among Enterobacteriaceae in a few isolates in Tanzania [6,7].
However, no study has investigated molecular characteristics
of Escherichia coli ESBL-producing isolates in detail from this
region of the world. For the first time we report the
existence of the ST131 and multiple other sequence type
(ST) clones carrying blaCTX-M-15 in a single tertiary hospital in
Tanzania, East Africa.
A total of 32 consecutive antimicrobial-resistant Escherichia
coli clinical isolates were recovered from various wards and
clinics in a tertiary hospital in Tanzania. Of these, 27 were
from inpatients who had been on the ward for more than
72 h when the specimens were collected, whereas five
strains were obtained from outpatients. Strains were identi-
fied as E. coli using in-house biochemical profiles [8]. Sus-
ceptibility patterns to ampicillin, amoxicillin/clavulanic acid,
sulphamethaxazole/trimethoprim, tetracycline, gentamicin,
ciprofloxacin, ceftriaxone, cefotaxime, cefepime and merope-
nem were determined by disk diffusion [9]; a disk synergy
test was performed to detect ESBL production [8]. Escherichi-
a coli ATCC 25922 was used as the quality control strain.
PCR amplification of bla genes (blaTEM, blaSHV and blaCTX-M)
was performed using primers and methods described previ-
ously [10]. All PCR products were sequenced (LGC genom-
ics GmbH, Berlin, Germany) and the resulting sequences
were compared with known sequences using DNASTAR soft-
ware (DNASTAR Inc, Madison, WI, USA) and the Basic
Local Alignment Search Tool (BLAST, National Center for
Biotechnology Information, Bethesda, MA, USA).
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Objectives: This study focused on the population structure of OXA-23-producing Acinetobacter baumannii clini-
cal isolates from Rio de Janeiro, Brazil.
Methods: The analysis included several genomic typing methods, including PFGE, two multilocus sequence
typing (MLST) schemes, sequence group (SG) determination and blaOXA-51-like sequencing. The genomic
context of the blaOXA-23 gene was also evaluated using I-CeuI hybridizations and PCR assays.
Results: Congruent clustering was obtained revealing four lineages. In accordance, four new sequence types
(STs) (ST131, ST132, ST133 and ST134) were obtained with the MLST-OD scheme (associated with the
Oxford Database) and four (ST79, ST15 and two new allelic profiles) with the MLST-IP scheme (developed by
the Institute Pasteur). Four SGs (SG1, SG4 and two new profiles) were identified, allowing the association of
70% of the isolates with European clone II. blaOXA-51-like sequencing revealed the presence of blaOXA-66,
blaOXA-69, blaOXA-95 and blaOXA-132.
Conclusions: Identification of new STs together with new SG profiles are findings suggestive of a local diversity
hotspot that is worth exploring.
Keywords: blaOXA-23, PFGE, MLST, sequence groups, blaOXA-51-like
Introduction
In recent years, Brazil has faced the emergence of multidrug-
resistant Acinetobacter baumannii with some reports implicating
the production of OXA-23 as the main carbapenem resistance
mechanism.1–3
Although several methodologies have been proposed for
assessing the genomic diversity of carbapenem-resistant
A. baumannii (CRAB) isolates, the recently developed multilocus
sequence typing (MLST) seems to represent a reliable tool for
providing consistent data on its epidemiology, especially due to
the possibility of results being compared between different lab-
oratories by easy access to international databases.4,5 Recent
MLST studies on the clonal diversity of blaOXA-23-carrying isolates
revealed their association mainly with sequence type (ST) 92
(formerly designated ST22) and with European clone II
(EU-II).6,7 A single description of an OXA-23-producing isolate
from Brazil by MLST,7 and studies reporting genomic diversity
among OXA-23-carrying CRAB determined by PFGE,1,3 constitute
the only available information regarding the Brazilian CRAB
population structure. Moreover, the relationship of most of
these isolates to the major CRAB lineages disseminated world-
wide,8 namely EU-I, EU-II and EU-III, is still unknown.
The present study reports the characterization of the
population structure of a previously published collection of
OXA-23-producing A. baumannii isolates disseminated through-
out Rio de Janeiro, Brazil.1
Material and methods
In this study, 96 OXA-23-producing A. baumannii clinical isolates col-
lected between January 2006 and September 2007, from eight hospitals
in Rio de Janeiro, Brazil, were included.1 PFGE typing was performed as
previously described,9 using ApaI restriction enzyme, and the patterns
obtained were analysed by InfoQuestTM FP version 5.4 software
(Bio-Rad Laboratories) with Dice coefficient analysis of peak positions
executed. The unweighted-pair group method using average linkages
was applied and the bandwidth tolerance was set at 1.5%. Isolates clus-
tering together with .85% level of similarity were considered to belong
to the same PFGE type.10 The PFGE types obtained were additionally
# The Author 2010. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
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compared with representative isolates that belong to ST92 (mainly
OXA-23 producers), ST98 (OXA-40 producers) and ST103 (OXA-58 produ-
cers) from Portugal and the Czech Republic (F. Grosso, S. Quinteira and
L. Peixe, unpublished results).
One isolate representing each of these PFGE types was selected and
submitted to sequence-based typing methods including PCR-based
sequence group (SG) identification,11 blaOXA-51-like sequencing
12 and two
MLST schemes.4,5 Identification of PCR-based SGs was conducted in
order to establish the association with the European A. baumannii
clones [EU-I (SG2), EU-II (SG1) and EU-III (SG3)].8,10,11 Sequence-based
typing of blaOXA-51-like genes was also performed as described pre-
viously.12 MLST analysis was conducted according to two distinct
schemes that will be referred to from now on as MLST-OD (associated
with the Oxford Database) and MLST-IP (developed by the Institute
Pasteur).4,5 Nucleotide sequences were submitted to the A. baumannii
MLST databases (MLST-OD, http://pubmlst.org/abaumannii/; and
MLST-IP, http://www.pasteur.fr/recherche/genopole/PF8/mlst/Abaumannii.
html) for assignment of allele numbers and STs. Isolates with five or
more identical alleles (MLST-OD) were considered part of the same
clonal complex (CC), according to the eBURST software program
(http://eburst.mlst.net/).13 CCs based on MLST-IP were deduced with a
minimum spanning tree analysis of A. baumannii isolates.8
The genetic location of the blaOXA-23 gene was identified using I-CeuI
digestion, transfer and hybridization with specific probes for blaOXA-23 and
16S rRNA.14 The association of the blaOXA-23 gene with the composite
transposon Tn2006 was determined using a PCR assay.14
Results and discussion
The 96 OXA-23-producing A. baumannii were grouped into four
PFGE types showing no relationship to representative carbapenem-
resistant isolates that belong to ST92, ST98 and ST103 (data not
shown). The four clusters arising from PFGE typing were also dis-
cerned by sequence-based typing methods. With MLST-OD four
new STs were detected: ST131, ST132, ST133 and ST134 (Table 1
and Figure 1). These new allelic profiles were not related to the
worldwide-predominant ST92/OXA-23 producers described in
several European countries, Korea and China (F. Grosso,
S. Quinteira and L. Peixe, unpublished results).6,7 Moreover, three
of the new STs are singletons (Table 1 and Figure 1). ST79, ST15
and two new allelic profiles were detected when MLST-IP was
applied (Table 1). The SGs identified were SG1 (the most frequently
described among OXA-23-producing isolates),7 SG4 and two new
profiles (Table 1). The blaOXA-51-like sequencing approach revealed
the presence of blaOXA-66 (the most widespread), blaOXA-69,
blaOXA-95 and blaOXA-132 (Table 1).
PFGE type A (70% of the OXA-23-producing isolates found
within seven hospitals) was assigned to ST131 (MLST-OD), ST79
(MLST-IP) and SG1, and presented the blaOXA-66 gene. ST131
belongs to CC113, which includes STs found in Argentina
(Figure 1). Although belonging to SG1 (EU-II), ST79 is not
closely related to either CC2 or ST15. These lineages were
described recently as widespread clonal clusters that include
most of the CRAB isolates.8 PFGE type B (25% of isolates) was
assigned to ST133 (MLST-OD), ST15 (MLST-IP) and SG4, and pre-
sented the blaOXA-132 gene, only previously reported in Saudi
Arabian15 and Portuguese isolates (F. Grosso, S. Quinteira and
L. Peixe, unpublished results). The identification of ST15 as an
emergent international multidrug-resistant clone8 and recently
reported for another Brazilian OXA-23-producing A. baumannii7
is worthy of note. Ta
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The representative isolate of PFGE type C (4% of isolates)
belonged to ST132 (MLST-OD), revealed new allelic profiles
when MLST-IP and SG identification were applied and presented
the blaOXA-95 gene. Finally, PFGE type D (1% of the isolates) was
assigned to ST134 (MLST-OD), also revealed new allelic profiles
with MLST-IP and SG identification, and presented the blaOXA-69
gene (Table 1).
We identified the presence of four unrelated OXA-23-
producing A. baumannii clonal lineages currently causing infec-
tions in Rio de Janeiro hospitals. Interestingly, despite the
clonal diversity, the blaOXA-23 gene was consistently found
associated with Tn2006 and was chromosomally encoded in all
isolates.
Even considering that the currently used sequence-based
typing methods can differ in their intrinsic degree of robustness,
a factor that might ultimately impair their discriminatory power,
it should be stressed that the observed pattern of results was
coherent, independent of the selected methodology, always pin-
pointing the existence of congruent clusters of isolates charac-
terized by very distinctive features. As the application of these
methods becomes more widely established, a process of
‘natural selection’ will surely narrow down the array of available
options, highlighting the advantages and drawbacks of each
approach. Simultaneously, further studies will help to validate
the applicability of each particular method at both the micro-
and the macro-geographical level.
Our results clearly highlighted the clustering of most
OXA-23-producing isolates (70%) collected in Rio de Janeiro
with EU-II.7,8,10,11 However, the detection of new STs, together
with new allelic profiles determined by SG identification, suggests
a local diversity hotspot that is worth exploring.
Funding
F. G. is a PhD student from Fundac¸a˜o para a Cieˆncia e a Tecnologia
(SFRH/BD/31647/2006). This work was also supported by grants from
FAPERJ (Fundac¸a˜o de Amparo a` Pesquisa do Estado do Rio de Janeiro)
and CNPQ.
Transparency declarations
None to declare.
References
1 Carvalho KR, Carvalho-Assef AP, Peirano G et al. Dissemination of
multidrug-resistant Acinetobacter baumannii genotypes carrying
blaOXA-23 collected from hospitals in Rio de Janeiro, Brazil. Int J
Antimicrob Agents 2009; 34: 25–8.
2 Dalla-Costa LM, Coelho JM, Souza HA et al. Outbreak of
carbapenem-resistant Acinetobacter baumannii producing the OXA-23
enzyme in Curitiba, Brazil. J Clin Microbiol 2003; 41: 3403–6.
3 Martins AF, Kuchenbecker R, Sukiennik T et al. Carbapenem-resistant
Acinetobacter baumannii producing the OXA-23 enzyme: dissemination
in Southern Brazil. Infection 2009; 37: 474–6.
4 Bartual SG, Seifert H, Hippler C et al. Development of a multilocus
sequence typing scheme for characterization of clinical isolates of
Acinetobacter baumannii. J Clin Microbiol 2005; 43: 4382–90.
25
147 128 13 14
5336
110
35
30
11
129
2914112328
1
79
39
93
44
91
34
22
20 9
76
8875
74 90
CC92
138
118
6 5
98 130
27
21
102
100
113
114
CC113
131
136
137
122
106
10
4
92
146
127
31
24
54
61
26
38
51
71
69
7080
132
134
37
57
81
19
48
83
8
41 12
64
42
43
49 50 52 55
18 66
56
58
59
67
60
62
65
115
145
144
94 82
78112
120
15
40
111
2
84
96
87
117
133
103
104
107
85 86
68
77
101
119 139
121
124
99
14097
108
109 16
32
33
46
47
17
95
142
116
7
143
126
135
105
3
7223
63 73
125
45
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abaumannii/; 30 June 2010, date last accessed). Each ST is represented as a node (the relative size of each node is indicative of its prevalence among
the isolates) and lines connect single-locus variants. CC92 and CC113 are shown in circles. STs determined for isolates from the present study are
indicated by arrows.
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Abstract 
Objectives The aim of this study was to characterize the genetic determinants of 
carbapenem resistance and the molecular epidemiology of multidrug-resistant (MDR) 
Acinetobacter baumannii isolates involved in an outbreak at the University Hospital of 
Pilsen, Czech Republic. 
Methods. Nine non-repetitive isolates representative were selected from a total of 97 
clinical isolates collected in different units involved in the outbreak– Cardiosurgery 
(n=5), Surgery (n=3) and Pulmonary (n=1). These isolates were characterized in what 
concerns their antimicrobial susceptibility, carbapenem resistance determinants and 
clonal relatedness by Apa I-PFGE, blaOXA-51-like type identification and two MLST 
schemes.  
Results. Isolates were resistant to all β-lactams, with the exception of one isolate 
susceptible to meropenem, and to ciprofloxacin. The susceptibility to aminoglycosides 
was variable and all isolates were susceptible to colistin. Although ISAba1 has been 
found upstream of blaOXA-66 in all isolates, no carbapenemase activity was detected and 
carbapenem resistance could not be associated with an efflux system. Two isolates 
revealed the insertion sequence ISAba1 disrupting the carO gene but presented 
completely different MICs to carbapenems.  PFGE indicated a common pattern, and 
the two MLST schemes clustered the isolates on ST92/ST2. 
Conclusions. Spread of ST92/ST2 A. baumannii, a globally disseminated lineage, was 
responsible for the emergence of carbapenem resistance in this hospital. Particular 
features of this lineage might contribute for its success and prevalence; however the 
carbapenem resistance mechanism could not be elucidated. 
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Multidrug-resistant (MDR) Acinetobacter baumannii has emerged as a major 
nosocomial infectious agent. Resistance to carbapenems, tigecycline and colistin is of 
particular concern, decreasing the therapeutic options for the treatment of A. baumannii 
infections. Carbapenem resistance has been mainly attributed to the production of 
carbapenem hydrolysing class D β-lactamases (CHDLs) (4, 7, 12). Non-enzymatic 
mechanisms such as penicillin-binding proteins (PBPs) modification, overexpression of 
efflux pumps like AdeABC, and the decreased expression of some porins, may play an 
important role in the resistance to this antibiotic, both alone or acting in synergy with β-
lactamases. For instance, the inactivation of carO gene, involved in the OM permeation 
of L-ornithine, a basic amino acid that displays structural similarity with carbapenems, 
have been associated with resistance to this class of antibiotics (8).  
Since 2003 was observed a rise on A. baumannii resistant to carbapenems in several 
hospitals from Czech Republic. This emergence was associated with the spread of A. 
baumannii strains of European clone II, belonging to sequence type (ST) 2 and ST47 
according to Acinetobacter MLST scheme from Institut Pasteur, with isolates carrying 
blaOXA-58-like, blaOXA-24-like or ISAba1 adjacent to blaOXA-51-like (9). 
At the University Hospital in Pilsen, carbapenem resistant A. baumannii isolates were 
firstly identified in 2005, but by the end of 2007 a dramatic increase in infections 
caused by multidrug-resistant (MDR) A. baumannii was observed in different units.  
In this study we investigate the clonal relatedness and carbapenem resistance 
determinants of MDR A. baumannii isolates recovered during this outbreak. 
 
In the beginning of 2008, 1-month survey of carbapenem resistant strains of A. 
baumannii was performed at the University Hospital in Pilsen, Czech Republic. From a 
total of 97 isolates collected during this period, nine non-repetitive multidrug-resistant 
isolates were selected from different units involved in the outbreak– Cardiosurgery 
(n=5), Surgery (n=3) and Pulmonary (n=1) (Table 1). Seven of them were associated 
with clinically manifested infections.  Isolates identification was performed with the 
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Vitek 2 system and confirmed by16S rRNA gene sequencing and by the detection of 
blaOXA-51-like (6,11).  
Minimum Inhibitory Concentrations (MICs) to imipenem and meropenem were 
performed with E-test (AB-Biodisk, Sweden). MICs to gentamicin, amikacin, 
ciprofloxacin, and colistin were determined by standard microdilution broth 
method.  Results were interpreted according to EUCAST recommendations 
(http://www.eucast.org/clinical_breakpoints/). 
MBLs genes (blaIMP and blaVIM) and CHDL genes (blaOXA-23-like, blaOXA-24-like, blaOXA-58-like, 
and blaOXA-143) were sought by PCR (3, 12). Carbapenemase activity was investigated 
by a bioassay method and by spectrophotometry (4). Imipenem susceptibilitiy in the 
absence and presence of one-half of the MIC for the efflux pump inhibitor carbonyl 
cyanide m-chlorophenylhydrazone (CCCP) was examined in all isolates (Shi, 2005). 
Sequence analysis of carO gene was performed after amplification with primers 
described by Mussi et al, 2011 (8) in three representative isolates (RC-Ab1, RC-Ab2 
and RC-Ab6; Table 1). 
Pulsed-field gel electrophoresis (PFGE) was performed with the ApaI restriction 
enzyme, and pattern analysis was conducted with InfoQuestTM FP v5.4 (BioRad 
Laboratories, Hercules, CA, USA). Isolates clustering together with >85% similarity 
levels were considered to belong to the same PFGE type.  Sequence-based typing of 
blaOXA-51-like gene was performed as previously described (7) and the presence of 
ISAba1 upstream this gene was sought by PCR (10) and confirmed by sequencing. 
MLST analysis was conducted according to two distinct schemes that will be referred 
from now on as MLST1, developed by Bartual et al., 2005 (1) and MLST2, published by 
Nemec et al, 2008 (9).  
 
Isolates were resistant to ciprofloxacin and carbapenems with exception of one isolate 
(RC-Ab1) that was susceptible to meropenem (MIC=2 mg/L). The susceptibility to 
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aminoglycosides was variable and all isolates were susceptible to colistin. The main 
characteristics of A. baumannii isolates used in this study are summarized in Table 1. 
PFGE indicated related patterns and computer-assisted analysis revealed similarity 
values >95% for the studied isolates. 
MLST1 and MLST2 schemes clustered the isolates in the ST92 and ST2 respectively, 
which correspond to worldwide disseminated lineages (5, 7).  
The isolates presented the naturally occurring blaOXA-66 gene with the insertion 
sequence ISAba1 located upstream this gene. We did not observed any known 
acquired carbapenemase genes, which was confirmed by the absence of 
carbapenemase activity investigated both by bioassays and spectrophotometry. 
It was not observed any reduction in MIC values after the addition CCCP excluding the 
role of protonic efflux pumps overexpression in the carbapenem resistance of these 
isolates (10). 
PCR amplification with carO-specific primers yielded the expected fragments of ca. 750 
bp for all isolates except for RC-Ab1 and RC-Ab4 that displayed a fragment with ca 
1900 bp. Sequence analysis of carO gene for RC-Ab2 and RC-Ab6, taken as 
representative of carbapenem-resistant isolates, revealed the absence of stop codons. 
On the other hand, for RC-Ab1 isolate, which displayed lower carbapenem MIC values, 
carO gene was disrupted by the insertion sequence ISAba1 at the nucleotide 462. This 
way, carbapenem resistance could not be attributed to alterations observed on carO 
nucleotide sequence. It is worth to note that in the majority of reports referring carO 
disruption as being responsible for non-susceptibility to carbapenems the analysed 
isolates also presented additional resistance mechanisms, such as acquired 
carbapenemases or efflux pumps overexpression. In addition, reports referring carO 
gene alterations, even in the absence of carbapenemase activity, as being associated 
with carbapenem resistance, did not investigate the role of other non-enzymatic 
mechanisms (Mussi, 2005).  
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In summary, our results confirm the current dominance and global dissemination of the 
ST92/ST2 lineage and its association with the increasing of multi-drug resistant A. 
baumannii infections observed in several wards of University Hospital in Pilsen. Some 
studies suggest that the presence of ISAba1 upstream blaOXA-66 might be responsible 
for the carbapenem resistance, but it was not observed any carbapenemase activity in 
these isolates. Carbapenem resistance could not be attributed to alterations observed 
in the carO gene. Probably an additional unidentified resistance mechanism was the 
main responsible for the resistance observed to carbapenems. 
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Table 1. Characteristics of A. baumannii isolates 
    Clonality analysis  Antimicrobial susceptibility pattern – MIC 
(mg/L) 
Isolate Ag
e 
Department Specimen PFGE MLST1 MLST2 OXA-51-type 
 IPM MEM CIP AMK GEN COL 
RC-
Ab1 
63 Surgery - ICU1 bronchoalveolar 
lavage 
A ST92 ST2 OXA-66  4 2 4 4 1 0.5 
RC-
Ab2 
73 Cardiosurgery - 
ICU 
sputum  A ST92 ST2 OXA-66  >32 16 16 4 0.25 0.5 
RC-
Ab3 
73 Cardiosurgery - 
ICU 
urine  A ST92 ST2 OXA-66  >32 16 16 4 0.25 0.5 
RC-
Ab4 
69 Cardiosurgery - 
ICU 
sputum  A ST92 ST2 OXA-66  >32 32 16 4 16 0.5 
RC-
Ab5 
78 Cardiosurgery - 
ICU 
sputum  A ST92 ST2 OXA-66  8 16 16 2 32 0.5 
RC-
Ab6 
71 Cardiosurgery - 
ICU 
sputum  A ST92 ST2 OXA-66  8 16 16 8 32 0.5 
RC-
Ab7 
62 Surgery - ICU2 wound A ST92 ST2 OXA-66  >32 8 8 16 16 0.5 
RC-
Ab8 
59 Surgery wound A ST92 ST2 OXA-66  8 16 8 32 >32 0.5 
RC-
Ab9 
73 Pulmonary catheter A ST92 ST2 OXA-66  8 8 16 4 8 0.5 
 
IPM, imipenem; MEM, meropenem; CIP, ciprofloxacin; AMK, amikacin; GEN, gentamicin; COL, colistin.  
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Emergence of an extreme-drug-resistant (XDR)
Acinetobacter baumannii carrying blaOXA-23 in
a patient with acute necrohaemorrhagic
pancreatitis
Madam,
Acinetobacter baumannii is an opportunistic pathogen often
associated with serious nosocomial infections and, more recently,
with community-acquired pneumonia.1–3 Although carbapenems
and aminoglycosides have been traditionally used in the treatment
of these infections, resistance to these antibiotics is now a common
occurrence, with Portugal presenting a leading position in terms of
incidence rates.1–3 The acquisition of OXA-type carbapenemases
(OXA-23, OXA-40 and OXA-58) is the main documented carbapen-
emase resistance mechanism, with numerous outbreaks occurring
in hospitals worldwide.1–4 The few remaining therapeutic options
include tigecycline and ‘old’ polimyxins, despite previous with-
drawal because of reports of nephrotoxicity and neurotoxicity.
Even with these therapeutic alternatives, an increasing recovery
of multidrug-resistant (MDR) A. baumannii isolates has been
observed.1–3,5 As recently predicted, the emergence of an A. bau-
mannii isolate with resistance to all available antibiotics (extreme
drug resistance: XDR) is considered an alarming occurrence.5
Four A. baumannii isolates were recovered from a 37-year-old
woman with a history of alcohol abuse, admitted, in 2006, in the
emergency ward of the Hospital S. Teoto´nio, Viseu, Portugal, with
acute necrohaemorrhagic pancreatitis. Therapy was initiated with
meropenem and ﬂuconazole on the day of admission. Nine days
after meropenem administration, Enterococcus faecium, Entero-
coccus casseliﬂavus and A. baumannii (HST1) isolates were recov-
ered from intraperitoneal ﬂuid. Another A. baumannii isolate
(HST1a) was obtained from blood samples, revealing an identical
susceptibility proﬁle to that of HST1, including resistance to all
available antibiotics, except amikacin. Therapy was replaced by
a combination of ampicillin and amikacin, for 19 days, maintain-
ing prophylaxis with ﬂuconazole. Nine days after changing
therapy a pancreatic abscess was drained. Cultures of the intra-
peritoneal ﬂuid revealed A. baumannii colonies (HST2 and
HST3) presenting not only an MDR pattern similar to that of
HST1, but also resistance to amikacin (Table I). HST2 and HST1
were further characterised. The patient was discharged after 18
weeks of hospitalisation. Identiﬁcation of the isolates was per-
formed both with the Vitek system and 16S rRNA gene
sequencing. A multiplex polymerase chain reaction (PCR) for
the carbapenemase genes blaOXA-23-like, blaOXA-24-like, blaOXA-51-
like, blaOXA-58-like was conducted, producing positive results for
blaOXA-23-like and blaOXA-51-like.
1 The blaOXA-23 complete gene
was conﬁrmed by PCR and sequencing using the primers
OXA-23fwd-50-ATGAATAAATATTTTACTTGC-30, OXA-23rev-50-
TTAAATAATATTCAGCTGTTT-30. The association of the blaOXA-23
gene with the composite transposon Tn2006 was determined
by PCR and a chromosomal location for this gene was observed
by I-CeuI technique.1 HST1 and HST2 revealed the same pulsed-
ﬁeld gel electrophoresis pattern, suggesting the in-vivo acquisi-
tion of resistance to amikacin during therapy. Even though the
main aminoglycoside resistance mechanism in A. baumannii
usually relates to integron inserted genes coding for aminoglyco-
side-modifying enzymes, these isolates revealed integrons with
w500 bp incompatible with the presence of gene cassettes.
Detection of genes coding both for aminoglycoside-modifying
enzymes and for 16S methylase Arm A was also negative.1 PCR
ampliﬁcation and sequencing of the regulatory genes for the
AdeABC efﬂux pump, adeS and adeR, were performed for HST1
and HST2 isolates, revealing the adeR substitutions already asso-
ciated with overexpression of the efﬂux pump, namely in the
residues 120 (isoleucine), 142 (leucine) and 158 (histidine).2
Reverse transcription–PCR assays for adeB gene expression were
performed using 16S RNA as a housekeeping gene, and A. bau-
mannii ATCC 19606 as a control strain. The results support the
overexpression of AdeABC efﬂux pump, which might explain
the observed tigecycline resistance. However, these overexpres-
sion levels were identical for both HST1 and HST2 isolates, which
does not allow the association of the efﬂux pump overexpression
with the acquired resistance to amikacin.2 Also, further assays
with the protonic efﬂux pump inhibitor carbonyl cyanide-
m-chlorophenylhydrazone, CCCP [16 mg/L; corresponding to
a quarter of minimum inhibitory concentration (MIC)], did not
demonstrate any effect on amikacin MIC levels.
Considerable debate on the proper terminology to be applied to
the degree of multidrug resistance in A. baumannii is still ongoing.
Whether called pandrug, extreme or extensively drug resistant, it
is crucial to differentiate strains that are truly resistant to all avail-
able therapeutic options.3,5,6 Recent reports of truly XDR A. bauman-
nii strains include OXA-23-producing isolates in South Korea,
several isolates from Spain, and one in the USA.3,4,6 Here, we show
the in-vivo evolution of an MDR A. baumannii isolate into an XDR,
after resistance enhancement to amikacin. This is the ﬁrst descrip-
tion of OXA-23 carbapenemase in Portugal, which may contribute
to an increase in the frequency of isolation of carbapenem-resistant
A. baumannii isolates. Our results also highlight the inactivity of
colistin and tigecycline, recently used as the last therapeutic options
for MDR A. baumannii infections. The emergence of XDR isolates, in
widely disparate regions, is worrying and suggests a spreading
pattern that will force public health agents to think globally.
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Table I
Antimicrobial susceptibility patterns of A. baumannii HST1 and HST2 clinical isolates
Antibiotic MIC (mg/L)a
HST1 HST2
Amoxicillin >256 >256
Amoxicillin–clavulanic acid >256 >256
Ticarcillin >256 >256
Ticarcillin–clavulanic acid >256 >256
Piperacillin >256 >256
Piperacillin–tazobactam >256 >256
Ceftazidime 64 64
Cefotaxime >256 >256
Cefpirome >256 >256
Cefpime >32 >32
Cefoxitin >256 >256
Cefalotin >256 >256
Imipenem >32 >32
Meropenem >32 >32
Colistin 32 32
Minocyclin 32 32
Tigecycline 16 32
Amikacin 16 64
a Minimum inhibitory concentrations (MICs) of b-lactams were determined by
the Etest method; for colistin, minocycline, tigecycline and amikacin the agar
dilution method was applied.7
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Effectiveness of podcasts as an adjunct learning
strategy in teaching clinical microbiology among
medical students
Madam,
The use of information and communication technologies is an
increasingly important aspect of medical education, with many
universities offering a variety of web-based teaching resources.1
Educational podcasts, which are audio or visual recordings of items
such as lectures, are increasing in number. The advantage of pod-
casts is that they are easy to use, can be accessed at any time and
carry the potential for adding new collaborative dimensions to
educational tools for students.
As podcasts are an emerging area of medical education, their
true potential is unknown. Whereas there are studies which have
assessed students’ experience and response to podcasts, there are
no studies which assess students’ knowledge of selected topics
before and after the release of podcasts.1–3 We aimed to assess
the impact of podcasts as an educational tool by ascertaining
whether podcasts have a positive impact on students’ knowledge
of key areas of a curriculum when described in a podcast.
A total of 260 third-year medical students in the Royal College
of Surgeons in Ireland studying clinical microbiology were asked
to participate in the study, which was carried out from
September 2008 to May 2009. A series of 18 podcasts were
recorded on individual microbiology topics, e.g. antibiotic treat-
ment of selected infections, prevention of healthcare-associated
infections, etc. Topics selected were those which the department
felt were important to emphasise, and formed an adjunct to
didactic lectures and tutorials. Each podcast, which was devel-
oped as an audio podcast, lasted 5–10 min in duration and
was recorded using Camtasia (TechSmith, Okemos, MI, USA)
and subsequently placed on our course management website,
Moodle, which allowed students to listen to or download the
podcast.
A short online quiz incorporating 10 multiple choice questions
relating to points covered in the podcast was devised for each
podcast. It was made clear to the students that although the
quizzes were not compulsory the department expected the
students to partake in the study and avail of the podcasts as an
additional educational tool. Over the nine-month period the pod-
casts and quizzes were released one week following completion of
lectures and tutorials on the topic. Initially students completed
a quiz relating to information contained in the podcast one day
before the release of the podcast. The quiz was then closed and
the podcast on the topic released. Following release of the pod-
cast, students performed the same quiz ﬁve days later. The
number of students completing the quizzes and the quiz results
were then recorded and analysed (Student’s t-test, Microsoft
Excel).
An average of 138 students (range: 74–202), from a class of
260, completed the pre- and post-podcast quizzes. The average
score (out of 10) of the 18 quizzes released before the podcast
was available was 4.94 (range: 2.5–7.3), whereas the average
score of the post-podcast quizzes was 6.0 (range: 4.2–8.5). This
represents a statistically signiﬁcant improvement in the post-
podcast quiz score (P< 0.01). The percentage difference between
pre- and post-podcast quizzes is illustrated in Figure 1. When
analysing all quiz results there was an average increase of
18.5% in the post-podcast quiz, and in all but one quiz series
there was an increase in the students’ scores in the post-podcast
quiz.
Studies on the use of podcasts in medical education report
a favourable response among students to such alternative
methods of course delivery. Pilarski et al. found that podcasts
aided students to learn course material.2 Shantikumar et al. inves-
tigated the perceptions of podcasts among students and
concluded that podcasts showed promise as a revision aid that
could be incorporated into the undergraduate curriculum.3 This
is the ﬁrst study to evaluate the educational beneﬁt of podcasts
by using an assessment of student knowledge before and after
access to a podcast. A limitation of this study was that the assess-
ments and uploading of podcasts by students was not compulsory,
which may indicate a bias in our results as only the motivated and
enthusiastic students may have taken part in the study. However,
we would argue that as there was a statistical improvement in our
study, which may have included a disproportionate number of
good students, these ﬁndings could also be extrapolated to poorer
students.
Although podcasts are not designed to replace traditional
teaching methods such as lectures and real-time classroom inter-
actions, we believe that podcasts and similar technological
advances have a key role to play in enhancing the learning expe-
rience for students and that, as we have shown in this study,
they increase the students’ knowledge of key areas of their
course.
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II. Contribution of mobile genetic elements for the dissemination of carbapenem 
resistance among Acinetobacter spp. 
The characterization of blaOXA-24/40-carrying plasmids and blaIMP-5 genetic environments, 
exploring the role of horizontal gene transfer in the dissemination of carbapenem 
resistance, was conducted and the collected data is presented and discussed within 
this chapter. 
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Role of Common blaOXA-24/OXA-40-Carrying Platforms and Plasmids in
the Spread of OXA-24/OXA-40 among Acinetobacter Species Clinical
Isolates
Filipa Grosso,a Sandra Quinteira,a,b,c Laurent Poirel,d Ângela Novais,a and Luísa Peixea
REQUIMTE, Laboratório de Microbiologia, Faculdade de Farmácia, Universidade do Porto, Porto, Portugala; Centro de Investigação em Tecnologias da Saúde (CITS)/IPSN
(CESPU), Vila Nova de Famalicão, Portugalb; Centro de Investigação em Biodiversidade e Recursos Genéticos (CIBIO), Vairão, Portugalc; and Service de Bactériologie-
Virologie, INSERM U914, Emerging Resistance to Antibiotics, Hôpital de Bicêtre, South-Paris Medical School, K.-Bicêtre, Franced
The spread of OXA-24/OXA-40 (OXA-24/40)-producing Acinetobacter spp. in the Iberian Peninsula has been strongly influ-
enced by clonal expansion, but the role of horizontal gene transfer has scarcely been explored. blaOXA-24/40-carrying plasmids
and genetic environments were characterized in representative (n 15) Acinetobacter species clinical isolates (obtained between
2001 and 2007) by Acinetobacter baumannii PCR-based replicon typing, sequencing, hybridization, and restriction fragment
length polymorphism. Besides the identification of blaOXA-24/40 within the chromosomes of some isolates, the circulation of com-
mon blaOXA-24/40-carrying plasmids (30-kb repA_AB; 10-kb aci2) and genetic backbones among Acinetobacter spp. was
demonstrated.
Carbapenem resistance in Acinetobacter spp. has been mostlyassociated with the production of OXA-23, OXA-24/OXA-40
(OXA-24/40), and OXA-58 carbapenem-hydrolyzing class D
-lactamases (1, 3, 5–12). Whereas OXA-23- and OXA-58-pro-
ducing Acinetobacter baumannii are widely disseminated (3, 6,
12), OXA-24/40 producers have been reported mainly as endemic
in the Iberian Peninsula, where the ongoing spread of OXA-24/40
since 1995 has been explained by clonal expansion (6, 10). In
addition, there have been reports of sporadic cases in Italy and
France and of outbreaks in the United States (5, 7, 8). Recently,
some studies demonstrated the mobilization of blaOXA-24/40 by
lateral gene transfer events (1, 5, 9, 10). In this study, the charac-
terization of the diversity of OXA-24/40-encoding plasmids and
the genetic environment of the blaOXA-24/40 genes was conducted
in A. baumannii and Acinetobacter haemolyticus clinical isolates
from Portugal.
Fifteen representative OXA-24/40-producing Acinetobacter
spp. isolates (13A. baumannii and 2A. haemolyticus) were selected
from a collection of 157 carbapenem-resistant Acinetobacter spe-
cies clinical isolates from two geographically distant Portuguese
hospitals (obtained between 2001 and 2007), (i) Hospital Geral de
Santo António (HGSA) and (ii) Centro Hospitalar da Cova da
Beira (CHCB) (Table 1) (6). Isolates were identified with the Vitek 2
system and 16S rRNA gene sequencing. Detection of the blaOXA-24/40
gene was performed as previously described (6, 10). Antibiotic
susceptibility testing was done by Etest and the disk diffusion
method following CLSI guidelines (4). Isolates were chosen on the
basis of their ApaI pulsed-field gel electrophoresis (PFGE) pat-
terns (4 subtypes arbitrarily designated A [n  4; obtained be-
tween 2001 and 2004 from HGSA], A1 [n 3; obtained between
2006 and 2007 from CHCB], A3 [n  5; obtained in 2006 from
HGSA], and A4 [n 1; obtained in 2003 from HGSA]) and plas-
mid content (1 to 3 plasmids ranging from 10 kb to 90 kb). They all
belonged to the ST98 lineage (6) according to the multilocus se-
quence typing (MLST) scheme proposed by Bartual et al. (2)
(http://pubmlst.org/abaumannii/). This sequence type (ST) is a
double-locus variant of the worldwide-disseminated ST92, which
is endemic in Portuguese hospitals and has been identified in
other European countries associated with the production of dif-
ferent OXA types (6, 12). Conjugative transfer (solid, 37°C) and
transformation by electroporation were conducted in a subset of
isolates using A. baumannii ATCC 19606, Escherichia coli K-12
BM21 (rifampin and nalidixic acid resistant, plasmid free), or
Acinetobacter baylyiADP1 as the recipient strain, as described pre-
viously (5). Transconjugants and transformants were selected using
tryptic soy agar (TSA) plates supplemented with rifampin (100 g/
ml) and/or ampicillin (30 g/ml) or imipenem (0.5 to 1 g/ml), as
reported. The location (chromosome/plasmid) of blaOXA-24/40 was
assessed by hybridization of I-CeuI and S1 gels with specific
probes (blaOXA-24/40, 16S rRNA genes) in the wild-type and trans-
formant strains. Plasmid characterization was further accom-
plished by the recently proposed PCR-based replicon typing
scheme for A. baumannii plasmids (AB-PBRT), sequencing and
hybridization with replicase (rep) probes (3), and restriction frag-
ment length polymorphism (RFLP) (EcoRI, BamHI, or HindIII).
An in silico comparative analysis of six fully sequenced and
one partially sequenced Acinetobacter species blaOXA-24/40-car-
rying plasmids deposited in the GenBank database (pABVA01,
pMMCU3, pMMCU1, pMMCU2, pMMD, pAB02, and
pMMA2, with the respective accession numbers NC_012813.1,
GQ904227.1, GQ342610.1, NC_013506.1, GQ904226.1,
AY228470.1, and GQ377752.1) was performed at the NCBI
website using the BLAST software and the nucleotide database
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). Based on those se-
quences, the vicinity of the blaOXA-24/40 gene was characterized
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in representative plasmids from our collection by a PCR map-
ping strategy and further sequencing (Fig. 1).
A. baumannii isolates were resistant to almost all -lactams,
showing variable susceptibility to aztreonam, whereas A. haemo-
lyticus isolates (n 2) exhibited resistance to all -lactams except
cefepime, ceftazidime, and aztreonam. All isolates were resistant
to ciprofloxacin, whereas susceptibility to aminoglycosides and
tetracycline was variable, according to CLSI guidelines (Table 1)
(4). As consistently observed in other studies, attempts to obtain
OXA-24/40-producing transconjugants were unsuccessful (9).
Transformants were obtained forA. baumannii isolates belonging
to PFGE type A (n  1) and PFGE type A4 (n  1) and one A.
haemolyticus isolate by usingA. baylyiADP1 as the receptor strain,
and they acquired resistance to all -lactams except ceftazidime,
aztreonam, and cefepime. Resistance to other groups of antibiot-
ics was not cotransferred. Variable plasmid size (90 kb, 70 kb, 30
kb and/or 10 kb) and rep content (GR2 group aci2 and/or aci6
and/or GR12 group repA_AB) were observed among the different
species and PFGE types. The blaOXA-24/40 gene was identified
within distinct plasmids (70 to 90 kb and 30 kb, 90 kb and 10 kb, 30
kb, or 10 kb) and additionally within the chromosomes of someA.
baumannii and A. haemolyticus isolates (Table 1).
Highly related 30-kb blaOXA-24/40-carrying plasmids (arbi-
trarily designated RFLP pattern A) were identified in A. bauman-
nii (PFGE subtypes A and A3) and A. haemolyticus isolates col-
lected within the same hospital (obtained between 2001 and 2006)
(Table 1). These plasmids belonged to the GR12 group (3) and
showed rep content (100% identity to repA_AB) and sequences
surrounding blaOXA-24/40 identical to those of the partially se-
quenced prototype pAB02 plasmid (GenBank accession number
AY228470.1) (Fig. 1). A module consisting of an open reading
frame (ORF) of unknown function, the replicase repA_AB, oriV,
andmobA (represented within a rectangle in Fig. 1) was also found
within that structure. Interestingly, it has been previously identi-
fied in other 10-kb repA_AB plasmids and seems to be a recurrent
platform in plasmids (10 kb/30 kb) from different A. baumannii
clones and Acinetobacter species in several European countries
(Portugal, Spain, and France) (Fig. 1) (1, 9). The presence of mob
genes probably facilitates plasmid mobilization by self-transmis-
sible plasmids and may ultimately explain their occurrence in
non-A. baumannii species (3, 9, 10).
A 10-kb OXA-24/40-encoding plasmid (arbitrarily designated
RFLP pattern B) was also frequently identified amongA. bauman-
nii isolates (PFGE subtypes A1, A3, and A4) collected from differ-
ent hospitals (obtained between 2003 and 2007) (Table 1). This
plasmid belonged to the GR2 group (3), with a rep sequence iden-
tical to that of aci2 and a blaOXA-24/40 genetic environment closely
related to those from the pABVA01 and pMMCU3 plasmids
(GenBank accession numbers NC_012813 and GQ904227.1, re-
spectively) identified in A. baumannii isolates from Italy and
Spain, respectively (1, 5, 9).
The same rep genes (GR2, GR6, and GR12) have been pre-
sumptively associated with other OXA-24/40-producing A. bau-
mannii plasmids from Portugal and Spain by AB-PBRT, thus sug-
gesting the circulation of a common plasmid pool (3, 12). Both
blaOXA-24/40 genes and larger contiguous modules are flanked by
XerC/XerD-like binding sites (Fig. 1), which might be responsible
for their mobilization (5, 9) and may explain the identification of
blaOXA-24/40 and/or common modules in different plasmid scaf-
folds or in chromosomes. Furthermore, the variability observed in
the number and location of the orfof unknown function, oriV, and
iteron sequences suggests frequent recombinatorial events (5, 9).
This study not only confirms the horizontal transmission of com-
mon resistance modules between Acinetobacter plasmids but also
highlights interspecies plasmid transfer. Although conjugative
transfer was not detected, the aci6 replicase (GR6; 100% identity
to that of plasmid pACICU2 [GenBank accession number
NC_010606]) was able to mediate horizontal transfer of antibiotic
resistance plasmids, as previously suggested (3, 12). Moreover, a
recently described mechanism involving the release of outer
membrane vesicles harboring blaOXA-24/40-carrying plasmids
might also shed some light on this process (11). It is interesting to
highlight that the blaOXA-24/40 genetic environment and plasmid
types are different from those observed for blaOXA-23 or blaOXA-58,
thus suggesting independent acquisition and subsequent selection
events (3, 12).
TABLE 1 Epidemiology and plasmid characterization of representative OXA-24/40-producing Acinetobacter species clinical isolates from Portugal
Species
PFGE subtype
(no. of
isolates)
Yr(s) of
isolation Hospitala
blaOXA-24/40 plasmid
size(s) (kb)b
(RFLP profile)
(no. of isolates) rep contentb (plasmid size [kb]) Antibiotic resistance profiled
A. baumannii A (4) 2001–2004 HGSA 90, 30 (A) (3) repA_AB (30), repAci2, repAci6 CAZ, ATM, IPM, MEM, PIP, FEP,
CIP, TOB, TET, MIN
2001–2004 HGSA 70, 30 (ND) (1) repA_AB (30), repAci2, repAci6 CAZ, ATM, IPM, MEM, PIP, FEP, CIP
A1 (3) 2006–2007 CHCB 10c (B2) (3) repA_AB, repAci2 (10), repAci6 CAZ, ATM, IPM, MEM, PIP, FEP, CIP
A3 (5) 2006 HGSA 90, 10 (B2)c (1) repA_AB, repAci2 (10), repAci6 CAZ, ATM, IPM, MEM, PIP, FEP,
CIP, (TOB)2006 HGSA 30 (A1) (4) repA_AB (30), repAci2, repAci6
A4 (1) 2003 HGSA 30 (ND), 10 (B)c (1) repA_AB, repAci2 (10) CAZ, ATM, IPM, MEM, PIP, FEP,
CIP, MIN
A. haemolyticus (2) 2002 HGSA 90, 30 (A1=)c (2) repA_AB (30), repAci2 IPM, MEM, PIP, CIP, TOB, TET
a HGSA, Hospital Geral de Santo António (Northern region); CHCB, Centro Hospitalar da Cova da Beira (Center region).
b Plasmid number, size, type, and rep content were determined by RFLP, PCR, and hybridization of S1- and I-CeuI-digested genomic DNA with specific probes (blaOXA-24/40,
repAci2, rep_AB, and repAci6). ND, not done. Plasmids harboring blaOXA-24/40 appear in bold. Plasmid transfer by transformation is shown as underlined.
c The blaOXA-24/40 probe additionally hybridized in a chromosomal band.
d Parentheses indicate variability of a given resistance determinant. Resistance among transformants is represented by underlining. Abbreviations: CAZ, ceftazidime; ATM,
aztreonam; IPM, imipenem; MEM, meropenem; PIP, piperacillin; FEP, cefepime; CIP, ciprofloxacin; TOB, tobramycin; TET, tetracycline; MIN, minocycline.
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In this study, common blaOXA-24/40-carrying plasmids (30-kb
repA_AB and 10-kb aci2) were identified among representative
ST98 A. baumannii and A. haemolyticus clinical isolates collected
over a large period of time (2001 to 2007). In addition, with a
systematic in silico analysis, we were able to identify the same
plasmid types and closely related blaOXA-24/40 genetic sur-
roundings in OXA-24/40-producing isolates from different
European countries. These findings, together with some previ-
ous evidence for horizontal gene transfer of blaOXA-24/40-carry-
ing modules, strongly supports the role of common platforms
and plasmids in the dissemination process of OXA-24/40
among Acinetobacter spp.
Nucleotide sequence accession numbers. The nucleotide se-
quences obtained in this study that correspond to the representa-
tive 30-kb repA_AB (pAC63) and 10-kb aci2 (pAC92) OXA-24/
40-encoding plasmids have been submitted to the GenBank
database (GenBank accession numbers JN982951 and JN982952,
respectively).
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Sir, 
The survival chances of premature infants have remarkably increased with the 
development of incubators. Nevertheless, the thermoneutral environment provided by 
these devices increases the risk of microbial infection, which is also associated with the 
growing proportion of very low birth weight neonates and with the invasive 
diagnostic/therapeutic procedures they undergo. As a result, nosocomial infections 
remain important and critical issues related to high morbidity and mortality in high-risk 
neonates, a very unique population that naturally present immaturity of immune system 
and impaired defense mechanisms (8). 
Most nosocomial infections in neonatal intensive care units (NICU) have been 
attributed to Acinetobacter species, which surprisingly and successively evolved, within 
the last decades, from traditionally harmless organisms into important nosocomial 
pathogens (5, 6, 8). Additionally, the spread of multidrug resistant strains became a 
worldwide threat and, with extremely limited therapeutic options, carbapenems emerged 
as last resource to treat Acinetobacter-causing infections. Unfortunately, A. baumannii 
strains resistant to all known antibiotics have now been reported and carbapenem 
resistance within this genus is now a global phenomenon (6).  
Acinetobacter species other than A. baumannii, although less frequently reported in 
neonatal population, are also known to play a role within the clinical setting (5, 7-9). In 
fact, its prevalence as etiologic agents of nosocomial infections has increased in last 
years, as demonstrated by Acinetobacter lwoffii, a commensal organism found on 
human skin, perineum and oropharynx. This species has been associated with catheter-
related bloodstream infections in immunocompromised patients and with bacteremia 
associated with community-acquired gastroenteritis and gastritis (9).  
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Both the increased resistance to irradiation observed for A. lwoffii (which raises 
concerns about the efficacy of sterilization of medical devices by this method) together 
with the species ability to acquire foreign genetic determinants might partially explain 
the current emergence of this new opportunistic pathogen (9). Recently, Figueiredo et al 
demonstrated that A. lwoffii intrinsically possesses a chromosomal gene encoding a 
CHDL, OXA-134-like, and concluded that this species could therefore constitute a 
reservoir for carbapenemase genes that may spread among other Acinetobacter species 
(5). Besides this naturally occurring gene, which nevertheless does not confer resistance 
to carbapenems, a recent report of multi-drug resistant A. lwoffii clinical isolates 
harboring blaNDM-1-bearing plasmids illustrates the clinical role that this species might 
play in the near future (7). Anyhow, as far as we know, no other carbapenem resistance 
determinant has been yet reported for A. lwoffii.  
In this report, we describe and characterize an A. lwoffii isolate, obtained from a 
newborn incubator’s humidity chamber, which drew our attention by its unusual multi-
drug resistance phenotype, which includes resistance to carbapenems. 
In June of 2008, a newborn kept in an incubator at a University Hospital in Porto, 
Portugal, presented a feverish condition. Environmental samples obtained from the 
water reservoir associated with the incubator´s humidity system led to the detection of 
an A. lwoffii isolate (strain HGSA93). Identification was performed with the Vitek 2 
system and confirmed by 16S rRNA gene sequencing and by the presence of blaOXA-134-
like (5). HGSA93 revealed an unusual multi-drug resistance pattern, including resistance 
to carbapenems (imipenem and meropenem MICs >32mg/L). Antibiotic susceptibility 
testing was performed by disc diffusion method and E-test (2), revealing that HGSA93 
was resistant to other β-lactams, including amoxycillin (>256 mg/L), 
amoxycillin/clavulanate (32 mg/L), piperacillin/tazobactam (32 mg/L), ceftazidime 
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(>256 mg/L), cefepime (>32 mg/L), aztreonam (32 mg/L), but remained susceptible to 
aminoglycosides (except kanamycin), minocycline and tigecycline. A bioassay 
conducted with the isolates’ crude extracts, incubated with imipenem (with and without 
EDTA), strongly suggested the presence of a MBL, identified as blaIMP-5 after PCR (3) 
and sequencing. Isoelectric focusing only showed a band with a pI compatible with 
IMP-5 (3). The chromosomal location of the MBL gene was assessed by hybridization 
assays. PCR mapping showed the association of blaIMP-5 gene with In76 class 1 
integron, embedded in a Tn402-like transposon, as previously described (4), 
emphasizing the possibility of inter-specific transference. Curiously, sequence analysis 
indicated the presence of a weak -35 promoter (TTGACA instead of TTGATA) (1), 
contrarily to what was expected by the high carbapenem resistance level observed in 
HGSA93.  
IMP-5 has only been described so far in Portugal, initially in an A. baumannii clinical 
isolate belonging to the sequence type (ST) 120 (3) and
 
posteriorly in Pseudomonas 
aeruginosa clinical isolates (1). Notwithstanding, the reservoir of this “exclusively 
Portuguese” blaIMP-5 gene is yet to be known.  
It is unclear whether the blaIMP-5-carrying A. lwoffii strain of environmental origin 
identified in this study represents a sporadic case or the early stage of a wide 
dissemination trend. Therefore, we believe that further studies focused on the local 
microbial ecology of carbapenemase-producers are imperative for the full understanding 
of the observed endemicity of blaIMP-5 in our country and for the effective prevention of 
its dissemination.  
In this report, A. lwoffii was not associated with newborn infection, however its 
detection in the newborn incubator’s humidity chamber should warn to the possibility of 
“environmental” species emerge as etiologic agents of infection within vulnerable 
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populations, or more worryingly, as reservoir/source of genetic determinants of 
antibiotic resistance. Recently, A. lwoffii was associated to severe infections in infants at 
a NICU with high mortality rate, as only one case was successfully treated with 
imipenem, while three cases died from severe ventilator-associated pneumonia, and 
severe sepsis (7). 
Our data highlight the potential of non-baumannii Acinetobacter species to act as 
possible reservoirs of clinically relevant resistance genes and to emerge as important 
pathogens as occurred with A. baumannii, thus constituting a challenge for therapeutic 
management.  
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III. Contribution of adhesion and biofilm production for the persistence of 
carbapenem-resistant A. baumannii lineages 
 
 
In this study the biofilm formation ability of spread carbapenem resistant A. baumannii 
lineages was investigated. The possible role of blaOXA-24/40-carrying plasmids as a 
genetic platform for the anchorage of biofilm formation capabilities, as well as its 
contribution for the endemicity of some lineages in Portugal, is also discussed. 
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Abstract 
 
Biofilm formation ability has been associated with persistence of Acinetobacter 
baumannii (AB) in the hospital environment and propensity to cause infection. In this 
study we investigated the ability to form biofilm of disseminated carbapenem resistant 
AB (CRAB) lineages and the possibility for this feature to be encoded by blaOXA-24/40-
carrying plasmids. Adherence and biofilm formation was evaluated in AB clinical 
isolates (n=25) belonging to the main lineages circulating in Portugal, blaOXA-23-
carrying/ST92, blaOXA-40-carrying/ST98, and blaOXA-58-carrying/ST103. Biofilm production 
was confirmed with ultramicroscopic analysis (CLSM and FESEM). Overall, isolates of 
globally disseminated AB (CRAB) lineages demonstrated strong adherence properties 
and ability to form biofilms in abiotic surfaces which might contribute to their 
emergence and persistence, particularly among those belonging to blaOXA-40-
carrying/ST98 lineage. Confirmation of a complex structure compatible with biofilm 
production was observed by ultramicroscopic analysis in three blaOXA-24/40-carrying 
isolates. Although acquisition of blaOXA-24/40-carrying plasmids could contribute to 
enhance AB virulence, these plasmids do not contribute to improve adherence and 
biofilm formation in AB. 
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Acinetobacter baumannii has become in the last decades one of the most troublesome 
pathogens, particularly in the hospital setting (2, 4, 5-9).  
Its persistence has been attributed to a remarkable ability to acquire genetic resistance 
determinants and capacity to form biofilms. Multidrug- and, in particular, carbapenem-
resistant, A. baumannii population structure is highly clonal (1, 5). Until now only very 
few lineages were associated with carbapenem resistance dissemination, probably 
because besides resistance, they present particular features that confer additional 
selective advantages. Among them we can find those belonging to the worldwide 
disseminated clonal complex (CC) 92, represented in Portugal by the blaOXA-23-
carrying/ST92 and blaOXA-40-carrying/ST98 (5). A third lineage, blaOXA-58-carrying/ST103, 
with no apparent relationship with CC92, was also identified. We previously 
demonstrated that OXA-40, a carbapenem hydrolyzing class D β-lactamase (CHDL), 
was encoded in plasmids, belonging to GR2 (repAci2) and GR12 (repA_AB) homology 
groups (6), but the possibility that other features contributing for this lineage 
persistence might be encoded on these plasmids has not been explored until now, 
particularly because they harbor a TonB-dependent receptor gene coding for an outer 
membrane protein involved in iron uptake and virulence (1, 6).   
Biofilms are highly structured communities of bacteria attached to a surface, either 
biotic or abiotic, and constitute an important requirement for chronic colonization of 
human tissues and persistence in implanted medical devices (7). Biofilms are 
associated with multiple drug resistance and to higher resistance to desiccation, 
environmental stress (nutritional or oxidative stress), UV light exposure and 
phagocytosis (8, 9). 
In this study we investigated the biofilm formation ability of disseminated carbapenem 
resistant A. baumannii (CRAB) lineages, a feature usually accessed by a biomass 
quantification assay, which only measures adhesion ability. Biofilm production was 
further confirmed by fluorescence microscopy and field emission scanning electron 
microscopy. The possibility of this feature being favored by blaOXA-24/40-carrying 
plasmids acquisition was also explored. 
 
From a collection of 213 CRAB clinical isolates were selected 25 CHDL-producing 
isolates obtained from five Portuguese hospitals (2001-2008). This selection aimed to 
include in this study isolates with different acquired CHDLs, belonging to distinct 
sequence types, and collected from different hospitals over the course of several years. 
Isolates were distributed among three different lineages: blaOXA-23–carrying/ST92 (n=5; 
2006–2008), blaOXA-40-carrying/ST98 (n=12; 2001–2007) and blaOXA-58-carrying/ST103 
(n=8; 2001-2008), and obtained from different sources (Table 1). ST98 and ST92 
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belong to the worldwide disseminated CC92, which has been previously associated 
with European lineage II (6). The study also included two transformants harboring 
blaOXA-40-carrying plasmids and the respective receptor strain Acinetobacter baylyi 
ADP1. 
Adherence was tested by a biomass quantification assay as described by Donelli et al, 
2007 (3), with LB Broth cultures incubated in 96-well plates. The optical density (OD) of 
each well was measured at 570 nm by using an automated spectrophotometer, with 
each assay being performed in triplicate and repeated 3 times. As a negative control 
was used a well with fresh LB supplemented with 1% glucose without bacteria and as a 
positive control for the biofilm phenotype was used the reference strain A. baumannii 
ATCC 19606T. Isolates were classified into the following categories: non-adherent 
(OD≤ODc), weakly adherent (ODc<OD≤2XODc), moderately adherent 
(2ODc<OD≤4XODc), strongly adherent (4xODc<OD). The cut-off OD (ODc) was 
defined as three standard deviations above the mean OD of the negative control. 
Biofilm growth for three highly adherent isolates was assessed by fluorescence 
microscopy and field emission scanning electron microscopy (FESEM). Image analysis 
was performed by using ImageJ software (National Institutes of Health, Bethesda, MD; 
http://rsb.info.nih.gov/ij/). Biofilm surface area coverage was measured by image 
analysis of micrographs taken at a magnification of 10KX and 25KX. The average area 
of coverage was obtained from five measurements taken at randomly sorted locations 
over the polymer surface (3).  
Most of the studied isolates were classified as strongly adherents, a feature which, in 
addition to multidrug resistance observed among them, might explain these lineages 
persistence in Portuguese hospitals. However, it is interesting to note the diversity in 
adhesion ability observed among clonally related isolates, similar to what was obtained 
by other studies (4). Among the three different lineages studied, those belonging to 
CC92 presented higher adhesion values, which is in accordance to what has already 
been established for isolates belonging to European lineage II (4). On the other hand, 
blaOXA-58-carrying/ST103 isolates were those who presented lower adhesion values, 
particularly the more recent ones (Table 1). These findings together with their 
susceptibility profile might explain the restricted dissemination of this lineage (5). In 
what concerns the pandrug resistant isolate (HST2; Table1), it was observed a strong 
adhesion value, suggesting that resistance acquisition do not interfere with biofilm 
production, which contrast with observations of fitness reduction as a result of 
resistance acquisition (8).  It is interesting to note that isolates from catheters were the 
ones who presented higher adhesion values.  
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Biomass quantification assay results were further confirmed with the observation of 
complex structures compatible with biofilm production by FESEM: exopolysaccharide, 
pili and water channels (Figure 2D), were observed in three blaOXA-40-carrying isolates. 
Although blaOXA-40-carrying/ST98 presented higher adherence values we could not 
associate the presence of blaOXA-40-carrying plasmids with this feature, since were not 
observed differences in adhesion values between the blaOXA-40-transformants and A. 
baylyi ADP1 receptor strain (Figure 2).  
 
In summary, our study confirms the strong ability presented by most of A. baumannii 
isolates to adhere to abiotic surfaces and to produce biofilms, revealing that adhesion 
values obtained by biomass quantification assays are good predictors of biofilm 
production. Antimicrobial resistance does not seem to be diminished in isolates with 
strong ability to adhere and produce biofilm. In addition, blaOXA-40-carrying plasmids are 
not associated with this feature. 
Further studies involving genetic determinants responsible for these characteristics are 
needed to better understand the main features that confer selective advantages among 
these lineages and the mechanisms underlying biofilm production. 
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Figure 1. Adhesion values for isolates harboring blaOXA-40-carrying plasmids, respective 
transformants, and receptor strain obtained by the biomass quantification assay. The 
discontinuous line indicates the cut-off above which isolates are classified as strongly 
adherent (4xODc<OD).  
 
 
  A     B 
 
  C     D 
Figure 2. Micrographs of biofilm-producers observed with a magnification of 10.00 KX 
using an EHT = 5.00 kV: (A) AC92; (B) AC111; (C) HGSA25. D Micrograph of HGSA25 
with a magnification of 20.00 KX. 
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Table 1. Characteristics of the isolates included in the study 
Isolate Year Hospitala Sourceb CHDLc PFGE d STe RFLP/repf Adhesiong 
Ac2 2001 HGSA BS OXA-40 A ST98 ND +++ 
Ac32 2001 HGSA  BS OXA-40 A ST98 A/repA_AB +++ 
Ac55 2002 HGSA BS OXA-40 A ST98 ND + 
Ac92 2003 HGSA BS OXA-40 A4 ST98 B/repAci2 +++ 
Ac111 2003 HGSA CT OXA-40 A ST98 ND +++ 
Ac250 2004 HGSA BS OXA-40 A ST98 A/repA_AB +++ 
HGSA7 2006 HGSA BS OXA-40 A3 ST98 A1/repA_AB +++ 
HGSA8 2006 HGSA  BS OXA-40 A3 ST98 B2/repAci2 - 
HGSA11 2006 HGSA CT OXA-40 A3 ST98 B2/repAci2 +++ 
HGSA20 2006 HGSA U OXA-40 A3 ST98 B2/repAci2 +++ 
HGSA25 2006 HGSA CT OXA-40 A3 ST98 B2/repAci2 +++ 
CHCB10 2007 CHCB U OXA-40 A1 ST98 B2/repAci2 +++ 
 
 
HST1 2006 HST IPF OXA-23 A4 ST92 - +++ 
HST2 2006 HST IPF OXA-23 A4 ST92 - +++ 
HPH1 2006 HPH BS OXA-23 A4 ST92 - +++ 
HA2 2007 HA INA OXA-23 A4 ST92 - +++ 
HGSA21 2007 HGSA INA OXA-23 A4 ST92 - +++ 
HST21 2008 HST CT OXA-23 A4 ST92 - +++ 
 
 
Ac23 2001 HGSA CT OXA-58 B ST103 - +++ 
Ac42 2001 HGSA CT OXA-58 B ST103 - +++ 
Ac67 2002 HGSA CT OXA-58 B ST103 - +++ 
Ac70 2002 HGSA U OXA-58 B ST103 - +++ 
Ac156 2003 HGSA  CT OXA-58 C ST103 - +++ 
Ac174 2004 HGSA U OXA-58 C ST103 - + 
Ac246 2004 HGSA U OXA-58 B ST103 - + 
HGSA140 2008 HGSA BS OXA-58 B ST103 - + 
     
 
 
 
 
A. baylyi  ADP1 - - - - - - - + 
Ac32_T2h - - - OXA-40 - - A/repA_AB + 
Ac92_T2h - - - OXA-40 - - B/repAci2 + 
 
a HGSA, Hospital Geral de Santo António; CHCB, Centro Hospitalar da Cova da Beira; HST, Hospital de 
São Teotónio; HPH, Hospital de Pedro Hispano; HA, Hospital de Amarante; b BS, bronchial secretions; 
CT, catheter; U, urine; IPF, intraperitoneal fluid; INA, information not available; cCHDL, acquired 
carbapenem hydrolyzing class D β-lactamases; dPFGE, ApaI-Pulsed-field gel electrophoresis profile;  eST, 
sequence type determined according to Bartual et al (2005) scheme; f RFLP, restriction fragment length 
polymorphism profile (EcoRI, BamHI, or HindIII)/rep, blaOXA-40 carrying plasmid replicase content: repA_AB 
(GR12), repAci2 (GR2); g adhesion classification: +++, strongly adherent; +, weakly adherent; -, non-
adherent; e; h Transformants harboring blaOXA-40 carrying plasmid from isolates Ac32 and Ac92. 
  
 
  
 
  
“Experimental science is the queen of sciences and the goal of all speculation.” 
Roger Bacon 
(1214-1294) 
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CHAPTER 4 – SUMMARY CONCLUSIONS 
 
The overall results of this thesis evidence that carbapenem resistance in A. baumannii 
results from the interplay of two events: the presence of particular lineages with a great 
capacity to disseminate and acquire resistance, and the frequent association of 
carbapenem resistance determinants with mobile genetic elements. This late 
characteristic also contributes for carbapenem resistance dissemination to other 
Acinetobacter species, which may constitute a widespread and worrisome reservoir of 
carbapenem resistance genes. In addition, dissemination and persistence of particular 
carbapenem resistance lineages seems also to depend on virulence factors, such as 
adhesion and biofilm production, a characteristic that may provide selective 
advantages to these organisms.  
These conclusions result after the fulfillment of the specific objectives of this study:  
1. To characterize the population structure of carbapenem-resistant 
Acinetobacter baumannii clinical isolates collected in the hospital setting 
in Portugal (1995-2008), Brazil (2006-2007) and Czech Republic (2008).  
Sequence based typing methods used to analyze population structure of A. 
baumannii clinical isolates revealed that very few lineages are associated with 
carbapenem-resistance. Remarkably, our data point to higher resolution of 
Bartual MLST scheme, which provided a better association between 
epidemiological features, acquired CHDL content and temporal distribution of 
the studied isolates. 
Very few lineages seem to be contributing for carbapenem-resistance in A. 
baumannii. Our results show the overrepresentation of the CC92 in Portugal, 
with the current dominance of ST92 carrying blaOXA-23, a lineage also 
disseminated worldwide. In our country this lineage was able to gradually 
replace the endemic clone ST98 carrying blaOXA-24/40, an event only detected by 
the use of an MLST scheme developed by Bartual et al (2005), which provided 
a better insight on A. baumannii population dynamics. An enhanced multidrug 
resistance profile seems to have contributed to the population switching 
observed. A third lineage identified corresponds to ST103 carrying blaOXA-58, 
presenting a lower expression in the context of CRAB lineages, probably due to 
a more susceptible phenotype. In Czech Republic ST92 also seems to be 
disseminated and contributing to carbapenem resistance, although not 
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associated with blaOXA-23. The identification of new STs among A. baumannii 
clinical isolates from Brazilian hospitals suggests a local diversity hotspot, 
although was possible to relate them with the main European lineages.  
 
 
2. To characterize the carbapenem resistance mechanisms and mobile 
genetic elements responsible for the spread of carbapenem resistance 
determinants among Acinetobacter species.  
 
Carbapenem resistance was associated with the presence of carbapenemases, 
with the exception of Czech Republic’s isolates, which demonstrates 
impairment on CarO porin encoding gene, compromising carbapenems cell 
entrance. The majority of carbapenemases identified belonged to the group of 
carbapenem-hydrolyzing class D β-lactamases (CHDLs), thus confirming 
CHDLs as the main mechanism responsible for resistance to this class of 
antibiotics. In Portugal were identified OXA-23, OXA-24/40 and OXA-58, and, 
although associated with mobile genetic elements, was observed stability of a 
specific acquired CHDL within each lineage. Concerning Czech Republic’s 
isolates, was not possible to elucidate the carbapenem-resistance mechanism, 
but this finding highlight the possibility that other unidentified resistance 
mechanisms start to spread in the near future. Only two types of non- 
conjugative plasmids harbouring blaOXA-24/40 were identified: 30-kb repA_AB 
(GR12) and 10-kb repaci2 (GR2) were identified both among A. baumannii and 
A. haemolyticus clinical isolates collected over a large period of time (2001 to 
2007). This is in accordance to what has been described in other countries, 
although associated with isolates belonging to different STs, which stresses the 
contribution of these plasmids in the dissemination process of OXA-24/40. 
Moreover, both blaOXA-24/40 genes and larger contiguous modules are flanked by 
XerC/XerD-like binding sites, which might be responsible for their mobilization 
and may explain the identification of blaOXA-24/40 and/or common modules in 
different plasmid scaffolds or in chromosomes. Furthermore, the variability 
observed in the number and location of the orf of unknown function, oriV, and 
iteron sequences suggests frequent recombinatorial events on these plasmids. 
This study not only confirms the horizontal transmission of common resistance 
modules between Acinetobacter plasmids but also highlights interspecies 
plasmid transfer. 
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3. To explore the mechanisms that might drive the antimicrobial resistance 
evolution in A. baumannii. 
 
The detection of an A. baumannii clinical isolate resistant to all available 
antibiotics in the course of antibiotic therapy emphasizes the contribution of 
antimicrobial pressure in the in vivo evolution of multidrug-resistant clones into 
pandrug-resistant ones. This constitutes a concerning event, particularly when 
occurs within largely disseminated lineages like ST92. In addition, this isolate 
revealed increased expression of AdeABC efflux pump, possibly associated 
with the inactivity of tigecycline, a last resource antibiotic for the treatment of 
MDR A. baumannii infections. 
 
 
4. To explore the role of environmental Acinetobacter species in the 
acquisition and dissemination of carbapenem resistance mechanisms. 
 
The occurrence of an environmental blaIMP-5-carrying A. lwoffii pointed for the 
possible contribution of non-baumannii Acinetobacter to act as possible 
reservoirs of clinically relevant resistance genes and to emerge as important 
pathogens. Moreover, the observation of blaOXA-24/40 carrying A. haemolyticus is 
of great concern due to the ubiquity of this Acinetobacter species.  
 
5. To characterize the adhesion ability and biofilm formation displayed by 
the main A. baumannii lineages disseminated in Portuguese hospitals. 
 
Adhesion ability and biofilm formation together with an enhanced antimicrobial 
resistance seem to be important features responsible for the persistence and 
dissemination of the main A. baumannii lineages in the Portuguese hospitals. 
Adhesion abilitie seems do not be favoured by the presence of plasmids of 
incompatibility group 12 or 2 carrying blaOXA-24/40. Future studies concerning the 
genetic basis of these traits will be needed for a better understanding of 
Acinetobacter pathogenesis.  
 
 
  
 
  
Information is a source of learning. But unless it is organized,  
processed, and available …, it is a burden, not a benefit. 
William Pollard 
 (1911-1989) 
Chapter 5 REFERENCES 
  
 
 
 
Chapter 5 - References 
 
107 
 
CHAPTER 5 - REFERENCES 
1. Adams-Haduch, J. M., E. O. Onuoha, T. Bogdanovich, G. B. Tian, J. 
Marschall, C. M. Urban, B. J. Spellberg, D. Rhee, D. C. Halstead, A. W. Pasculle, 
and Y. Doi. 2011. Molecular epidemiology of carbapenem-nonsusceptible 
Acinetobacter baumannii in the United States. J Clin Microbiol 49:3849-3854. 
2. Adams, M. D., G. C. Nickel, S. Bajaksouzian, H. Lavender, A. R. Murthy, M. 
R. Jacobs, and R. A. Bonomo. 2009. Resistance to colistin in Acinetobacter 
baumannii associated with mutations in the PmrAB two-component system. Antimicrob 
Agents Chemother 53:3628-3634. 
3. Akers, K. S., K. Mende, H. C. Yun, D. R. Hospenthal, M. L. Beckius, X. Yu, 
and C. K. Murray. 2009. Tetracycline susceptibility testing and resistance genes in 
isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus complex from a U.S. 
military hospital. Antimicrob Agents Chemother 53:2693-2695. 
4. Ambler, R. P. 1980. The structure of beta-lactamases. Philos Trans R Soc 
Lond B Biol Sci 289:321-331. 
5. Anandham, R., H. Y. Weon, S. J. Kim, Y. S. Kim, B. Y. Kim, and S. W. 
Kwon. 2010. Acinetobacter brisouii sp. nov., isolated from a wetland in Korea. J 
Microbiol 48:36-39. 
6. Anstey, N. M., B. J. Currie, M. Hassell, D. Palmer, B. Dwyer, and H. Seifert. 
2002. Community-acquired bacteremic Acinetobacter pneumonia in tropical Australia is 
caused by diverse strains of Acinetobacter baumannii, with carriage in the throat in at-
risk groups. J Clin Microbiol 40:685-686. 
7. Antunes, L. C., F. Imperi, K. J. Towner, and P. Visca. 2011. Genome-
assisted identification of putative iron-utilization genes in Acinetobacter baumannii and 
their distribution among a genotypically diverse collection of clinical isolates. Res 
Microbiol 162:279-284. 
8. Barnaud, G., N. Zihoune, J. D. Ricard, M. C. Hippeaux, M. Eveillard, D. 
Dreyfuss, and C. Branger. 2010. Two sequential outbreaks caused by multidrug-
resistant Acinetobacter baumannii isolates producing OXA-58 or OXA-72 oxacillinase 
in an intensive care unit in France. J Hosp Infect 76:358-360. 
Chapter 5 - References 
108 
 
9. Bartual, S. G., H. Seifert, C. Hippler, M. A. Luzon, H. Wisplinghoff, and F. 
Rodriguez-Valera. 2005. Development of a multilocus sequence typing scheme for 
characterization of clinical isolates of Acinetobacter baumannii. J Clin Microbiol 
43:4382-4390. 
10. Bassetti, M., E. Repetto, E. Righi, S. Boni, M. Diverio, M. P. Molinari, M. 
Mussap, S. Artioli, F. Ansaldi, P. Durando, G. Orengo, F. Bobbio Pallavicini, and 
C. Viscoli. 2008. Colistin and rifampicin in the treatment of multidrug-resistant 
Acinetobacter baumannii infections. J Antimicrob Chemother 61:417-420. 
11. Baumann, P. 1968. Isolation of Acinetobacter from soil and water. J Bacteriol 
96:39-42. 
12. Baumann, P., M. Doudoroff, and R. Y. Stanier. 1968. A study of the Moraxella 
group. II. Oxidative-negative species (genus Acinetobacter). J Bacteriol 95:1520-1541. 
13. Beijerinck, M. 1911. Pigmenten als oxydatieproducten gevormd door bacterien. 
Versl. Koninklijke Akad. Wetensch. Amsterdam 19:1092-1103. 
14. Bergogne-Berezin, E., and K. J. Towner. 1996. Acinetobacter spp. as 
nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin 
Microbiol Rev 9:148-165. 
15. Berlau, J., H. Aucken, H. Malnick, and T. Pitt. 1999. Distribution of 
Acinetobacter species on skin of healthy humans. Eur J Clin Microbiol Infect Dis 
18:179-183. 
16. Berlau, J., H. M. Aucken, E. Houang, and T. L. Pitt. 1999. Isolation of 
Acinetobacter spp. including A. baumannii from vegetables: implications for hospital-
acquired infections. J Hosp Infect 42:201-204. 
17. Bertini, A., L. Poirel, S. Bernabeu, D. Fortini, L. Villa, P. Nordmann, and A. 
Carattoli. 2007. Multicopy blaOXA-58 gene as a source of high-level resistance to 
carbapenems in Acinetobacter baumannii. Antimicrob Agents Chemother 51:2324-
2328. 
18. Bertini, A., L. Poirel, P. D. Mugnier, L. Villa, P. Nordmann, and A. Carattoli. 
2010. Characterization and PCR-based replicon typing of resistance plasmids in 
Acinetobacter baumannii. Antimicrob Agents Chemother 54:4168-4177. 
Chapter 5 - References 
 
109 
 
19. Bonnin, R. A., P. Nordmann, A. Potron, H. Lecuyer, J. R. Zahar, and L. 
Poirel. 2011. Carbapenem-hydrolyzing GES-type extended-spectrum beta-lactamase 
in Acinetobacter baumannii. Antimicrob Agents Chemother 55:349-354. 
20. Bonnin, R. A., L. Poirel, T. Naas, M. Pirs, K. Seme, J. Schrenzel, and P. 
Nordmann. 2012. Dissemination of New Delhi metallo-beta-lactamase-1-producing 
Acinetobacter baumannii in Europe. Clin Microbiol Infect. 
21. Bonnin, R. A., A. Potron, L. Poirel, H. Lecuyer, R. Neri, and P. Nordmann. 
2011. PER-7, an Extended-Spectrum {beta}-Lactamase with Increased Activity toward 
Broad-Spectrum Cephalosporins in Acinetobacter baumannii. Antimicrob Agents 
Chemother 55:2424-2427. 
22. Bonomo, R. A., and D. Szabo. 2006. Mechanisms of multidrug resistance in 
Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 43 Suppl 2:S49-
56. 
23. Bou, G., and J. Martinez-Beltran. 2000. Cloning, nucleotide sequencing, and 
analysis of the gene encoding an AmpC beta-lactamase in Acinetobacter baumannii. 
Antimicrob Agents Chemother 44:428-432. 
24. Bou, G., A. Oliver, and J. Martinez-Beltran. 2000. OXA-24, a novel class D 
beta-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical 
strain. Antimicrob Agents Chemother 44:1556-1561. 
25. Bouvet, P. J., and P. A. Grimont. 1987. Identification and biotyping of clinical 
isolates of Acinetobacter. Ann Inst Pasteur Microbiol 138:569-578. 
26. Bouvet, P. J., and S. Jeanjean. 1989. Delineation of new proteolytic genomic 
species in the genus Acinetobacter. Res Microbiol 140:291-299. 
27. Brisou, J., and A. R. Prevot. 1954. Studies on bacterial taxonomy. X. The 
revision of species under Acromobacter group. Ann Inst Pasteur (Paris) 86:722-728. 
28. Brizio, A., T. Conceicao, M. Pimentel, G. Da Silva, and A. Duarte. 2006. 
High-level expression of IMP-5 carbapenemase owing to point mutation in the -35 
promoter region of class 1 integron among Pseudomonas aeruginosa clinical isolates. 
Int J Antimicrob Agents 27:27-31. 
Chapter 5 - References 
110 
 
29. Brown, S., H. K. Young, and S. G. Amyes. 2005. Characterisation of OXA-51, 
a novel class D carbapenemase found in genetically unrelated clinical strains of 
Acinetobacter baumannii from Argentina. Clin Microbiol Infect 11:15-23. 
30. Cabral, M. P., N. C. Soares, J. Aranda, J. R. Parreira, C. Rumbo, M. Poza, J. 
Valle, V. Calamia, I. Lasa, and G. Bou. 2011. Proteomic and functional analyses 
reveal a unique lifestyle for Acinetobacter baumannii biofilms and a key role for 
histidine metabolism. J Proteome Res. 
31. Camarena, L., V. Bruno, G. Euskirchen, S. Poggio, and M. Snyder. 2010. 
Molecular mechanisms of ethanol-induced pathogenesis revealed by RNA-sequencing. 
PLoS Pathog 6:e1000834. 
32. Cambray, G., A. M. Guerout, and D. Mazel. 2010. Integrons. Annu Rev Genet 
44:141-166. 
33. Carattoli, A. 2011. Plasmids in Gram negatives: molecular typing of resistance 
plasmids. Int J Med Microbiol 301:654-658. 
34. Carr, E. L., P. Kampfer, B. K. Patel, V. Gurtler, and R. J. Seviour. 2003. 
Seven novel species of Acinetobacter isolated from activated sludge. Int J Syst Evol 
Microbiol 53:953-963. 
35. Castellanos Martinez, E., M. Telenti Asensio, V. M. Rodriguez Blanco, M. L. 
Rodriguez Suarez, A. Morena Torrico, and A. Cortina Llosa. 1995. Infective 
endocarditis of an interventricular patch caused by Acinetobacter haemolyticus. 
Infection 23:243-245. 
36. CDC (Centers for Disease Control and Prevention). 2004. Acinetobacter 
baumannii infections among patients at military medical facilities treating injured U.S. 
service members, 2002-2004. MMWR Morb Mortal Wkly Rep 53:1063-1066. 
37. Chan, J. D., J. A. Graves, and T. H. Dellit. 2010. Antimicrobial treatment and 
clinical outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-
associated pneumonia. J Intensive Care Med 25:343-348. 
38. Chau, S. L., Y. W. Chu, and E. T. Houang. 2004. Novel resistance-nodulation-
cell division efflux system AdeDE in Acinetobacter genomic DNA group 3. Antimicrob 
Agents Chemother 48:4054-4055. 
Chapter 5 - References 
 
111 
 
39. Chen, D., R. Lal, K. Zomorodi, H. Atluri, J. Ho, W. Luo, J. Tovera, D. Bonzo, 
and K. Cundy. 2012. Evaluation of gabapentin enacarbil on cardiac repolarization: a 
randomized, double-blind, placebo- and active-controlled, crossover thorough QT/QTc 
study in healthy adults. Clin Ther 34:351-362 e353. 
40. Chen, T. L., L. K. Siu, Y. T. Lee, C. P. Chen, L. Y. Huang, R. C. Wu, W. L. 
Cho, and C. P. Fung. 2008. Acinetobacter baylyi as a pathogen for opportunistic 
infection. J Clin Microbiol 46:2938-2944. 
41. Chen, Y., Z. Zhou, Y. Jiang, and Y. Yu. 2011. Emergence of NDM-1-producing 
Acinetobacter baumannii in China. J Antimicrob Chemother 66:1255-1259. 
42. Chen, Z., S. Qlu, Y. Wang, S. Liu, Z. Wang, X. Du, L. Wang, J. Guo, N. Liu, 
J. Yuan, H. Song, and L. Huang. 2011. Coexistence of blaNDM-1 with the prevalent 
blaOXA23 and blaIMP in pan-drug resistant Acinetobacter baumannii isolates in China. Clin 
Infect Dis 52:692-693. 
43. Cho, Y. J., D. C. Moon, J. S. Jin, C. H. Choi, Y. C. Lee, and J. C. Lee. 2009. 
Genetic basis of resistance to aminoglycosides in Acinetobacter spp. and spread of 
armA in Acinetobacter baumannii sequence group 1 in Korean hospitals. Diagn 
Microbiol Infect Dis 64:185-190. 
44. Choi, A. H., L. Slamti, F. Y. Avci, G. B. Pier, and T. Maira-Litran. 2009. The 
pgaABCD locus of Acinetobacter baumannii encodes the production of poly-beta-1-6-
N-acetylglucosamine, which is critical for biofilm formation. J Bacteriol 191:5953-5963. 
45. Choi, C. H., S. H. Hyun, J. Y. Lee, J. S. Lee, Y. S. Lee, S. A. Kim, J. P. Chae, 
S. M. Yoo, and J. C. Lee. 2008. Acinetobacter baumannii outer membrane protein A 
targets the nucleus and induces cytotoxicity. Cell Microbiol 10:309-319. 
46. Choi, C. H., E. Y. Lee, Y. C. Lee, T. I. Park, H. J. Kim, S. H. Hyun, S. A. Kim, 
S. K. Lee, and J. C. Lee. 2005. Outer membrane protein 38 of Acinetobacter 
baumannii localizes to the mitochondria and induces apoptosis of epithelial cells. Cell 
Microbiol 7:1127-1138. 
47. Choi, S. H., E. J. Choo, Y. G. Kwak, M. Y. Kim, J. B. Jun, M. N. Kim, N. J. 
Kim, J. Y. Jeong, Y. S. Kim, and J. H. Woo. 2006. Clinical characteristics and 
outcomes of bacteremia caused by Acinetobacter species other than A. baumannii: 
comparison with A. baumannii bacteremia. J Infect Chemother 12:380-386. 
Chapter 5 - References 
112 
 
48. Chu, Y. W., S. L. Chau, and E. T. Houang. 2006. Presence of active efflux 
systems AdeABC, AdeDE and AdeXYZ in different Acinetobacter genomic DNA 
groups. J Med Microbiol 55:477-478. 
49. Chu, Y. W., C. M. Leung, E. T. Houang, K. C. Ng, C. B. Leung, H. Y. Leung, 
and A. F. Cheng. 1999. Skin carriage of acinetobacters in Hong Kong. J Clin Microbiol 
37:2962-2967. 
50. Clark, R. B. 1996. Imipenem resistance among Acinetobacter baumannii: 
association with reduced expression of a 33-36 kDa outer membrane protein. J 
Antimicrob Chemother 38:245-251. 
51. Coburn, C. A., Y. Luo, M. Cui, J. Wang, R. Soll, J. Dong, B. Hu, M. A. Lyon, 
V. P. Santarelli, R. L. Kraus, Y. Gregan, Y. Wang, S. V. Fox, J. Binns, S. M. Doran, 
D. R. Reiss, P. L. Tannenbaum, A. L. Gotter, P. T. Meinke, and J. J. Renger. 2012. 
Discovery of a pharmacologically active antagonist of the two-pore-domain potassium 
channel K2P9.1 (TASK-3). ChemMedChem 7:123-133. 
52. Cornaglia, G., H. Giamarellou, and G. M. Rossolini. 2011. Metallo-beta-
lactamases: a last frontier for beta-lactams? Lancet Infect Dis 11:381-393. 
53. Corvec, S., L. Poirel, T. Naas, H. Drugeon, and P. Nordmann. 2007. 
Genetics and expression of the carbapenem-hydrolyzing oxacillinase gene blaOXA-23 
in Acinetobacter baumannii. Antimicrob Agents Chemother 51:1530-1533. 
54. Costerton, J. W., Z. Lewandowski, D. E. Caldwell, D. R. Korber, and H. M. 
Lappin-Scott. 1995. Microbial biofilms. Annu Rev Microbiol 49:711-745. 
55. Coyne, S., P. Courvalin, and B. Perichon. 2011. Efflux-mediated antibiotic 
resistance in Acinetobacter spp. Antimicrob Agents Chemother 55:947-953. 
56. Coyne, S., N. Rosenfeld, T. Lambert, P. Courvalin, and B. Perichon. 2010. 
Overexpression of resistance-nodulation-cell division pump AdeFGH confers multidrug 
resistance in Acinetobacter baumannii. Antimicrob Agents Chemother 54:4389-4393. 
57. D'Andrea, M. M., T. Giani, S. D'Arezzo, A. Capone, N. Petrosillo, P. Visca, F. 
Luzzaro, and G. M. Rossolini. 2009. Characterization of pABVA01, a plasmid 
encoding the OXA-24 carbapenemase from Italian isolates of Acinetobacter baumannii. 
Antimicrob Agents Chemother 53:3528-3533. 
Chapter 5 - References 
 
113 
 
58. D'Arezzo, S., L. Principe, A. Capone, N. Petrosillo, A. Petrucca, and P. 
Visca. 2011. Changing carbapenemase gene pattern in an epidemic multidrug-
resistant Acinetobacter baumannii lineage causing multiple outbreaks in central Italy. J 
Antimicrob Chemother 66:54-61. 
59. Da Silva, G., L. Dijkshoorn, T. van der Reijden, B. van Strijen, and A. 
Duarte. 2007. Identification of widespread, closely related Acinetobacter baumannii 
isolates in Portugal as a subgroup of European clone II. Clin Microbiol Infect 13:190-
195. 
60. Da Silva, G. J., M. Correia, C. Vital, G. Ribeiro, J. C. Sousa, R. Leitao, L. 
Peixe, and A. Duarte. 2002. Molecular characterization of bla(IMP-5), a new integron-
borne metallo-beta-lactamase gene from an Acinetobacter baumannii nosocomial 
isolate in Portugal. FEMS Microbiol Lett 215:33-39. 
61. Da Silva, G. J., S. Quinteira, E. Bertolo, J. C. Sousa, L. Gallego, A. Duarte, 
and L. Peixe. 2004. Long-term dissemination of an OXA-40 carbapenemase-producing 
Acinetobacter baumannii clone in the Iberian Peninsula. J Antimicrob Chemother 
54:255-258. 
62. Dalla-Costa, L. M., J. M. Coelho, H. A. Souza, M. E. Castro, C. J. Stier, K. L. 
Bragagnolo, A. Rea-Neto, S. R. Penteado-Filho, D. M. Livermore, and N. 
Woodford. 2003. Outbreak of carbapenem-resistant Acinetobacter baumannii 
producing the OXA-23 enzyme in Curitiba, Brazil. J Clin Microbiol 41:3403-3406. 
63. Damier-Piolle, L., S. Magnet, S. Bremont, T. Lambert, and P. Courvalin. 
2008. AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in 
Acinetobacter baumannii. Antimicrob Agents Chemother 52:557-562. 
64. Davis, K. A., K. A. Moran, C. K. McAllister, and P. J. Gray. 2005. Multidrug-
resistant Acinetobacter extremity infections in soldiers. Emerg Infect Dis 11:1218-1224. 
65. de Vries, J., P. Meier, and W. Wackernagel. 2001. The natural transformation 
of the soil bacteria Pseudomonas stutzeri and Acinetobacter sp. by transgenic plant 
DNA strictly depends on homologous sequences in the recipient cells. FEMS Microbiol 
Lett 195:211-215. 
66. Diancourt, L., V. Passet, A. Nemec, L. Dijkshoorn, and S. Brisse. 2010. The 
population structure of Acinetobacter baumannii: expanding multiresistant clones from 
an ancestral susceptible genetic pool. PLoS One 5:e10034. 
Chapter 5 - References 
114 
 
67. Dijkshoorn, L., H. Aucken, P. Gerner-Smidt, P. Janssen, M. E. Kaufmann, 
J. Garaizar, J. Ursing, and T. L. Pitt. 1996. Comparison of outbreak and nonoutbreak 
Acinetobacter baumannii strains by genotypic and phenotypic methods. J Clin Microbiol 
34:1519-1525. 
68. Dijkshoorn, L., A. Nemec, and H. Seifert. 2007. An increasing threat in 
hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol 5:939-951. 
69. Dijkshoorn, L., E. van Aken, L. Shunburne, T. J. van der Reijden, A. T. 
Bernards, A. Nemec, and K. J. Towner. 2005. Prevalence of Acinetobacter 
baumannii and other Acinetobacter spp. in faecal samples from non-hospitalised 
individuals. Clin Microbiol Infect 11:329-332. 
70. Dobrindt, U., B. Hochhut, U. Hentschel, and J. Hacker. 2004. Genomic 
islands in pathogenic and environmental microorganisms. Nat Rev Microbiol 2:414-
424. 
71. Docquier, J. D., J. Lamotte-Brasseur, M. Galleni, G. Amicosante, J. M. 
Frere, and G. M. Rossolini. 2003. On functional and structural heterogeneity of VIM-
type metallo-beta-lactamases. J Antimicrob Chemother 51:257-266. 
72. Doi, Y., and Y. Arakawa. 2007. 16S ribosomal RNA methylation: emerging 
resistance mechanism against aminoglycosides. Clin Infect Dis 45:88-94. 
73. Doi, Y., S. Husain, B. A. Potoski, K. R. McCurry, and D. L. Paterson. 2009. 
Extensively drug-resistant Acinetobacter baumannii. Emerg Infect Dis 15:980-982. 
74. Doi, Y., J. Wachino, K. Yamane, N. Shibata, T. Yagi, K. Shibayama, H. Kato, 
and Y. Arakawa. 2004. Spread of novel aminoglycoside resistance gene aac(6')-Iad 
among Acinetobacter clinical isolates in Japan. Antimicrob Agents Chemother 48:2075-
2080. 
75. Dolzani, L., E. Tonin, C. Lagatolla, L. Prandin, and C. Monti-Bragadin. 
1995. Identification of Acinetobacter isolates in the A. calcoaceticus-A. baumannii 
complex by restriction analysis of the 16S-23S rRNA intergenic-spacer sequences. J 
Clin Microbiol 33:1108-1113. 
76. Dorsey, C. W., A. P. Tomaras, P. L. Connerly, M. E. Tolmasky, J. H. Crosa, 
and L. A. Actis. 2004. The siderophore-mediated iron acquisition systems of 
Chapter 5 - References 
 
115 
 
Acinetobacter baumannii ATCC 19606 and Vibrio anguillarum 775 are structurally and 
functionally related. Microbiology 150:3657-3667. 
77. Dortet, L., P. Legrand, C. J. Soussy, and V. Cattoir. 2006. Bacterial 
identification, clinical significance, and antimicrobial susceptibilities of Acinetobacter 
ursingii and Acinetobacter schindleri, two frequently misidentified opportunistic 
pathogens. J Clin Microbiol 44:4471-4478. 
78. Doughari, H. J., P. A. Ndakidemi, I. S. Human, and S. Benade. 2011. The 
Ecology, Biology and Pathogenesis of Acinetobacter spp.: An Overview. Microbes 
Environ 26:101-112. 
79. Dubnau, D. 1999. DNA uptake in bacteria. Annu Rev Microbiol 53:217-244. 
80. Dupont, M., J. M. Pages, D. Lafitte, A. Siroy, and C. Bollet. 2005. 
Identification of an OprD homologue in Acinetobacter baumannii. J Proteome Res 
4:2386-2390. 
81. Ecker, J. A., C. Massire, T. A. Hall, R. Ranken, T. T. Pennella, C. Agasino 
Ivy, L. B. Blyn, S. A. Hofstadler, T. P. Endy, P. T. Scott, L. Lindler, T. Hamilton, C. 
Gaddy, K. Snow, M. Pe, J. Fishbain, D. Craft, G. Deye, S. Riddell, E. Milstrey, B. 
Petruccelli, S. Brisse, V. Harpin, A. Schink, D. J. Ecker, R. Sampath, and M. W. 
Eshoo. 2006. Identification of Acinetobacter species and genotyping of Acinetobacter 
baumannii by multilocus PCR and mass spectrometry. J Clin Microbiol 44:2921-2932. 
82. Eisen, J. A. 2000. Horizontal gene transfer among microbial genomes: new 
insights from complete genome analysis. Curr Opin Genet Dev 10:606-611. 
83. Endimiani, A., K. M. Hujer, A. M. Hujer, I. Bertschy, A. Rossano, C. Koch, 
V. Gerber, T. Francey, R. A. Bonomo, and V. Perreten. 2011. Acinetobacter 
baumannii isolates from pets and horses in Switzerland: molecular characterization and 
clinical data. J Antimicrob Chemother 66:2248-2254. 
84. Endimiani, A., F. Luzzaro, R. Migliavacca, E. Mantengoli, A. M. Hujer, K. M. 
Hujer, L. Pagani, R. A. Bonomo, G. M. Rossolini, and A. Toniolo. 2007. Spread in 
an Italian hospital of a clonal Acinetobacter baumannii strain producing the TEM-92 
extended-spectrum beta-lactamase. Antimicrob Agents Chemother 51:2211-2214. 
Chapter 5 - References 
116 
 
85. Espinal, P., H. Seifert, L. Dijkshoorn, J. Vila, and I. Roca. 2011. Rapid and 
accurate identification of genomic species from the Acinetobacter baumannii (Ab) 
group by MALDI-TOF MS. Clin Microbiol Infect. 
86. Evans, B. A., S. Brown, A. Hamouda, J. Findlay, and S. G. Amyes. 2007. 
Eleven novel OXA-51-like enzymes from clinical isolates of Acinetobacter baumannii. 
Clin Microbiol Infect 13:1137-1138. 
87. Evans, B. A., A. Hamouda, K. J. Towner, and S. G. Amyes. 2008. OXA-51-
like beta-lactamases and their association with particular epidemic lineages of 
Acinetobacter baumannii. Clin Microbiol Infect 14:268-275. 
88. Falagas, M. E., E. A. Karveli, I. Kelesidis, and T. Kelesidis. 2007. 
Community-acquired Acinetobacter infections. Eur J Clin Microbiol Infect Dis 26:857-
868. 
89. Fernandez-Cuenca, F., L. Martinez-Martinez, M. C. Conejo, J. A. Ayala, E. J. 
Perea, and A. Pascual. 2003. Relationship between beta-lactamase production, outer 
membrane protein and penicillin-binding protein profiles on the activity of carbapenems 
against clinical isolates of Acinetobacter baumannii. J Antimicrob Chemother 51:565-
574. 
90. Figueiredo, S., R. A. Bonnin, L. Poirel, J. Duranteau, and P. Nordmann. 
2011. Identification of the naturally occurring genes encoding carbapenem-hydrolysing 
oxacillinases from Acinetobacter haemolyticus, Acinetobacter johnsonii, and 
Acinetobacter calcoaceticus. Clin Microbiol Infect. 
91. Figueiredo, S., L. Poirel, A. Papa, V. Koulourida, and P. Nordmann. 2009. 
Overexpression of the naturally occurring blaOXA-51 gene in Acinetobacter baumannii 
mediated by novel insertion sequence ISAba9. Antimicrob Agents Chemother 53:4045-
4047. 
92. Fishbain, J., and A. Y. Peleg. 2010. Treatment of Acinetobacter infections. 
Clin Infect Dis 51:79-84. 
93. Fondi, M., G. Bacci, M. Brilli, M. C. Papaleo, A. Mengoni, M. Vaneechoutte, 
L. Dijkshoorn, and R. Fani. 2010. Exploring the evolutionary dynamics of plasmids: 
the Acinetobacter pan-plasmidome. BMC Evol Biol 10:59. 
Chapter 5 - References 
 
117 
 
94. Fournier, P. E., D. Vallenet, V. Barbe, S. Audic, H. Ogata, L. Poirel, H. 
Richet, C. Robert, S. Mangenot, C. Abergel, P. Nordmann, J. Weissenbach, D. 
Raoult, and J. M. Claverie. 2006. Comparative genomics of multidrug resistance in 
Acinetobacter baumannii. PLoS Genet 2:e7. 
95. Francey, T., F. Gaschen, J. Nicolet, and A. P. Burnens. 2000. The role of 
Acinetobacter baumannii as a nosocomial pathogen for dogs and cats in an intensive 
care unit. J Vet Intern Med 14:177-183. 
96. Fu, Y., J. Zhou, H. Zhou, Q. Yang, Z. Wei, Y. Yu, and L. Li. 2010. Wide 
dissemination of OXA-23-producing carbapenem-resistant Acinetobacter baumannii 
clonal complex 22 in multiple cities of China. J Antimicrob Chemother 65:644-650. 
97. Fulnecky, E. J., D. Wright, W. M. Scheld, L. Kanawati, and S. Shoham. 
2005. Amikacin and colistin for treatment of Acinetobacter baumannii meningitis. J 
Infect 51:e249-251. 
98. Gaddy, J. A., and L. A. Actis. 2009. Regulation of Acinetobacter baumannii 
biofilm formation. Future Microbiol 4:273-278. 
99. Gehrlein, M., H. Leying, W. Cullmann, S. Wendt, and W. Opferkuch. 1991. 
Imipenem resistance in Acinetobacter baumanii is due to altered penicillin-binding 
proteins. Chemotherapy 37:405-412. 
100. Gerner-Smidt, P., and W. Frederiksen. 1993. Acinetobacter in Denmark: I. 
Taxonomy, antibiotic susceptibility, and pathogenicity of 112 clinical strains. APMIS 
101:815-825. 
101. Ghazawi, A., A. Sonnevend, R. A. Bonnin, L. Poirel, P. Nordmann, R. 
Hashmey, T. A. Rizvi, B. H. M, and T. Pal. 2012. NDM-2 carbapenemase-producing 
Acinetobacter baumannii in the United Arab Emirates. Clin Microbiol Infect 18:E34-36. 
102. Gordon, N. C., and D. W. Wareham. 2010. Multidrug-resistant Acinetobacter 
baumannii: mechanisms of virulence and resistance. Int J Antimicrob Agents 35:219-
226. 
103. Gospodarek, E., K. Krasnicki, G. Ziolkowski, H. Kasprzak, and W. Beuth. 
2000. Cerebrospinal meningitis with the presence of Acinetobacter spp. Med Sci Monit 
6:50-54. 
Chapter 5 - References 
118 
 
104. Gribun, A., Y. Nitzan, I. Pechatnikov, G. Hershkovits, and D. J. Katcoff. 
2003. Molecular and structural characterization of the HMP-AB gene encoding a pore-
forming protein from a clinical isolate of Acinetobacter baumannii. Curr Microbiol 
47:434-443. 
105. Guardabassi, L., A. Dalsgaard, and J. E. Olsen. 1999. Phenotypic 
characterization and antibiotic resistance of Acinetobacter spp. isolated from aquatic 
sources. J Appl Microbiol 87:659-667. 
106. Gulati, A., P. Vyas, P. Rahi, and R. C. Kasana. 2009. Plant growth-promoting 
and rhizosphere-competent Acinetobacter rhizosphaerae strain BIHB 723 from the cold 
deserts of the Himalayas. Curr Microbiol 58:371-377. 
107. Hacker, J., and J. B. Kaper. 2000. Pathogenicity islands and the evolution of 
microbes. Annu Rev Microbiol 54:641-679. 
108. Hallal, A., S. M. Cohn, N. Namias, F. Habib, G. Baracco, R. J. Manning, B. 
Crookes, and C. I. Schulman. 2007. Aerosolized tobramycin in the treatment of 
ventilator-associated pneumonia: a pilot study. Surg Infect (Larchmt) 8:73-82. 
109. Hamouda, A., and S. G. Amyes. 2004. Novel gyrA and parC point mutations in 
two strains of Acinetobacter baumannii resistant to ciprofloxacin. J Antimicrob 
Chemother 54:695-696. 
110. Hamouda, A., B. A. Evans, K. J. Towner, and S. G. Amyes. 2010. 
Characterization of epidemiologically unrelated Acinetobacter baumannii isolates from 
four continents by use of multilocus sequence typing, pulsed-field gel electrophoresis, 
and sequence-based typing of bla(OXA-51-like) genes. J Clin Microbiol 48:2476-2483. 
111. Hawley, J. S., C. K. Murray, and J. H. Jorgensen. 2008. Colistin 
heteroresistance in Acinetobacter and its association with previous colistin therapy. 
Antimicrob Agents Chemother 52:351-352. 
112. Heinemann, B., H. Wisplinghoff, M. Edmond, and H. Seifert. 2000. 
Comparative activities of ciprofloxacin, clinafloxacin, gatifloxacin, gemifloxacin, 
levofloxacin, moxifloxacin, and trovafloxacin against epidemiologically defined 
Acinetobacter baumannii strains. Antimicrob Agents Chemother 44:2211-2213. 
Chapter 5 - References 
 
119 
 
113. Heritier, C., L. Poirel, D. Aubert, and P. Nordmann. 2003. Genetic and 
functional analysis of the chromosome-encoded carbapenem-hydrolyzing oxacillinase 
OXA-40 of Acinetobacter baumannii. Antimicrob Agents Chemother 47:268-273. 
114. Hidron, A. I., J. R. Edwards, J. Patel, T. C. Horan, D. M. Sievert, D. A. 
Pollock, and S. K. Fridkin. 2008. NHSN annual update: antimicrobial-resistant 
pathogens associated with healthcare-associated infections: annual summary of data 
reported to the National Healthcare Safety Network at the Centers for Disease Control 
and Prevention, 2006-2007. Infect Control Hosp Epidemiol 29:996-1011. 
115. Higgins, P. G., C. Dammhayn, M. Hackel, and H. Seifert. 2010. Global 
spread of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 
65:233-238. 
116. Higgins, P. G., L. Poirel, M. Lehmann, P. Nordmann, and H. Seifert. 2009. 
OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter 
baumannii. Antimicrob Agents Chemother 53:5035-5038. 
117. Higgins, P. G., T. Schneiders, A. Hamprecht, and H. Seifert. 2010. In vivo 
selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene 
into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a 
hospitalized patient. Antimicrob Agents Chemother 54:5021-5027. 
118. Hornsey, M., M. J. Ellington, M. Doumith, C. P. Thomas, N. C. Gordon, D. 
W. Wareham, J. Quinn, K. Lolans, D. M. Livermore, and N. Woodford. 2010. 
AdeABC-mediated efflux and tigecycline MICs for epidemic clones of Acinetobacter 
baumannii. J Antimicrob Chemother 65:1589-1593. 
119. Hornsey, M., N. Loman, D. W. Wareham, M. J. Ellington, M. J. Pallen, J. F. 
Turton, A. Underwood, T. Gaulton, C. P. Thomas, M. Doumith, D. M. Livermore, 
and N. Woodford. 2011. Whole-genome comparison of two Acinetobacter baumannii 
isolates from a single patient, where resistance developed during tigecycline therapy. J 
Antimicrob Chemother. 
120. Houang, E. T., Y. W. Chu, C. M. Leung, K. Y. Chu, J. Berlau, K. C. Ng, and 
A. F. Cheng. 2001. Epidemiology and infection control implications of Acinetobacter 
spp. in Hong Kong. J Clin Microbiol 39:228-234. 
121. Hujer, K. M., N. S. Hamza, A. M. Hujer, F. Perez, M. S. Helfand, C. R. Bethel, 
J. M. Thomson, V. E. Anderson, M. Barlow, L. B. Rice, F. C. Tenover, and R. A. 
Chapter 5 - References 
120 
 
Bonomo. 2005. Identification of a new allelic variant of the Acinetobacter baumannii 
cephalosporinase, ADC-7 beta-lactamase: defining a unique family of class C 
enzymes. Antimicrob Agents Chemother 49:2941-2948. 
122. Huys, G., K. Bartie, M. Cnockaert, D. T. Hoang Oanh, N. T. Phuong, T. 
Somsiri, S. Chinabut, F. M. Yusoff, M. Shariff, M. Giacomini, A. Teale, and J. 
Swings. 2007. Biodiversity of chloramphenicol-resistant mesophilic heterotrophs from 
Southeast Asian aquaculture environments. Res Microbiol 158:228-235. 
123. Ito, M., Y. Koyama, K. Aida, and T. Uemura. 1970. Biosynthesis of colistin by 
a cell-free system Bacillus colistinus Koyama. Biochim Biophys Acta 215:418-420. 
124. Jacobs, A. C., I. Hood, K. L. Boyd, P. D. Olson, J. M. Morrison, S. Carson, 
K. Sayood, P. C. Iwen, E. P. Skaar, and P. M. Dunman. 2010. Inactivation of 
phospholipase D diminishes Acinetobacter baumannii pathogenesis. Infect Immun 
78:1952-1962. 
125. Jin, J. S., S. O. Kwon, D. C. Moon, M. Gurung, J. H. Lee, S. I. Kim, and J. C. 
Lee. 2011. Acinetobacter baumannii secretes cytotoxic outer membrane protein A via 
outer membrane vesicles. PLoS One 6:e17027. 
126. Juni, E. 1972. Interspecies transformation of Acinetobacter: genetic evidence 
for a ubiquitous genus. J Bacteriol 112:917-931. 
127. Kaase, M., P. Nordmann, T. A. Wichelhaus, S. G. Gatermann, R. A. Bonnin, 
and L. Poirel. 2011. NDM-2 carbapenemase in Acinetobacter baumannii from Egypt. J 
Antimicrob Chemother 66:1260-1262. 
128. Kang, Y. S., J. Jung, C. O. Jeon, and W. Park. 2011. Acinetobacter oleivorans 
sp. nov. is capable of adhering to and growing on diesel-oil. J Microbiol 49:29-34. 
129. Karah, N., B. Haldorsen, N. O. Hermansen, Y. Tveten, E. Ragnhildstveit, D. 
H. Skutlaberg, S. Tofteland, A. Sundsfjord, and O. Samuelsen. 2011. Emergence of 
OXA-carbapenemase- and 16S rRNA methylase-producing international clones of 
Acinetobacter baumannii in Norway. J Med Microbiol 60:515-521. 
130. Karthikeyan, K., M. A. Thirunarayan, and P. Krishnan. 2010. Coexistence of 
blaOXA-23 with blaNDM-1 and armA in clinical isolates of Acinetobacter baumannii from 
India. J Antimicrob Chemother 65:2253-2254. 
Chapter 5 - References 
 
121 
 
131. Kempf, M., L. Djouhri-Bouktab, J. M. Brunel, D. Raoult, and J. M. Rolain. 
2012. Synergistic activity of sulbactam combined with colistin against colistin-resistant 
Acinetobacter baumannii. Int J Antimicrob Agents 39:180-181. 
132. Kempf, M., and J. M. Rolain. 2012. Emergence of resistance to carbapenems 
in Acinetobacter baumannii in Europe: clinical impact and therapeutic options. Int J 
Antimicrob Agents 39:105-114. 
133. Kilic, A., H. Li, A. Mellmann, A. C. Basustaoglu, M. Kul, Z. Senses, H. 
Aydogan, C. W. Stratton, D. Harmsen, and Y. W. Tang. 2008. Acinetobacter 
septicus sp. nov. association with a nosocomial outbreak of bacteremia in a neonatal 
intensive care unit. J Clin Microbiol 46:902-908. 
134. Kim, D., K. S. Baik, M. S. Kim, S. C. Park, S. S. Kim, M. S. Rhee, Y. S. Kwak, 
and C. N. Seong. 2008. Acinetobacter soli sp. nov., isolated from forest soil. J 
Microbiol 46:396-401. 
135. Krizova, L., R. A. Bonnin, P. Nordmann, A. Nemec, and L. Poirel. 2012. 
Characterization of a multidrug-resistant Acinetobacter baumannii strain carrying the 
blaNDM-1 and blaOXA-23 carbapenemase genes from the Czech Republic. J Antimicrob 
Chemother 67:1550-1552. 
136. Kuo, L. C., C. C. Lai, C. H. Liao, C. K. Hsu, Y. L. Chang, C. Y. Chang, and P. 
R. Hsueh. 2007. Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical 
features, antimicrobial therapy and outcome. Clin Microbiol Infect 13:196-198. 
137. Kuo, S. C., C. P. Fung, Y. T. Lee, C. P. Chen, and T. L. Chen. 2010. 
Bacteremia due to Acinetobacter genomic species 10. J Clin Microbiol 48:586-590. 
138. La Scola, B., V. A. Gundi, A. Khamis, and D. Raoult. 2006. Sequencing of 
the rpoB gene and flanking spacers for molecular identification of Acinetobacter 
species. J Clin Microbiol 44:827-832. 
139. La Scola, B., and D. Raoult. 2004. Acinetobacter baumannii in human body 
louse. Emerg Infect Dis 10:1671-1673. 
140. Lee, H. J., and S. S. Lee. 2010. Acinetobacter kyonggiensis sp. nov., a beta-
glucosidase-producing bacterium, isolated from sewage treatment plant. J Microbiol 
48:754-759. 
Chapter 5 - References 
122 
 
141. Lee, J. S., K. C. Lee, K. K. Kim, I. C. Hwang, C. Jang, N. G. Kim, W. H. Yeo, 
B. S. Kim, Y. M. Yu, and J. S. Ahn. 2009. Acinetobacter antiviralis sp. nov., from 
Tobacco plant roots. J Microbiol Biotechnol 19:250-256. 
142. Lee, K., J. H. Yum, D. Yong, H. M. Lee, H. D. Kim, J. D. Docquier, G. M. 
Rossolini, and Y. Chong. 2005. Novel acquired metallo-beta-lactamase gene, 
bla(SIM-1), in a class 1 integron from Acinetobacter baumannii clinical isolates from 
Korea. Antimicrob Agents Chemother 49:4485-4491. 
143. Lee, Y., C. K. Kim, H. Lee, S. H. Jeong, D. Yong, and K. Lee. 2011. A novel 
insertion sequence, ISAba10, inserted into ISAba1 adjacent to the bla(OXA-23) gene 
and disrupting the outer membrane protein gene carO in Acinetobacter baumannii. 
Antimicrob Agents Chemother 55:361-363. 
144. Lee, Y. T., J. F. Turton, T. L. Chen, R. C. Wu, W. C. Chang, C. P. Fung, C. P. 
Chen, W. L. Cho, L. Y. Huang, and L. K. Siu. 2009. First identification of blaOXA-51-like 
in non-baumannii Acinetobacter spp. J Chemother 21:514-520. 
145. Lepe, J. A., E. Garcia-Cabrera, M. V. Gil-Navarro, and J. Aznar. 2012. 
Rifampin breakpoint for Acinetobacter baumannii based on pharmacokinetic-
pharmacodynamic models with Monte Carlo simulation. Rev Esp Quimioter 25:134-
138. 
146. Lewis, J. S., Jr., O. C. Ukpo, X. J. Ma, J. J. Flanagan, Y. Luo, W. L. 
Thorstad, and R. D. Chernock. 2012. Transcriptionally-active high-risk human 
papillomavirus is rare in oral cavity and laryngeal/hypopharyngeal squamous cell 
carcinomas--a tissue microarray study utilizing E6/E7 mRNA in situ hybridization. 
Histopathology 60:982-991. 
147. Lim, S. K., S. O. Lee, S. H. Choi, J. P. Choi, S. H. Kim, J. Y. Jeong, J. H. 
Woo, and Y. S. Kim. 2011. The outcomes of using colistin for treating multidrug 
resistant Acinetobacter species bloodstream infections. J Korean Med Sci 26:325-331. 
148. Limansky, A. S., M. A. Mussi, and A. M. Viale. 2002. Loss of a 29-kilodalton 
outer membrane protein in Acinetobacter baumannii is associated with imipenem 
resistance. J Clin Microbiol 40:4776-4778. 
149. Lin, L., B. D. Ling, and X. Z. Li. 2009. Distribution of the multidrug efflux pump 
genes, adeABC, adeDE and adeIJK, and class 1 integron genes in multiple-
Chapter 5 - References 
 
123 
 
antimicrobial-resistant clinical isolates of Acinetobacter baumannii-Acinetobacter 
calcoaceticus complex. Int J Antimicrob Agents 33:27-32. 
150. Liu, Y. H., S. C. Kuo, Y. T. Lee, I. C. Chang, S. P. Yang, T. L. Chen, and C. P. 
Fung. 2012. Amino acid substitutions of quinolone resistance determining regions in 
GyrA and ParC associated with quinolone resistance in Acinetobacter baumannii and 
Acinetobacter genomic species 13TU. J Microbiol Immunol Infect 45:108-112. 
151. Loehfelm, T. W., N. R. Luke, and A. A. Campagnari. 2008. Identification and 
characterization of an Acinetobacter baumannii biofilm-associated protein. J Bacteriol 
190:1036-1044. 
152. Lolans, K., T. W. Rice, L. S. Munoz-Price, and J. P. Quinn. 2006. Multicity 
outbreak of carbapenem-resistant Acinetobacter baumannii isolates producing the 
carbapenemase OXA-40. Antimicrob Agents Chemother 50:2941-2945. 
153. Lopes, B. S., B. A. Evans, and S. G. Amyes. 2012. Disruption of the blaOXA-51-
like gene by ISAba16 and activation of the blaOXA-58 gene leading to carbapenem 
resistance in Acinetobacter baumannii Ab244. J Antimicrob Chemother 67:59-63. 
154. Lopez-Otsoa, F., L. Gallego, K. J. Towner, L. Tysall, N. Woodford, and D. 
M. Livermore. 2002. Endemic carbapenem resistance associated with OXA-40 
carbapenemase among Acinetobacter baumannii isolates from a hospital in northern 
Spain. J Clin Microbiol 40:4741-4743. 
155. Lopez-Rojas, R., J. Dominguez-Herrera, M. J. McConnell, F. Docobo-Perez, 
Y. Smani, M. Fernandez-Reyes, L. Rivas, and J. Pachon. 2011. Impaired virulence 
and in vivo fitness of colistin-resistant Acinetobacter baumannii. J Infect Dis 203:545-
548. 
156. Lu, P. L., M. Doumith, D. M. Livermore, T. P. Chen, and N. Woodford. 2009. 
Diversity of carbapenem resistance mechanisms in Acinetobacter baumannii from a 
Taiwan hospital: spread of plasmid-borne OXA-72 carbapenemase. J Antimicrob 
Chemother 63:641-647. 
157. Luo, G., L. Lin, A. S. Ibrahim, B. Baquir, P. Pantapalangkoor, R. A. 
Bonomo, Y. Doi, M. D. Adams, T. A. Russo, and B. Spellberg. 2012. Active and 
passive immunization protects against lethal, extreme drug resistant-Acinetobacter 
baumannii infection. PLoS One 7:e29446. 
Chapter 5 - References 
124 
 
158. Maegele, M., S. Gregor, E. Steinhausen, B. Bouillon, M. M. Heiss, W. 
Perbix, F. Wappler, D. Rixen, J. Geisen, B. Berger-Schreck, and R. Schwarz. 2005. 
The long-distance tertiary air transfer and care of tsunami victims: injury pattern and 
microbiological and psychological aspects. Crit Care Med 33:1136-1140. 
159. Magiorakos, A. P., A. Srinivasan, R. B. Carey, Y. Carmeli, M. E. Falagas, C. 
G. Giske, S. Harbarth, J. F. Hindler, G. Kahlmeter, B. Olsson-Liljequist, D. L. 
Paterson, L. B. Rice, J. Stelling, M. J. Struelens, A. Vatopoulos, J. T. Weber, and 
D. L. Monnet. 2012. Multidrug-resistant, extensively drug-resistant and pandrug-
resistant bacteria: an international expert proposal for interim standard definitions for 
acquired resistance. Clin Microbiol Infect 18:268-281. 
160. Magnet, S., P. Courvalin, and T. Lambert. 2001. Resistance-nodulation-cell 
division-type efflux pump involved in aminoglycoside resistance in Acinetobacter 
baumannii strain BM4454. Antimicrob Agents Chemother 45:3375-3380. 
161. Mahillon, J., and M. Chandler. 1998. Insertion sequences. Microbiol Mol Biol 
Rev 62:725-774. 
162. Mahillon, J., C. Leonard, and M. Chandler. 1999. IS elements as constituents 
of bacterial genomes. Res Microbiol 150:675-687. 
163. Mak, J. K., M. J. Kim, J. Pham, J. Tapsall, and P. A. White. 2009. Antibiotic 
resistance determinants in nosocomial strains of multidrug-resistant Acinetobacter 
baumannii. J Antimicrob Chemother 63:47-54. 
164. Malhotra, J., S. Anand, S. Jindal, R. Raman, and R. Lal. 2012. Acinetobacter 
indicus sp. nov., isolated from hexachlorocyclohexane (HCH) dumpsite. Int J Syst Evol 
Microbiol. 
165. Maragakis, L. L., and T. M. Perl. 2008. Acinetobacter baumannii: 
epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis 46:1254-
1263. 
166. Marchand, I., L. Damier-Piolle, P. Courvalin, and T. Lambert. 2004. 
Expression of the RND-type efflux pump AdeABC in Acinetobacter baumannii is 
regulated by the AdeRS two-component system. Antimicrob Agents Chemother 
48:3298-3304. 
Chapter 5 - References 
 
125 
 
167. Mazel, D. 2006. Integrons: agents of bacterial evolution. Nat Rev Microbiol 
4:608-620. 
168. McConnell, M. J., and J. Pachon. 2010. Active and passive immunization 
against Acinetobacter baumannii using an inactivated whole cell vaccine. Vaccine 
29:1-5. 
169. McConnell, M. J., and J. Pachon. 2011. Expression, purification, and refolding 
of biologically active Acinetobacter baumannii OmpA from Escherichia coli inclusion 
bodies. Protein Expr Purif 77:98-103. 
170. Mendes, R. E., T. Spanu, L. Deshpande, M. Castanheira, R. N. Jones, and 
G. Fadda. 2009. Clonal dissemination of two clusters of Acinetobacter baumannii 
producing OXA-23 or OXA-58 in Rome, Italy. Clin Microbiol Infect 15:588-592. 
171. Merino, M., J. Acosta, M. Poza, F. Sanz, A. Beceiro, F. Chaves, and G. Bou. 
2010. OXA-24 carbapenemase gene flanked by XerC/XerD-like recombination sites in 
different plasmids from different Acinetobacter species isolated during a nosocomial 
outbreak. Antimicrob Agents Chemother 54:2724-2727. 
172. Mihu, M. R., and L. R. Martinez. 2011. Novel therapies for treatment of multi-
drug resistant Acinetobacter baumannii skin infections. Virulence 2:97-102. 
173. Mihu, M. R., U. Sandkovsky, G. Han, J. M. Friedman, J. D. Nosanchuk, and 
L. R. Martinez. 2010. The use of nitric oxide releasing nanoparticles as a treatment 
against Acinetobacter baumannii in wound infections. Virulence 1:62-67. 
174. Moffatt, J. H., M. Harper, B. Adler, R. L. Nation, J. Li, and J. D. Boyce. 2011. 
Insertion Sequence ISAba11 Is Involved in Colistin Resistance and Loss of 
Lipopolysaccharide in Acinetobacter baumannii. Antimicrob Agents Chemother 
55:3022-3024. 
175. Moffatt, J. H., M. Harper, P. Harrison, J. D. Hale, E. Vinogradov, T. 
Seemann, R. Henry, B. Crane, F. St Michael, A. D. Cox, B. Adler, R. L. Nation, J. 
Li, and J. D. Boyce. 2010. Colistin resistance in Acinetobacter baumannii is mediated 
by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother 
54:4971-4977. 
Chapter 5 - References 
126 
 
176. Montefour, K., J. Frieden, S. Hurst, C. Helmich, D. Headley, M. Martin, and 
D. A. Boyle. 2008. Acinetobacter baumannii: an emerging multidrug-resistant 
pathogen in critical care. Crit Care Nurse 28:15-25; quiz 26. 
177. Moon, D. C., C. H. Choi, J. H. Lee, C. W. Choi, H. Y. Kim, J. S. Park, S. I. 
Kim, and J. C. Lee. 2012. Acinetobacter baumannii outer membrane protein A 
modulates the biogenesis of outer membrane vesicles. J Microbiol 50:155-160. 
178. Moreira Silva G, M. L., Marques L, Senra V. 2012. Acinetobacter community-
acquired pneumonia in a healthy child. Rev Port Pneumol 18:96-98. 
179. Mugnier, P. D., L. Poirel, T. Naas, and P. Nordmann. 2010. Worldwide 
dissemination of the blaOXA-23 carbapenemase gene of Acinetobacter baumannii. Emerg 
Infect Dis 16:35-40. 
180. Mugnier, P. D., L. Poirel, and P. Nordmann. 2009. Functional analysis of 
insertion sequence ISAba1, responsible for genomic plasticity of Acinetobacter 
baumannii. J Bacteriol 191:2414-2418. 
181. Mussi, M. A., A. S. Limansky, and A. M. Viale. 2005. Acquisition of resistance 
to carbapenems in multidrug-resistant clinical strains of Acinetobacter baumannii: 
natural insertional inactivation of a gene encoding a member of a novel family of beta-
barrel outer membrane proteins. Antimicrob Agents Chemother 49:1432-1440. 
182. Mussi, M. A., V. M. Relling, A. S. Limansky, and A. M. Viale. 2007. CarO, an 
Acinetobacter baumannii outer membrane protein involved in carbapenem resistance, 
is essential for L-ornithine uptake. FEBS Lett 581:5573-5578. 
183. Naas, T., P. Bogaerts, C. Bauraing, Y. Degheldre, Y. Glupczynski, and P. 
Nordmann. 2006. Emergence of PER and VEB extended-spectrum beta-lactamases in 
Acinetobacter baumannii in Belgium. J Antimicrob Chemother 58:178-182. 
184. Naas, T., F. Namdari, H. Reglier-Poupet, C. Poyart, and P. Nordmann. 2007. 
Panresistant extended-spectrum beta-lactamase SHV-5-producing Acinetobacter 
baumannii from New York City. J Antimicrob Chemother 60:1174-1176. 
185. Nagano, N., Y. Nagano, C. Cordevant, N. Shibata, and Y. Arakawa. 2004. 
Nosocomial transmission of CTX-M-2 beta-lactamase-producing Acinetobacter 
baumannii in a neurosurgery ward. J Clin Microbiol 42:3978-3984. 
Chapter 5 - References 
 
127 
 
186. Navon-Venezia, S., A. Leavitt, and Y. Carmeli. 2007. High tigecycline 
resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 
59:772-774. 
187. Nemec, A., T. De Baere, I. Tjernberg, M. Vaneechoutte, T. J. van der 
Reijden, and L. Dijkshoorn. 2001. Acinetobacter ursingii sp. nov. and Acinetobacter 
schindleri sp. nov., isolated from human clinical specimens. Int J Syst Evol Microbiol 
51:1891-1899. 
188. Nemec, A., L. Dijkshoorn, I. Cleenwerck, T. De Baere, D. Janssens, T. J. 
Van Der Reijden, P. Jezek, and M. Vaneechoutte. 2003. Acinetobacter parvus sp. 
nov., a small-colony-forming species isolated from human clinical specimens. Int J Syst 
Evol Microbiol 53:1563-1567. 
189. Nemec, A., L. Dolzani, S. Brisse, P. van den Broek, and L. Dijkshoorn. 
2004. Diversity of aminoglycoside-resistance genes and their association with class 1 
integrons among strains of pan-European Acinetobacter baumannii clones. J Med 
Microbiol 53:1233-1240. 
190. Nemec, A., L. Krizova, M. Maixnerova, L. Diancourt, T. J. van der Reijden, 
S. Brisse, P. van den Broek, and L. Dijkshoorn. 2008. Emergence of carbapenem 
resistance in Acinetobacter baumannii in the Czech Republic is associated with the 
spread of multidrug-resistant strains of European clone II. J Antimicrob Chemother 
62:484-489. 
191. Nemec, A., L. Krizova, M. Maixnerova, T. J. van der Reijden, P. Deschaght, 
V. Passet, M. Vaneechoutte, S. Brisse, and L. Dijkshoorn. 2011. Genotypic and 
phenotypic characterization of the Acinetobacter calcoaceticus-Acinetobacter 
baumannii complex with the proposal of Acinetobacter pittii sp. nov. (formerly 
Acinetobacter genomic species 3) and Acinetobacter nosocomialis sp. nov. (formerly 
Acinetobacter genomic species 13TU). Res Microbiol 162:393-404. 
192. Nemec, A., M. Musilek, M. Maixnerova, T. De Baere, T. J. van der Reijden, 
M. Vaneechoutte, and L. Dijkshoorn. 2009. Acinetobacter beijerinckii sp. nov. and 
Acinetobacter gyllenbergii sp. nov., haemolytic organisms isolated from humans. Int J 
Syst Evol Microbiol 59:118-124. 
193. Nemec, A., M. Musilek, O. Sedo, T. De Baere, M. Maixnerova, T. J. van der 
Reijden, Z. Zdrahal, M. Vaneechoutte, and L. Dijkshoorn. 2010. Acinetobacter 
Chapter 5 - References 
128 
 
bereziniae sp. nov. and Acinetobacter guillouiae sp. nov., to accommodate 
Acinetobacter genomic species 10 and 11, respectively. Int J Syst Evol Microbiol 
60:896-903. 
194. Nemec, A., M. Musilek, M. Vaneechoute, E. Falsen, and L. Dijkshoorn. 
2008. Lack of evidence for "Acinetobacter septicus" as a species different from 
Acinetobacter ursingii? J Clin Microbiol 46:2826-2827; author reply 2827. 
195. Nigro, S. J., and R. M. Hall. 2012. Tn6167, an antibiotic resistance island in an 
Australian carbapenem-resistant Acinetobacter baumannii GC2, ST92 isolate. J 
Antimicrob Chemother 67:1342-1346. 
196. Nishimura, Y., T. Ino, and H. Iizuka. 1988. Acinetobacter radioresistens sp. 
nov. Isolated from Cotton and Soil. Int J Syst Bacteriol 38:209-211. 
197. Nishimura, Y., H. Kanzaki, and H. Iizuka. 1988. Taxonomic studies of 
Acinetobacter species based on the electrophoretic analysis of enzymes. J Basic 
Microbiol 28:363-370. 
198. Oliva, M. E., A. Rekha, A. Yellin, J. Pasternak, M. Campos, G. M. Rose, T. 
Babinchak, E. J. Ellis-Grosse, and E. Loh. 2005. A multicenter trial of the efficacy 
and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-
abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: 
NCT00081744]. BMC Infect Dis 5:88. 
199. Oncul, O., O. Keskin, H. V. Acar, Y. Kucukardali, R. Evrenkaya, E. M. 
Atasoyu, C. Top, S. Nalbant, S. Ozkan, G. Emekdas, S. Cavuslu, M. H. Us, A. 
Pahsa, and M. Gokben. 2002. Hospital-acquired infections following the 1999 
Marmara earthquake. J Hosp Infect 51:47-51. 
200. Pachon-Ibanez, M. E., F. Docobo-Perez, R. Lopez-Rojas, J. Dominguez-
Herrera, M. E. Jimenez-Mejias, A. Garcia-Curiel, C. Pichardo, L. Jimenez, and J. 
Pachon. 2010. Efficacy of rifampin and its combinations with imipenem, sulbactam, 
and colistin in experimental models of infection caused by imipenem-resistant 
Acinetobacter baumannii. Antimicrob Agents Chemother 54:1165-1172. 
201. Pagkalis, S., E. Mantadakis, M. N. Mavros, C. Ammari, and M. E. Falagas. 
2011. Pharmacological considerations for the proper clinical use of aminoglycosides. 
Drugs 71:2277-2294. 
Chapter 5 - References 
 
129 
 
202. Park, Y. K., G. H. Lee, J. Y. Baek, D. R. Chung, K. R. Peck, J. H. Song, and 
K. S. Ko. 2010. A single clone of Acinetobacter baumannii, ST22, is responsible for 
high antimicrobial resistance rates of Acinetobacter spp. isolates that cause bacteremia 
and urinary tract infections in Korea. Microb Drug Resist 16:143-149. 
203. Park, Y. K., K. R. Peck, H. S. Cheong, D. R. Chung, J. H. Song, and K. S. 
Ko. 2009. Extreme drug resistance in Acinetobacter baumannii infections in intensive 
care units, South Korea. Emerg Infect Dis 15:1325-1327. 
204. Park, Y. S., H. Lee, K. S. Lee, S. S. Hwang, Y. K. Cho, H. Y. Kim, Y. Uh, B. S. 
Chin, S. H. Han, S. H. Jeong, K. Lee, and J. M. Kim. 2010. Extensively drug-resistant 
Acinetobacter baumannii: risk factors for acquisition and prevalent OXA-type 
carbapenemases--a multicentre study. Int J Antimicrob Agents 36:430-435. 
205. Patil, J. R., and B. A. Chopade. 2001. Distribution and in vitro antimicrobial 
susceptibility of Acinetobacter species on the skin of healthy humans. Natl Med J India 
14:204-208. 
206. Paton, R., R. S. Miles, J. Hood, and S. G. Amyes. 1993. ARI 1: beta-
lactamase-mediated imipenem resistance in Acinetobacter baumannii. Int J Antimicrob 
Agents 2:81-87. 
207. Peleg, A. Y., H. Seifert, and D. L. Paterson. 2008. Acinetobacter baumannii: 
emergence of a successful pathogen. Clin Microbiol Rev 21:538-582. 
208. Pellegrino, F. L., V. V. Vieira, P. V. Baio, R. M. Dos Santos, A. L. Dos 
Santos, N. G. Santos, M. M. Meohas, R. T. Santos, T. C. de Souza, R. C. da Silva 
Dias, G. Santoro-Lopes, L. W. Riley, and B. M. Moreira. 2011. Acinetobacter soli as 
a Cause of Bloodstream Infection in a Neonatal Intensive Care Unit. J Clin Microbiol 
49:2283-2285. 
209. Poirel, L., R. A. Bonnin, and P. Nordmann. 2012. Genetic support and 
diversity of acquired extended-spectrum beta-lactamases in Gram-negative rods. Infect 
Genet Evol 12:883-893. 
210. Poirel, L., S. Corvec, M. Rapoport, P. Mugnier, A. Petroni, F. Pasteran, D. 
Faccone, M. Galas, H. Drugeon, V. Cattoir, and P. Nordmann. 2007. Identification of 
the novel narrow-spectrum beta-lactamase SCO-1 in Acinetobacter spp. from 
Argentina. Antimicrob Agents Chemother 51:2179-2184. 
Chapter 5 - References 
130 
 
211. Poirel, L., S. Marque, C. Heritier, C. Segonds, G. Chabanon, and P. 
Nordmann. 2005. OXA-58, a novel class D {beta}-lactamase involved in resistance to 
carbapenems in Acinetobacter baumannii. Antimicrob Agents Chemother 49:202-208. 
212. Poirel, L., and P. Nordmann. 2006. Carbapenem resistance in Acinetobacter 
baumannii: mechanisms and epidemiology. Clin Microbiol Infect 12:826-836. 
213. Poirel, L., and P. Nordmann. 2006. Genetic structures at the origin of 
acquisition and expression of the carbapenem-hydrolyzing oxacillinase gene blaOXA-58 
in Acinetobacter baumannii. Antimicrob Agents Chemother 50:1442-1448. 
214. Post, V., P. A. White, and R. M. Hall. 2010. Evolution of AbaR-type genomic 
resistance islands in multiply antibiotic-resistant Acinetobacter baumannii. J Antimicrob 
Chemother 65:1162-1170. 
215. Potron, A., L. Poirel, J. Croize, V. Chanteperdrix, and P. Nordmann. 2009. 
Genetic and biochemical characterization of the first extended-spectrum CARB-type 
beta-lactamase, RTG-4, from Acinetobacter baumannii. Antimicrob Agents Chemother 
53:3010-3016. 
216. Principe, L., S. D'Arezzo, A. Capone, N. Petrosillo, and P. Visca. 2009. In 
vitro activity of tigecycline in combination with various antimicrobials against multidrug 
resistant Acinetobacter baumannii. Ann Clin Microbiol Antimicrob 8:18. 
217. Queenan, A. M., and K. Bush. 2007. Carbapenemases: the versatile beta-
lactamases. Clin Microbiol Rev 20:440-458, table of contents. 
218. Quinteira, S., F. Grosso, H. Ramos, and L. Peixe. 2007. Molecular 
epidemiology of imipenem-resistant Acinetobacter haemolyticus and Acinetobacter 
baumannii isolates carrying plasmid-mediated OXA-40 from a Portuguese hospital. 
Antimicrob Agents Chemother 51:3465-3466. 
219. Ravasi, P., A. S. Limansky, R. E. Rodriguez, A. M. Viale, and M. A. Mussi. 
2011. ISAba825, a functional insertion sequence modulating genomic plasticity and 
bla(OXA-58) expression in Acinetobacter baumannii. Antimicrob Agents Chemother 
55:917-920. 
220. Regalado, N. G., G. Martin, and S. J. Antony. 2009. Acinetobacter lwoffii: 
bacteremia associated with acute gastroenteritis. Travel Med Infect Dis 7:316-317. 
Chapter 5 - References 
 
131 
 
221. Ribera, A., J. Ruiz, and J. Vila. 2003. Presence of the Tet M determinant in a 
clinical isolate of Acinetobacter baumannii. Antimicrob Agents Chemother 47:2310-
2312. 
222. Roberts, M. C. 2006. Multidrug-resistant genes are associated with an 86-kb 
island in Acinetobacter baumannii. Trends Microbiol 14:375-378. 
223. Robledo, I. E., E. E. Aquino, M. I. Sante, J. L. Santana, D. M. Otero, C. F. 
Leon, and G. J. Vazquez. 2010. Detection of KPC in Acinetobacter spp. in Puerto 
Rico. Antimicrob Agents Chemother 54:1354-1357. 
224. Robledo, I. E., E. E. Aquino, and G. J. Vazquez. 2011. Detection of the KPC 
Gene in Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and 
Acinetobacter baumannii during a PCR-Based Nosocomial Surveillance Study in 
Puerto Rico. Antimicrob Agents Chemother 55:2968-2970. 
225. Roca, I., P. Espinal, S. Marti, and J. Vila. 2011. First identification and 
characterization of an AdeABC-like efflux pump in Acinetobacter genomospecies 
13TU. Antimicrob Agents Chemother 55:1285-1286. 
226. Roca, I., P. Espinal, X. Vila-Farres, and J. Vila. 2012. The Acinetobacter 
baumannii Oxymoron: Commensal Hospital Dweller Turned Pan-Drug-Resistant 
Menace. Frontiers in microbiology 3:148. 
227. Rodriguez-Martinez, J. M., P. Nordmann, E. Ronco, and L. Poirel. 2010. 
Extended-spectrum cephalosporinase in Acinetobacter baumannii. Antimicrob Agents 
Chemother 54:3484-3488. 
228. Rodriguez-Martinez, J. M., L. Poirel, and P. Nordmann. 2010. Genetic and 
functional variability of AmpC-type beta-lactamases from Acinetobacter baumannii. 
Antimicrob Agents Chemother 54:4930-4933. 
229. Rudant, E., P. Bourlioux, P. Courvalin, and T. Lambert. 1994. 
Characterization of the aac(6')-Ik gene of Acinetobacter sp. 6. FEMS Microbiol Lett 
124:49-54. 
230. Rumbo, C., E. Fernandez-Moreira, M. Merino, M. Poza, J. A. Mendez, N. C. 
Soares, A. Mosquera, F. Chaves, and G. Bou. 2011. Horizontal Transfer of the OXA-
24 Carbapenemase Gene via Outer Membrane Vesicles: A New Mechanism of 
Chapter 5 - References 
132 
 
Dissemination of the Carbapenem Resistance Genes in Acinetobacter baumannii. 
Antimicrob Agents Chemother. 
231. Runnegar, N., H. Sidjabat, H. M. Goh, G. R. Nimmo, M. A. Schembri, and D. 
L. Paterson. 2010. Molecular epidemiology of multidrug-resistant Acinetobacter 
baumannii in a single institution over a 10-year period. J Clin Microbiol 48:4051-4056. 
232. Ruzin, A., D. Keeney, and P. A. Bradford. 2007. AdeABC multidrug efflux 
pump is associated with decreased susceptibility to tigecycline in Acinetobacter 
calcoaceticus-Acinetobacter baumannii complex. J Antimicrob Chemother 59:1001-
1004. 
233. Santillana, E., A. Beceiro, G. Bou, and A. Romero. 2007. Crystal structure of 
the carbapenemase OXA-24 reveals insights into the mechanism of carbapenem 
hydrolysis. Proc Natl Acad Sci U S A 104:5354-5359. 
234. Scaife, W., H. K. Young, R. H. Paton, and S. G. Amyes. 1995. Transferable 
imipenem-resistance in Acinetobacter species from a clinical source. J Antimicrob 
Chemother 36:585-586. 
235. Scott, P., G. Deye, A. Srinivasan, C. Murray, K. Moran, E. Hulten, J. 
Fishbain, D. Craft, S. Riddell, L. Lindler, J. Mancuso, E. Milstrey, C. T. Bautista, J. 
Patel, A. Ewell, T. Hamilton, C. Gaddy, M. Tenney, G. Christopher, K. Petersen, T. 
Endy, and B. Petruccelli. 2007. An outbreak of multidrug-resistant Acinetobacter 
baumannii-calcoaceticus complex infection in the US military health care system 
associated with military operations in Iraq. Clin Infect Dis 44:1577-1584. 
236. Sedo, O., A. Vorac, and Z. Zdrahal. 2011. Optimization of mass spectral 
features in MALDI-TOF MS profiling of Acinetobacter species. Syst Appl Microbiol 
34:30-34. 
237. Segal, H., S. Garny, and B. G. Elisha. 2005. Is IS(ABA-1) customized for 
Acinetobacter? FEMS Microbiol Lett 243:425-429. 
238. Seifert, H., L. Dijkshoorn, P. Gerner-Smidt, N. Pelzer, I. Tjernberg, and M. 
Vaneechoutte. 1997. Distribution of Acinetobacter species on human skin: comparison 
of phenotypic and genotypic identification methods. J Clin Microbiol 35:2819-2825. 
239. Shahcheraghi, F., M. Abbasalipour, M. Feizabadi, G. Ebrahimipour, and N. 
Akbari. 2011. Isolation and genetic characterization of metallo-beta-lactamase and 
Chapter 5 - References 
 
133 
 
carbapenamase producing strains of Acinetobacter baumannii from patients at Tehran 
hospitals. Iranian journal of microbiology 3:68-74. 
240. Shin, J. H., H. W. Lee, S. M. Kim, and J. Kim. 2009. Proteomic analysis of 
Acinetobacter baumannii in biofilm and planktonic growth mode. J Microbiol 47:728-
735. 
241. Siguier, P., J. Perochon, L. Lestrade, J. Mahillon, and M. Chandler. 2006. 
ISfinder: the reference centre for bacterial insertion sequences. Nucleic Acids Res 
34:D32-36. 
242. Solak, Y., H. Atalay, K. Turkmen, Z. Biyik, N. Genc, and M. Yeksan. 2011. 
Community-acquired carbapenem-resistant Acinetobacter baumannii urinary tract 
infection just after marriage in a renal transplant recipient. Transpl Infect Dis. 
243. Soon, R. L., R. L. Nation, S. Cockram, J. H. Moffatt, M. Harper, B. Adler, J. 
D. Boyce, I. Larson, and J. Li. 2011. Different surface charge of colistin-susceptible 
and -resistant Acinetobacter baumannii cells measured with zeta potential as a function 
of growth phase and colistin treatment. J Antimicrob Chemother 66:126-133. 
244. Strateva, T., A. Todorova, V. Ouzounova-Raykova, and I. Mitov. 2008. 
Emergence of a PER-1 extended-spectrum beta-lactamase-producing Acinetobacter 
baumannii clinical isolate in Bulgaria. J Chemother 20:391-392. 
245. Svara, F., and D. J. Rankin. 2011. The evolution of plasmid-carried antibiotic 
resistance. BMC Evol Biol 11:130. 
246. Tayabali, A. F., K. C. Nguyen, P. S. Shwed, J. Crosthwait, G. Coleman, and 
V. L. Seligy. 2012. Comparison of the virulence potential of Acinetobacter strains from 
clinical and environmental sources. PLoS One 7:e37024. 
247. Tian, G. B., J. M. Adams-Haduch, T. Bogdanovich, A. W. Pasculle, J. P. 
Quinn, H. N. Wang, and Y. Doi. 2011. Identification of diverse OXA-40 group 
carbapenemases, including a novel variant, OXA-160, from Acinetobacter baumannii in 
Pennsylvania. Antimicrob Agents Chemother 55:429-432. 
248. Timurkaynak, F., F. Can, O. K. Azap, M. Demirbilek, H. Arslan, and S. O. 
Karaman. 2006. In vitro activities of non-traditional antimicrobials alone or in 
combination against multidrug-resistant strains of Pseudomonas aeruginosa and 
Chapter 5 - References 
134 
 
Acinetobacter baumannii isolated from intensive care units. Int J Antimicrob Agents 
27:224-228. 
249. Tjernberg, I., and J. Ursing. 1989. Clinical strains of Acinetobacter classified 
by DNA-DNA hybridization. APMIS 97:595-605. 
250. Tomaras, A. P., C. W. Dorsey, R. E. Edelmann, and L. A. Actis. 2003. 
Attachment to and biofilm formation on abiotic surfaces by Acinetobacter baumannii: 
involvement of a novel chaperone-usher pili assembly system. Microbiology 149:3473-
3484. 
251. Tomaras, A. P., M. J. Flagler, C. W. Dorsey, J. A. Gaddy, and L. A. Actis. 
2008. Characterization of a two-component regulatory system from Acinetobacter 
baumannii that controls biofilm formation and cellular morphology. Microbiology 
154:3398-3409. 
252. Tong, M. J. 1972. Septic complications of war wounds. JAMA 219:1044-1047. 
253. Towner, K. J. 2009. Acinetobacter: an old friend, but a new enemy. J Hosp 
Infect 73:355-363. 
254. Towner, K. J., B. Evans, L. Villa, K. Levi, A. Hamouda, S. G. Amyes, and A. 
Carattoli. 2011. Distribution of Intrinsic Plasmid Replicase Genes and Their 
Association with Carbapenem-Hydrolyzing Class D {beta}-Lactamase Genes in 
European Clinical Isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 
55:2154-2159. 
255. Townsend, J. P., T. Bohn, and K. M. Nielsen. 2012. Assessing the probability 
of detection of horizontal gene transfer events in bacterial populations. Frontiers in 
microbiology 3:27. 
256. Turton, J. F., S. N. Gabriel, C. Valderrey, M. E. Kaufmann, and T. L. Pitt. 
2007. Use of sequence-based typing and multiplex PCR to identify clonal lineages of 
outbreak strains of Acinetobacter baumannii. Clin Microbiol Infect 13:807-815. 
257. Turton, J. F., J. Shah, C. Ozongwu, and R. Pike. 2010. Incidence of 
Acinetobacter species other than A. baumannii among clinical isolates of 
Acinetobacter: evidence for emerging species. J Clin Microbiol 48:1445-1449. 
Chapter 5 - References 
 
135 
 
258. Turton, J. F., M. E. Ward, N. Woodford, M. E. Kaufmann, R. Pike, D. M. 
Livermore, and T. L. Pitt. 2006. The role of ISAba1 in expression of OXA 
carbapenemase genes in Acinetobacter baumannii. FEMS Microbiol Lett 258:72-77. 
259. Turton, J. F., N. Woodford, J. Glover, S. Yarde, M. E. Kaufmann, and T. L. 
Pitt. 2006. Identification of Acinetobacter baumannii by detection of the blaOXA-51-like 
carbapenemase gene intrinsic to this species. J Clin Microbiol 44:2974-2976. 
260. van den Broek, P. J., T. J. van der Reijden, E. van Strijen, A. V. Helmig-
Schurter, A. T. Bernards, and L. Dijkshoorn. 2009. Endemic and epidemic 
Acinetobacter species in a university hospital: an 8-year survey. J Clin Microbiol 
47:3593-3599. 
261. van Dessel, H., L. Dijkshoorn, T. van der Reijden, N. Bakker, A. Paauw, P. 
van den Broek, J. Verhoef, and S. Brisse. 2004. Identification of a new 
geographically widespread multiresistant Acinetobacter baumannii clone from 
European hospitals. Res Microbiol 155:105-112. 
262. Vaneechoutte, M., T. De Baere, A. Nemec, M. Musilek, T. J. van der 
Reijden, and L. Dijkshoorn. 2008. Reclassification of Acinetobacter grimontii Carr et 
al. 2003 as a later synonym of Acinetobacter junii Bouvet and Grimont 1986. Int J Syst 
Evol Microbiol 58:937-940. 
263. Vaneechoutte, M., L. Dijkshoorn, I. Tjernberg, A. Elaichouni, P. de Vos, G. 
Claeys, and G. Verschraegen. 1995. Identification of Acinetobacter genomic species 
by amplified ribosomal DNA restriction analysis. J Clin Microbiol 33:11-15. 
264. Vaneechoutte, M., A. Nemec, M. Musilek, T. J. van der Reijden, M. van den 
Barselaar, I. Tjernberg, W. Calame, R. Fani, T. De Baere, and L. Dijkshoorn. 2009. 
Description of Acinetobacter venetianus ex Di Cello et al. 1997 sp. nov. Int J Syst Evol 
Microbiol 59:1376-1381. 
265. Vasilev, K., G. Reshedko, R. Orasan, M. Sanchez, J. Teras, T. Babinchak, 
G. Dukart, A. Cooper, N. Dartois, H. Gandjini, R. Orrico, and E. Ellis-Grosse. 2008. 
A Phase 3, open-label, non-comparative study of tigecycline in the treatment of 
patients with selected serious infections due to resistant Gram-negative organisms 
including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. J 
Antimicrob Chemother 62 Suppl 1:i29-40. 
Chapter 5 - References 
136 
 
266. Vaz-Moreira, I., A. Novo, E. Hantsis-Zacharov, A. R. Lopes, M. Gomila, O. 
C. Nunes, C. M. Manaia, and M. Halpern. 2011. Acinetobacter rudis sp. nov. isolated 
from raw milk and raw wastewater. Int J Syst Evol Microbiol. 
267. Vila, J., S. Marti, and J. Sanchez-Cespedes. 2007. Porins, efflux pumps and 
multidrug resistance in Acinetobacter baumannii. J Antimicrob Chemother 59:1210-
1215. 
268. Villegas, M. V., and A. I. Hartstein. 2003. Acinetobacter outbreaks, 1977-
2000. Infect Control Hosp Epidemiol 24:284-295. 
269. Villegas, M. V., J. N. Kattan, A. Correa, K. Lolans, A. M. Guzman, N. 
Woodford, D. Livermore, and J. P. Quinn. 2007. Dissemination of Acinetobacter 
baumannii clones with OXA-23 Carbapenemase in Colombian hospitals. Antimicrob 
Agents Chemother 51:2001-2004. 
270. Vincent, J. L., J. Rello, J. Marshall, E. Silva, A. Anzueto, C. D. Martin, R. 
Moreno, J. Lipman, C. Gomersall, Y. Sakr, and K. Reinhart. 2009. International 
study of the prevalence and outcomes of infection in intensive care units. JAMA 
302:2323-2329. 
271. Wagenvoort, J. H., E. I. De Brauwer, H. M. Toenbreker, and C. J. van der 
Linden. 2002. Epidemic Acinetobacter baumannii strain with MRSA-like behaviour 
carried by healthcare staff. Eur J Clin Microbiol Infect Dis 21:326-327. 
272. Wagenvoort, J. H., and E. J. Joosten. 2002. An outbreak Acinetobacter 
baumannii that mimics MRSA in its environmental longevity. J Hosp Infect 52:226-227. 
273. Walsh, T. R. 2005. The emergence and implications of metallo-beta-
lactamases in Gram-negative bacteria. Clin Microbiol Infect 11 Suppl 6:2-9. 
274. Walsh, T. R., M. A. Toleman, L. Poirel, and P. Nordmann. 2005. Metallo-
beta-lactamases: the quiet before the storm? Clin Microbiol Rev 18:306-325. 
275. Wang, Y., P. Hao, B. Lu, H. Yu, W. Huang, H. Hou, and K. Dai. 2010. Causes 
of infection after earthquake, China, 2008. Emerg Infect Dis 16:974-975. 
276. Wood, G. C., S. D. Hanes, B. A. Boucher, M. A. Croce, and T. C. Fabian. 
2003. Tetracyclines for treating multidrug-resistant Acinetobacter baumannii ventilator-
associated pneumonia. Intensive Care Med 29:2072-2076. 
Chapter 5 - References 
 
137 
 
277. Ws Coriolano, M. D., R. B. L, D. Carneiro, G. A. A, P. J. Al Oliveira, D. M. da 
Silva, and G. L. O. 2012. Swallowing in Patients with Parkinson's Disease: A Surface 
Electromyography Study. Dysphagia. 
278. Xu, N., D. P. Huang, H. S. Yang, Z. G. Lai, and Q. Luo. 2012. Ocular Surface 
Characteristics and Impression Cytology in Patients with Active versus Inactive Thyroid 
Eye Disease. Yan ke xue bao = Eye science / "Yan ke xue bao" bian ji bu 27:64-68. 
279. Yang, H., L. Liang, S. Lin, and S. Jia. 2010. Isolation and characterization of a 
virulent bacteriophage AB1 of Acinetobacter baumannii. BMC Microbiol 10:131. 
280. Yang, H. Y., H. J. Lee, J. T. Suh, and K. M. Lee. 2009. Outbreaks of imipenem 
resistant Acinetobacter baumannii producing OXA-23 beta-lactamase in a tertiary care 
hospital in Korea. Yonsei Med J 50:764-770. 
281. Yoon, J. H., I. G. Kim, and T. K. Oh. 2007. Acinetobacter marinus sp. nov. and 
Acinetobacter seohaensis sp. nov., isolated from sea water of the Yellow Sea in Korea. 
J Microbiol Biotechnol 17:1743-1750. 
282. Yuan, P., K. Meng, P. Shi, H. Luo, H. Huang, T. Tu, P. Yang, and B. Yao. 
2012. An alkaline-active and alkali-stable pectate lyase from Streptomyces sp. S27 
with potential in textile industry. J Ind Microbiol Biotechnol 39:909-915. 
283. Yun, S. H., C. W. Choi, S. O. Kwon, G. W. Park, K. Cho, K. H. Kwon, J. Y. 
Kim, J. S. Yoo, J. C. Lee, J. S. Choi, S. Kim, and S. I. Kim. 2011. Quantitative 
proteomic analysis of cell wall and plasma membrane fractions from multidrug-resistant 
Acinetobacter baumannii. J Proteome Res 10:459-469. 
284. Zarrilli, R., M. Giannouli, F. Tomasone, M. Triassi, and A. Tsakris. 2009. 
Carbapenem resistance in Acinetobacter baumannii: the molecular epidemic features 
of an emerging problem in health care facilities. J Infect Dev Ctries 3:335-341. 
285. Zhanel, G. G., R. Wiebe, L. Dilay, K. Thomson, E. Rubinstein, D. J. Hoban, 
A. M. Noreddin, and J. A. Karlowsky. 2007. Comparative review of the carbapenems. 
Drugs 67:1027-1052. 
286. Zhao, W. S., G. Y. Liu, Z. H. Mi, and F. Zhang. 2011. Coexistence of blaOXA-23 
with armA and novel gyrA mutation in a pandrug-resistant Acinetobacter baumannii 
isolate from the blood of a patient with haematological disease in China. J Hosp Infect 
77:278-279. 
Chapter 5 - References 
138 
 
287. Zhou, Y., H. Yu, Q. Guo, X. Xu, X. Ye, S. Wu, Y. Guo, and M. Wang. 2010. 
Distribution of 16S rRNA methylases among different species of Gram-negative bacilli 
with high-level resistance to aminoglycosides. Eur J Clin Microbiol Infect Dis 29:1349-
1353. 
288. Zordan, S., E. Prenger-Berninghoff, R. Weiss, T. van der Reijden, P. van 
den Broek, G. Baljer, and L. Dijkshoorn. 2011. Multidrug-resistant Acinetobacter 
baumannii in veterinary clinics, Germany. Emerg Infect Dis 17:1751-1754. 
 
 
  
 
  
“Measure what is measurable, and make measurable what is not so.” 
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CHAPTER 6 - APPENDIX 
 
6.1 MATERIAL AND METHODS 
 
6.1.1 Bacterial isolates and epidemiological background 
 
The collection of Acinetobacter spp isolates (n=265, corresponding to A. baumannii, 
n=262; A. haemolyticus, n=2; and A. lwoffii, n=1) included in this thesis was obtained 
between 1995 and 2008. This collection included previously published isolates 
obtained between 1995 and 2003 (A. baumannii, n=8; A. haemolyticus, n=2), with the 
purpose of plasmid characterization and for longitudinal epidemiological studies (12, 
37).  A new and unpublished collection (n=229, corresponding to A. baumannii, n=228; 
and A. lwoffii, n=1) was obtained between 2004 and 2008 from several hospitals and 
two clinical analysis laboratories, located in North and Centre of Portugal. These 
isolates were included for longitudinal epidemiological studies, and plasmid and 
carbapenem resistance characterization. 
International clinical isolates from Brazil (A. baumannii, n=17) and Czech Republic (A. 
baumannii, n=9) were included for population structure analysis and comparison with 
Portuguese isolates. Concerning the Czech Republic isolates, the associated 
carbapenem resistance mechanism was also investigated. 
The main characteristics of all isolates included in the present thesis are summarized in 
Table 5. Control and reference strains are indicated on Table 6.  
6.1.2  Media and growth conditions 
Different media were used for isolation and growth of Acinetobacter spp isolates. 
Isolates growth was performed aerobically at 37 ºC (8-24h). 
• Cystine Lactose Electrolyte Deficient (CLED) Agar medium (Liofilchem, Italy), 
an electrolyte deficient and non-inhibitory differential medium, was routinely 
used for bacterial growth;  
• Tryptone Soya Broth (TSB) (Oxoid Ltd.) supplemented with glycerol (15%) was 
used to stock Acinetobacter spp. cultures at -80 ºC; 
• Mueller-Hinton II (MH) Agar, a non-selective and non-differential medium, was 
used for antimicrobial susceptibility testing;  
• Luria-Bertani (LB) Broth, a nutritionally rich medium, was used to promote the 
growth of bacteria; 
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• Blood agar plate (BAP), a differential media generally used to isolate fastidious 
organisms and detect hemolytic activity, was employed to cultivate bacteria for 
agarose-embedded bacterial genomic DNA preparation. 
6.1.3  Species identification  
Isolate’s identification and antimicrobial susceptibilities were firstly conducted within 
each hospital by the automated Vitek 2 system (bioMérieux, Marcy l'Étoile, France). 
Identification of the isolates was, thereafter, confirmed at our laboratory by API 20NE 
system (bioMérieux, Marcy l'Étoile, France) with subsequent sequencing of 16S rRNA 
gene and by the detection of species-specific β-lactamases: OXA-51-like for A. 
baumannii and OXA-134-like for A. lwoffii (18, 46, 49) 
6.1.4  Antimicrobial susceptibility testing 
6.1.4.1  Disc diffusion method 
In vitro susceptibility for β-lactams, aminoglycosides, tetracyclines and fluoroquinolones 
was determined by standard disc diffusion method - the Kirby-Bauer method - following 
the CLSI (Clinical Laboratory Standards Institute) guidelines (10). The routine panel of 
antibiotics tested in Acinetobacter spp. included: amoxicillin (10 µg), amoxicillin–
clavulanic acid (20+10 µg), piperacillin (100 µg), ceftazidime (30 µg), cefepime (30 µg), 
cefotaxime (30 µg), cefoxitin (30 µg), ceftriaxone (30 µg), imipenem (10 µg), 
meropenem (10 µg), aztreonam (30 µg), gentamicin (10 µg), tobramycin (10 µg), 
netilmicin (30 µg), amikacin (30 µg), tetracycline (30 µg) and ciprofloxacin (5 µg) (Oxoid 
Ltd, Basingstoke, Hants, UK). The accuracy of the test was monitored by using the 
control strain Pseudomonas aeruginosa ATCC 27853 (susceptible and wild type 
strain). Inhibition zone diameters were measured and isolates were reported as 
susceptible (S), intermediate (I) or resistant (R) according to the CLSI Zone Diameter 
Interpretative Standards (10). 
6.1.4.2 Agar dilution method 
Minimum inhibitory concentration (MIC) is defined as the lowest concentration of an 
antimicrobial agent that will inhibit the visible growth of a microorganism after overnight 
incubation. MICs for minocycline, tigecycline and colistin were performed by an agar 
dilution technique (10) where MH plates are supplemented with antibiotic solutions in a 
range of concentrations with a two-fold dilution series. The inocula were transferred 
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both to the series of agar plates with an inoculum-replicating apparatus (Multipoint 
inoculator A400, Denley, Sussex, England), and to a control plate without antimicrobial 
agent. For minocycline, MICs results were interpreted according to CLSI guidelines 
(10). For colistin, the resistance breakpoint was defined as a MIC 4 µg/ml following 
EUCAST guidelines (http://www.eucast.org/clinical_breakpoints/). As no tigecycline 
interpretive criteria currently exist for Acinetobacter spp., the Food and Drug 
Administration approved breakpoints for members of the Enterobacteriaceae family of 
2, 4, and 8 µg/mL (designating tigecycline susceptible, intermediate and resistant, 
respectively), which were applied as provisional MIC breakpoints.  
6.1.4.3 Epsilon test (E-test) 
The E-test (AB Biodisk) method combines the principle of the agar diffusion test with 
the determination of the MIC value. A predefined stable antimicrobial gradient is 
present on a thin inert carrier strip. When this E-test strip is applied onto an inoculated 
agar plate, there is an immediate release of the drug. Following incubation, an elliptical 
zone of inhibition is produced. The point of intersection of the inhibitory zone edge and 
the calibrated carrier strip indicates the MIC value over a wide concentration range 
(>10 dilutions). MICs for amoxicillin, amoxicillin–clavulanic acid, ticarcillin, ticarcillin–
clavulanic acid, piperacillin, piperacillin–tazobactam, ceftazidime, cefotaxime, 
cefpirome, cefpime, cefoxitin, cefalotin, imipenem and meropenem were determined by 
E-test in representative isolates. 
6.1.5  Phenotypic characterization of antibiotic resistance 
6.1.5.1 Detection and characterization of carbapenemases  
Carbapenemase-producing clinical isolates usually display high carbapenem MICs. In 
accordance, several methodologies have been proposed for the routine phenotypic 
detection of carbapenemase activity in clinical isolates. Although generally considered 
as fast, efficacious and easy-to-perform methods, some concerns regarding their 
reliability emerged and have been pointed out (38).  
6.1.5.1.1 Modified Hodge Test (MHT) 
The Modified Hodge Test is based on the capacity displayed by a carbapenemase-
producing isolate to allow the growth of a carbapenem susceptible strain (E.coli ATCC 
25922) towards a carbapenem disk, resulting in a characteristic cloverleaf-like 
indentation (27). A cell suspension of E.coli ATCC 25922 was prepared in 5 ml of 
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0.85% physiological saline and adjusted to McFarland 0.5 standard. This suspension 
was diluted to 1:10 and streaked on MH agar plates, allowing to dry 3-5 minutes. An 
imipenem or meropenem disk (10 µg) was placed in the center of the test area. The 
tested isolates were streaked in a straight line from the edge of the disk to the edge of 
the plate. The plates were incubated at 37ºC (18-24 hours). An MHT positive test was 
revealed by a clover leaf-like indentation of the E.coli ATCC 25922 growing along the 
test organism growth streak within the disk diffusion zone.  
6.1.5.1.2 Imipenem - ethylenediaminetetraacetic acid (EDTA) double 
disk synergy test 
Metallo-β-lactamases belong to Ambler class B and require zinc for their catalytic 
activity, being inhibited by metal chelators, such as EDTA. The disk approximation test 
with EDTA is often used as a screening method for metallo-β-lactamases. In the 
presence of a metallo-β-lactamase, appeared a synergistic inhibition zone around the 
β-lactam disk (imipenem, ceftazidime, and cefepime) (28). Cell suspensions from 
strains were adjusted to the McFarland 0.5 standard and used to inoculate MH agar 
plates, where an imipenem disk (10µg) and a blank filter paper disk were placed at a 
distance of 10 mm (edge to edge). Then, 10 µl of a 0.2 M EDTA solution was added to 
the blank disk. It is important to remark that most papers describe the use of 0.5 M 
EDTA (27, 28), however disks containing solely EDTA can produce an inhibitory action 
against some bacteria due to permeabilization of the outer membrane and can lead to 
false positive results, especially when is used at higher concentrations (38). After 
overnight incubation, the presence of even a small synergistic inhibition zone was 
interpreted as positive. 
6.1.5.1.3 Detection of carbapenemase activity by a microbiological 
assay 
Detection of carbapenemase activity was carried out using enzymatic crude extracts 
that were prepared with overnight cultures (37ºC, 18 hours) grown in 50 mL of TSB 
(Oxoid). Cells were harvested by centrifugation at 3000 rpm, for 10 minutes at 4°C, 
washed twice with 10 mL of 0.85% physiological saline and suspended in 500 µL of 
sterile distilled water.  Lysis was obtained with 5-6 freeze-thaw cycles. The 
microbiological assay included the preparation of a cell suspension of E. coli ATCC 
25922 in 5 mL of 0.85% physiological saline and adjusted to McFarland 0.5 standard. 
This suspension was streaked to the plates allowing to dry 3-5 minutes and imipenem 
discs (10µg) impregnated with 10 µl of each enzymatic extract alone or with 10 µl of a 
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0.5 M EDTA solution were added. Plates were incubated at 37ºC overnight. 
Inactivation of imipenem by a carbapenemase was revealed by the E. coli ATCC 25922 
strain growth within the expected inhibition zone. If a MBL was present, the inactivation 
of imipenem was inhibited by the addition of EDTA.  
6.1.5.1.4 Detection of carbapenemase activity by 
spectrophotometric assay 
Investigation of carbapenemase activity in crude extracts was performed by UV 
spectrophotometric assays. The hydrolytic activity of crude extracts was determined 
against 100 µM imipenem in 100 mM phosphate buffer (pH 7.0), and measurements 
were carried out at 297 nm. Positive controls included VIM-2-producing Pseudomonas 
aeruginosa, IMP-5-producing A. baumannii and OXA-40-producing A. baumannii 
(Table 6). 
6.1.5.1.5 Isoelectric focusing of carbapenemases 
Isoelectric focusing (IEF) separates proteins by charge at their isoelectric points (pI) in 
an electrophoretically-produced pH gradient. Samples (crude extracts) were applied on 
the surface of the polyacrylamide gel with a pH gradient of 3-9 (PhastGel IEF 3-9, 
Amersham Biosciences) and a pre-focusing phase was performed in order to establish 
the gradient. The IEF conditions were set according to the apparatus PhastSystem 
(Pharmacia AB) manufacturer instructions. Detection of β-lactamase bands was 
facilitated by overlaying the gel with nitrocefin. The corresponding pIs were determined 
by comparing the migration distance between the obtained bands and those from a 
ladder pre-prepared with crude extracts of β-lactamase-producing strains containing 
known pIs (5.4, 5.7, 7, 7.4 and 8.2).  
6.1.5.2 Detection of antibiotic resistance mediated by efflux systems 
To determine the presence of an efflux mechanism involved in A. baumannii resistance 
to imipenem, tigecycline and amikacin, a MIC assay was conducted for the protonic 
efflux pump inhibitor carbonyl cyanide m-chlorophenylhydrazone (CCCP) (Sigma-
Aldrich, USA) using the agar dilution method, according to the guidelines established 
by CLSI (10). MH agar plates supplemented with the antibiotic under study (imipenem, 
tigecycline or amikacin) were prepared with and without CCCP. The final concentration 
of CCCP in the MH agar was 16 mg/L, corresponding to a quarter of MIC (6) previously 
determined. An inoculum of 0.5 Mcfarland standard of each isolate was inoculated onto 
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MH medium containing serial dilutions of the antibiotic. Four-fold or more reduction (41) 
of imipenem, tigecycline or amikacin MICs in the presence of CCCP was considered 
indicative for the presence of an efflux system mode of resistance against these 
antibiotics. 
6.1.6 Molecular Biology Techniques  
6.1.6.1 Extraction of bacterial DNA   
The different methods used for the isolation of chromosomal or plasmid DNA included 
the disruption of the cell, removal of cell debris and proteins, and the selective 
precipitation of double-stranded DNA of high molecular weight.  
6.1.6.1.1 Genomic DNA 
In most cases DNA samples were extracted by a boiling method. A loopfull from a 
colony was suspended in 200 µL of distilled water. The suspension was boiled for 
10 min and centrifuged at 13000 rpm for 15 min. The supernatant was used as a 
template (2µL in a final volume of 25 µL) for PCR reactions. DNA was stored at –20°C 
until further use. In particular cases (preparation of DNA templates for MLST PCR 
reactions) DNA was extracted by a commercial kit (InstaGene™Matrix, Bio-Rad 
Laboratories, Inc., Hercules, CA). Briefly, an isolated bacterial colony was suspended 
in 1 mL of sterile water in a microfuge tube and centrifuged for 1 min at 10000–12000 
rpm. The supernatant was removed and 200 µl of InstaGene matrix were added to the 
pellet and incubated at 56ºC for 15–30 min. The mixture was vortexed at high speed 
for 10 sec and the tube was placed in a 100ºC boiling water bath for 8 min. The mixture 
was vortexed at high speed for 10 sec and centrifuged at 10000–12000 rpm for 2–3 
min. The supernatant was used as the template for PCR and the remainder was stored 
at -20ºC.  
Standard procedures for DNA preparation do not yield intact, high molecular weight 
DNA molecules. Large DNA molecules are so fragile that they are sheared by 
mechanical forces during isolation. To prevent breakage of large DNA molecules, 
extraction was performed with intact cells embedded in agarose that were lysed and 
deproteinized in situ according to reference methods (9) . Briefly, individual bacterial 
colonies grown overnight on BAP medium, were suspended directly in 1 mL of Cell 
Suspension Buffer (100 mM Tris:100 mM EDTA, pH 8.0) with cotton swabs  moistened 
with the same buffer. Aliquots of 200 µL of the cell suspensions were transferred to 1.5-
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mL microcentrifuge tubes. Proteinase K (20 mg/mL stock solution) was added (10 µL) 
to each tube and mixed gently with pipet tip. Seakem Gold agarose (Lonza, Rockland, 
ME USA) was prepared in TE Buffer (10 mM Tris:1 mM EDTA, pH 8.0) and 20% SDS 
(pre-heated to 55ºC) to a final concentration of 1.0% agarose:1.0% SDS (sodium 
dodecyl sulfate), and maintained at 55°C in a shaki ng water bath. An equal volume of 
agarose (200 µL) was mixed with each bacterial suspension with the help of a pipette. 
This bacterium-agarose mixture was immediately added to plug molds (Bio-Rad 
Laboratories). The plugs were allowed to solidify for 15 min at room temperature and 
then transferred to 50 mL polypropylene screw-cap tubes containing 5 mL of Cell Lysis 
Buffer (50 mM Tris:50 mM EDTA, pH 8.0 + 1% Sarcosyl) and Proteinase K (final 
concentration of 0.1 mg/mL in the lysis buffer). They were incubated in a shaking water 
bath at 55°C for 2 h. After the completion of prote olysis, the plugs were transferred to 
50-mL tubes containing 8 to 10 mL of sterile, preheated (50°C) distilled water and 
incubated for 10 min at 50°C with gentle mixing in a shaker water bath. Subsequently, 
four 50°C washes were done in a shaking water bath for 15 min each with 8 to 10 ml of 
preheated (50°C) TE buffer. The plugs were then cooled to room temperature in TE 
buffer. At this point, they could be used immediately or stored at 4°C in 1 mL of TE 
buffer.  
6.1.6.1.2 Plasmid DNA 
Plasmid DNA was obtained using a commercial kit and following the manufacturer´s 
instructions (QIAGEN Plasmid Purification Midi Kit). Briefly, the protocol was based on 
a modified alkaline lysis procedure followed by binding of plasmid DNA to an anion-
exchange resin and further elution with an appropriate buffer. After this step the 
plasmid DNA was concentrated and desalted by isopropanol precipitation. 
6.1.6.1.3 DNA digestion 
Comparison of restriction fragment length polymorphism (RFLP) patterns was used to 
analyze similarities among plasmids. The restriction enzymes (EcoRI, BamHI and 
HindIII) were selected based on the plasmid nucleotide sequences deposited on 
GenBank for blaOXA-40-carrying plasmids. Reaction conditions were implemented 
according with the manufacturer’s instructions. The incubation time was overnight (16-
24h) at the optimal temperature for each enzyme (25 ºC or 37 ºC). 
Genomic DNA embedded in agarose plugs was digested in the same way to liquid-
phase reactions, but providing higher enzyme concentrations and longer incubation 
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times. One slice of 2 mm-thick from each plug was pre-equilibrated in the appropriate 
restriction enzyme buffer for 10-30 minutes and then digested [1X restriction enzyme 
buffer, 10-30 U of enzyme (ApaI, I-CeuI, S1) and 1X BSA)] at 25 ºC or 37 ºC and 
appropriated incubation time (15 min-16h).  
6.1.6.2 Extraction of bacterial messenger RNA (mRNA) 
The relative quantification of mRNA by quantitative real-time-PCR (qRT-PCR) can 
reflect the gene-expression profile of a given organism. However, RNA is relatively 
unstable, being very sensitive to degradation which occurs through cleavage with 
ribonucleases (RNases). For an accurate quantification of mRNA levels with 
quantitative real-time-PCR it is necessary to obtain intact mRNA. In this study RNA 
templates were prepared using an RNeasy kit (QIAGEN Sciences, MD) according to 
the manufacturer’s instructions. This commercial kit combines the technology of the 
selective binding properties of a silica-based membrane with the speed of microspin 
technology. Briefly, bacterial cells were grown aerobically in LB broth until mid-log 
phase. Then, cells were lysed and homogenized in the presence of a highly denaturing 
guanidine-thiocyanate–containing buffer, which immediately inactivates RNases to 
ensure purification of intact RNA. Ethanol was added to provide appropriate binding 
conditions, and the sample was applied to an RNeasy Mini spin column, where the total 
RNA was attached to the membrane and contaminants were washed away. RNA was 
eluted in 30µl water treated with 0.1% diethyl pyrocarbonate (DEPC). DEPC is a 
strong, but not absolute, inhibitor of RNases that works by covalently modifying 
RNases. Residual DNA was removed by DNase I digestion following RNA isolation, 
using the QIAGEN RNase-Free DNase Set (QIAGEN Sciences, MD). The 
concentration of RNA was determined by measuring the absorbance at 260 nm (A260).  
6.1.6.3 Amplification of Nucleic Acids 
6.1.6.3.1 Polymerase Chain Reaction - general conditions 
 
In this study, PCR reactions, both by simplex and multiplex schemes, were performed 
with the purpose of detection, identification and characterization of several DNA 
sequences. 
Primers, reagents and amplification conditions are described on Table 7. PCR 
amplifications were performed in termocyclers iCycler (BioRad) or MyCycler (BioRad). 
Primers synthesis was carried out by STAB Vida, Portugal. 
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PCR products purification was performed before sequencing or labeling. This 
purification was achieved by using a commercial kit, the Wizard SV Gel and PCR 
CleanUp System (Promega), following the manufacturer’s instructions. Briefly, after 
DNA binding to a silica membrane, residual primers, excess of nucleotides and Taq 
polymerase were removed by washing with an ethanol-based solution. Finally, the DNA 
was eluted in nuclease-free water. 
The amplified fragments were sequenced by STAB Vida, Portugal (Taq DyeDeoxy 
Terminator Cycle Sequencing and Model 373A gel apparatus, Applied Biosystems). 
Sequence analysis was conducted using the free sequence analysis software for PCs 
Chromas Lite (Technelysium Pty Ltd). Sequences were further compared with others, 
using the Basic Local Alignment Search Tool (BLASTN) from the public database of 
the National Center for Biotechnology Information (NCBI) 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). The ClustalW2 program was used to align 
multiple DNA sequences and to organize them according to their identities 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/). 
6.1.6.3.2 Quantitative Real Time PCR (qRT-PCR)  
Real-time PCR is PCR-based technique which is used to amplify and simultaneously 
evaluate in real-time how the reaction proceeds. A DNA-binding dye binds to all 
double-stranded (ds)DNA in PCR, causing dye fluorescence. An increase in DNA 
product during PCR leads therefore to an increase in fluorescence intensity, which is 
measured at each cycle, thus allowing DNA concentrations to be quantified.  Thus, 
quantitation is the most common use for real-time PCR, often referred to as 
quantitative PCR or qPCR [Real-Time (qRT-PCR)].  
6.1.6.3.2.1 Efflux system AdeABC - Gene expression  
AdeABC is an efflux pump that belongs to the resistance-nodulation-cell division (RND) 
family and displays a three-component structure: AdeB integrates the trans-membrane 
component, AdeA forms the inner membrane fusion protein, and AdeC forms the outer 
membrane protein. (31), (35) (32) The expression of AdeABC is regulated by a two-
component system that includes a response regulator (AdeR) and a sensor kinase 
(AdeS), whose genes are located upstream AdeABC locus and are transcribed in the 
opposite direction. Point mutations in adeS and adeR have been associated with 
overexpression of AdeABC and consequently with multidrug resistance.  
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To investigate whether the AdeABC efflux pump plays a role in decreased susceptibility 
to amikacin and tigecycline, the expression of adeB was measured by qRT-PCR. 
Oligonucleotide primers for the adeB and 16S rDNA genes were described elsewhere 
(24, 35) (25)  (Table 7). 16S rRNA gene was used as a housekeeping gene to 
normalize levels of adeB transcripts. A. baumannii ATCC 19606 was used as a control 
strain. Negative-control reactions included equal concentrations of RNA and all 
reagents except reverse transcriptase. Reverse transcription was performed on an 
iCycler iQ5TM Real-Time PCR Detection System (BioRad) using an iScriptTM SYBR® 
Green RT-PCR Kit (Bio-Rad) at a 1X concentration containing 125 nM of each primer 
and a 1:100 final dilution of the cDNA product. Following PCR cycling, melting point 
data were collected and a dissociation curve was examined for each well. Each sample 
was run in triplicate. The ∆CT for adeB was calculated comparatively to that for the 
16S rRNA housekeeping gene, and the ∆∆CT was calculated relatively to A. baumannii 
ATCC 19606, which was used as a calibrator sample.  
6.1.6.3.3 Nucleic acids separation and visualization 
The detection and characterization of DNA and RNA was performed by agarose gel 
electrophoresis. Agarose gel electrophoresis runnings were performed using either 
continuous or pulsed-field systems. 
6.1.6.3.3.1 Electric continuous-field gel electrophoresis 
PCR products and mRNA were resolved by conventional agarose gel electrophoresis 
in an electric continuous-field. Samples were loaded in agarose 1.5% w/v gels in TAE 
buffer (40 mM Tris base, 20mM Acetic acid, 1 mM EDTA, pH 8.3) and fragments were 
separated at 90V for 45 minutes. Plasmid DNA was resolved in agarose 0.8% w/v gels 
in 0.5X TBE buffer at 90V for 180 min. Gels were stained with ethidium bromide 
(0.5µg/mL) and the DNA was visualized by UV light trans-illumination at 302 nm. The 
specific size of the linear product(s) was determined by the routine inclusion of a DNA 
standard containing a range of fragments of known sizes. The used DNA standards 
were 100 bp DNA Ladder (Promega) or 250 bp DNA Ladder (Invitrogen). The specific 
size of plasmidic band(s) was determined by the inclusion of plasmid DNA from strains 
E.coli V517 (that contains eight plasmids with a range of sizes of 2.1-54.4 Kb) and E. 
coli NTCT 50192 (that presents four plasmids of 7.0, 36.2, 63.8 and 148.5 Kb). 
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6.1.6.3.3.2 Electric Pulsed-Field Gel Electrophoresis (PFGE) 
Pulsed field gel electrophoresis (PFGE) lies on an electric field that periodically 
changes direction to a gel matrix allowing the separation of large deoxyribonucleic acid 
(DNA) molecules. Electrophoresis of the prepared samples was performed on the 
contour-clamped homogeneous electric field (CHEF) mapper system (Bio-Rad 
Laboratories, Richmond, CA) by using 1.6% w/v pulsed-field-certified agarose (Seakem 
Gold agarose, Lonza, Rockland, ME USA) with 2 liters of standard 0.5X TBE (65 mM 
Tris, 22.5 mM boric acid, 1.25 mM EDTA) running buffer. The electrophoretic 
conditions used were as follows: i) ApaI macrorestriction - initial switch time, 5 s; final 
switch time, 13 s; run time, 25 h; ii) S1 and I-CeuI macrorestriction - initial switch time, 
5 s; final switch time, 60 s; running time, 20 h ; angle, 120°; gradient, 6.0 V/cm; 
temperature, 14°C; ramping factor, linear (12). Aft er electrophoresis, gels were stained 
for 30 min in 1 liter of sterile distilled water containing 100 mL of ethidium bromide (10 
mg/mL) and destained with two washes in 1 liter of distilled water (of 30 min each).  
6.1.6.4 DNA transfer and hybridization 
6.1.6.4.1 DNA separation 
In order to determine whether β-lactamase genes were chromosomal or plasmid 
located the I-CeuI endonuclease technique (New England Biolabs, Beverly, MA) was 
conducted. This enzyme digests a 26-bp sequence in rrn genes for the 23S large-
subunit rRNA. Whole-cell DNA was digested with 4 units of I-CeuI and the resulting 
fragments (usually seven, corresponding to the number of copies of the ribosomal RNA 
gene present in each cell) were separated by PFGE.  Electrophoresis was performed 
using 0.9% w/v pulsed-field-certified agarose (Seakem Gold agarose, Lonza, 
Rockland, ME USA) and 0.5X TBE (65 mM Tris, 22.5 mM boric acid, 1.25 mM EDTA) 
as the running buffer. The electrophoretic conditions were described above (section 
6.1.6.3.3.1). After electrophoresis, gels were stained for 30 min in 400 mL of sterile 
distilled water containing 40 mL of ethidium bromide (10 mg/mL).The sizes of the 
obtained fragments were determined by comparison with those from E.coli K12.  
S1 nuclease technique was used for plasmid size determination and replicase genes 
identification. With this restriction analysis, plasmids were converted into unit-length 
linear molecules, which migrate at rates that allow, by comparison with linear markers, 
an accurate sizing of the bands (2). The digested products were separated by PFGE 
according to previous described running conditions (section 6.1.6.3.3.1).  
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6.1.6.4.2 DNA transfer and fixation 
Southern Blot methodology includes an overnight transfer of DNA to a positively 
charged nylon membrane using an upward-transfer method. For this purpose, the gel 
was irradiated for 1min and 30s on the transilluminator. Then, it was denatured by 
soaking it in 500 mL of an alkaline solution of 0.4N NaOH for 90 min. This denaturation 
step of the DNA into single strands allows the hybridization with the probe. The transfer 
was setup from bottom to top by using (1) a large dish filled with 0.4N NaOH with glass 
plate on top of it to rest the gel, (2) one piece of Whatman paper cut to the width of the 
gel and length such that the wick is in contact with the bottom of the dish and pre-wet in 
0.4N NaOH, (3) the agarose gel, turned upside down because the flatter side makes a 
better contact surface for the nylon membrane, (4) the positively charged nylon 
membrane Hybond N+ (GE Healthcare Life Sciences) with the exact size of the gel, 
with a nick in the corner for orientation and pre-wet in 0.4N NaOH, (5) two pieces of 
blotting paper cut to size of the gel, (6) paper towels on top to pull the NaOH through 
the gel and (7) an additional weight was added to keep blot in place. The entire gel was 
covered with plastic wrap. The transfer occurred for 48 h. After this time the membrane 
was removed from the gel and washed in 0.5M Tris, pH 7-8 / 2X SSC for 5 min. Then 
the membrane was cross-linked with UV light. The resulting membrane was 
immediately used for hybridization or was stored at -20ºC. 
6.1.6.4.3 DNA labeling and hybridization 
The DNA probes included blaOXA-40, 16S rRNA and replicase genes, amplified by PCR 
(Table 7). The labeling was obtained with the probe denaturation by boiling and mixing 
with the labeling buffer and the alkaline phosphatase enzyme. Then formaldehyde was 
added to covalently cross-link the enzyme to the probe and the mixture was incubated 
at 37ºC for 30 min. During the labeling process of the probe the membrane was pre-
hybridized with the AlkPhos Direct™ hybridization buffer (GE Healthcare Life Sciences) 
for 15 min at 55 ºC. After that, the probe was added to the hybridization buffer and 
hybridization was performed overnight at 55ºC. 
6.1.6.4.4 Post hybridization washes, signal generation and detection 
After completion of hybridization, stringency washes were performed to remove 
residual labeled probe. Hybridized blots were detected by chemiluminescence with 
CDP-Star™ (GE Healthcare Life Sciences). After 2 min of incubation, the membrane 
was exposed to Hyperfilm™ ECL™ (GE Healthcare Life Sciences) for 2 h. 
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6.1.6.4.5 Stripping 
Following exposure of a Southern Blot, it might be needed to strip off the probe, while 
maintaining the nucleic acid target on the membrane, in order to hybridize the DNA 
with another probe. DNA probes were eliminated by washing the nylon membrane with 
a denaturing and boiling solution (SDS at 1%) for 1-2h, followed by a brief wash with 
2X SSC solution at room temperature. 
6.1.7  Typing methods 
The sources and pathway(s) of transmission for epidemic strains can be determined 
using typing methods, however it is not well established which one is more reliable for 
typing Acinetobacter spp. In this study, several typing methods were used in order to 
characterize the population structure of carbapenem-resistant A. baumannii in 
Portugal, Czech Republic and Brazil. 
6.1.7.1 DNA macrorestriction analysis of ApaI digests by pulsed-
field gel electrophoresis 
DNA macrorestriction followed by PFGE has been considered the gold standard 
method for typing A. baumannii clinical isolate (3). Generally, ApaI is used for 
restriction of intact chromosomal DNA and the resulting chromosomal fragments are 
separated by electrophoresis. The genomic DNA patterns obtained with this 
electrophoresis are highly specific for different strains and the resulting fingerprint 
profiles can be compared visually or using specialized computer programs. However, it 
is a laborious method that requires several days before generating a result, is 
considered more suitable for short-term outbreak investigations and is generally 
restricted to analyze small sets of isolates (1). In addition, the comparison process of 
results obtained from different laboratories remains a difficult task. 
Strain relatedness among A. baumannii isolates was determined according to 
Tenover’s criteria (43), where isolates are considered as i) indistinguishable (if their 
restriction patterns have the same numbers of bands and the corresponding bands are 
the same apparent size, with the isolates being considered to represent the same 
strain); ii) closely related (if PFGE patterns differ by changes consistent with a single 
genetic event, which typically results in two to three different bands);  iii) possibly 
related (if PFGE patterns differ by changes consistent with two independent genetic 
events i.e., four to six band differences) and iv) unrelated (if PFGE patterns differ by 
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changes consistent with three or more independent genetic events, generally seven or 
more band differences). In addition, PFGE patterns were analyzed by InfoQuestTM FP 
software version 5.4 (BioRad Laboratories) with Dice coefficient analysis of peak 
positions executed. The unweighted-pair group method using average linkages 
(UPGMA) was applied, and the bandwidth tolerance was set at 1.5%. Isolates 
clustering together with a >85% level of similarity were considered to belong to the 
same PFGE type (39, 42). 
6.1.7.2 PCR-based sequence group (SG) identification 
This PCR-based typing method relies on two multiplex PCRs, used for identification of 
allele variations in the ompA (outer-membrane protein A), csuE (part of a pilus 
assembly system required for biofilm formation) and blaOXA-51-like (the intrinsic 
carbapenemase gene in A. baumannii) genes. The combination of different alleles 
allows to assign the isolates onto
 
sequence groups which seems to correlate with the 
major A. baumannii epidemic lineages: i) SG1 isolates correspond to European Clone 
II; ii) SG2 isolates correspond to European Clone I; iii) SG3 is an outbreak strain with a 
lower expression (16, 44, 45). After the description of these three main groups, Higgins 
et al (2010) (22) performed a larger study that included outbreak strains from all over 
the world, increasing the number of sequence groups for eight and renaming them as 
WW1-WW8 (WW standing for worldwide). The primers and PCR conditions for this 
typing method are listed on Table 7 (45). 
  6.1.7.3 Sequence-based typing of blaOXA-51-like genes 
The OXA-51 class D β-lactamase was first identified in A. baumannii in 2004 and since 
then it has been suggested that blaOXA-51-like genes are ubiquitous in A. baumannii (16). 
Minor variations within the sequence encoding OXA-51 have subsequently been 
reported, constituting the OXA-51-like subgroup of enzymes (15, 16). With the 
increasing number of isolates being typed with the SG identification method, it was 
raised the possibility that isolates containing closely related OXA-51-like enzymes 
would be closely related and the sequencing of blaOXA-51 variant could constitute itself a 
typing scheme (16, 19). The sequence typing of blaOXA-51-like genes was performed for 
representative isolates of each PFGE type. The primers and PCR conditions are listed 
on Table 7. Sequence analysis was performed at the National Center for Biotechnology 
Information (NCBI) web site using the Basic Local Alignment Search Tool (BLAST) 
software and the nucleotide database (http://blast.ncbi.nlm.nih.gov/Blast.cgi).   
Chapter 6 - Appendix 
 
155 
 
6.1.7.4 Multilocus Sequence typing (MLST) 
MLST is used for characterizing bacterial isolates via the internet and has been applied 
successfully for the epidemiologic characterization of a variety of clinically important 
bacterial pathogens (3). The method relies on the comparison of nucleotide sequence 
data from internal fragments (approximately 450- to 500-bp) of protein encoding 
housekeeping genes. These genes codify for products that play vital functions, being 
present in all isolates of a given species, and mutations within them are assumed to be 
neutral (3). For each gene fragment, the different sequences are assigned as distinct 
alleles, and each isolate is defined by the alleles at each of the housekeeping loci (the 
allelic profile or sequence type [ST]) (3).  
6.1.7.4.1 MLST scheme develloped by Bartual et al (2005) 
This MLST scheme, hosted by the Oxford database (http://pubmlst.org/abaumannii/), is 
based on the allelic variations in seven housekeeping genes: citrate synthase (gltA), 
DNA gyrase subunit B (gyrB), glucose dehydrogenase B (gdhB), homologous 
recombination factor (recA), 60-kDa chaperonin (cpn60), glucose-6-phosphate 
isomerase (gpi), and RNA polymerase σ70 factor (rpoD) (3). Specific primers and 
amplification conditions are listed on Table 7. For the internal fragments of gpi and 
gyrB loci the PCR reaction mixture included BSA and DMSO at final concentrations of 
0.4% and 10% respectively. Additionally to the primers described in the database, 
another group of primers for the same loci, was applied (Table 7) with the advantage of 
being used both to amplify and sequencing the seven loci and the preparation of DNA 
templates did not included the use of InstanGene Matrix (Bio-Rad Laboratories, 
Hercules, CA).  
6.1.7.4.2 MLST scheme developed by the Institut Pasteur 
The MLST scheme developed by the Institut Pasteur 
(http://www.pasteur.fr/recherche/genopole/PF8/mlst/Abaumannii.html) for A. baumannii 
(and closely related species) uses internal fragments of the following seven 
housekeeping genes: 60-KDa chaperonin (cpn60), elongation factor EF-G (fusA), 
citrate synthase (gltA), CTP synthase (pyrG), homologous recombination factor (recA),  
50S ribosomal protein L2 (rplB), and RNA polymerase subunit B (rpoB). (34) Specific 
primers and amplification conditions are listed in Table 7. For this MLST scheme the 
DNA samples were also prepared using InstaGene Matrix (Bio-Rad Laboratories, 
Hercules, CA). 
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6.1.7.4.3 Sequences analysis and E-burst (Based Upon 
Related Sequences Types) 
The resulting sequences of the seven housekeeping genes amplification were 
analyzed using the online BLAST (http://www.ncbi.nlm.nih.gov/BLAST/) and the 
Pairwise Sequence Alignment tool from the European Bioinformatics Institute (EBI) 
(http://www.ebi.ac.uk/Tools/). Allele and ST assignments were performed on the 
respective A. baumannii MLST webpages (http://pubmlst.org/abaumannii/; 
http://www.pasteur.fr/recherche/genopole/PF8/mlst/Abaumannii.html). 
The E-Burst analysis allows grouping the isolates according to their allelic profiles and 
it is based on the number of Single Locus Variants (SLV), Double Locus Variants (DLV) 
and Satellites (SAT) for each sequence type (ST). In some cases it is also possible to 
identify the potential Ancestral Type (AT). This analysis was performed using the 
eBURST software program available at the eBurstv3 website (http://eburst.mlst.net/) 
(17). 
6.1.8  Transformation assays 
Genetic transformation occurs when a host organism takes up foreign DNA and 
expresses the foreign gene. Electroporation is a physical process that transiently 
permeabilizes cell membranes with an electrical pulse, thus permitting cell uptake of a 
wide variety of biological molecules, including plasmid DNA (14). Transformation was 
performed using A. baylyi ADP1 as the recipient strain (Table 6). MicroPulser 
Electroporation Apparatus (Bio-Rad) was used according to manufacturer’s 
instructions, following the high efficiency electrotransformation of E. coli protocol. 
6.1.8.1 Electrocompetent cells preparation 
The A. baylyi ADP1 electrocompetent cells were prepared according to the 
manufacturer’s instructions. Briefly, 1/100 volume of a fresh overnight culture was 
inoculated in 500 mL of LB medium. This suspension was incubated at 37ºC and 
shaking at 150 rpm to an OD600 of approximately 0.5-0.7. The cells were chilled on ice 
for 20 min and maintained as close to 0ºC as possible in all the subsequent steps. The 
cells were harvested at 4000 g for 15 min at 4ºC. The supernatant was discarded and 
the pellet resuspended in 500 mL of ice-cold 10% glycerol. The cells were harvested 
again at 4000 g for 15 min at 4ºC. After discarding the supernatant, the pellet was 
resuspended in 250 mL of ice-cold 10% glycerol. The harvest procedure was repeated 
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followed by pellet resuspension in 20 mL of ice-cold 10% glycerol. Finally, a last 
centrifugation was performed in the same previous conditions and the cell pellet was 
resuspended in a final volume of 1-2 mL of ice-cold 10% glycerol. This suspension was 
frozen in aliquots in dry ice and stored at -70ºC, being stable under these conditions for 
at least 6 months. 
6.1.8.2 Electroporation protocol and transformants selection 
For the electroporation process bacterial competent cells were thaw on ice. In a cold 
1.5-mL microcentrifuge tube 40 µL of the cell suspension were mixed with 5 µL of 
plasmid DNA (that had been eluted in a low ionic strength buffer – TE). The mixture 
was incubated on ice for 1 min. The mixture of cells and DNA was transferred to a cold 
electroporation cuvette and submitted to one pulse with a voltage of 3.0 kV. Then, 1 mL 
of SOC medium (2% Bacto tryptone, 0.5% Bacto yeast extract, 10 mM NaCl, 2.5 mM 
KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM glucose) was added to the cuvette. The cell 
suspension was transferred to a 15 mL polypropylene tube and incubated at 37ºC for 1 
h, shaking at 225 rpm. After incubation, the suspension (200 µL) was plated on TSA 
supplemented with imipenem (0.5 and 1 mg/L). 
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Table 5 – Characteristics of Acinetobacter spp. isolates included in this thesis. 
 
 
Country 
 
Origin  
 
Period 
 
Species (n) 
 
Sources (n) 
 
Applicability 
 
Reference(s) 
Portugal 
HPA 1995a A. baumannii  (1) sputum (1) Epidemiological studies This study, (12) 
HUC 1998-2000 a A. baumannii  (2) exsudate (1); urine (1) Epidemiological studies; control strains for 
PCR reactions 
This study, (12) 
HGSA  
2001-2003 a 
 
 
 
 
2004 
 
 
 
2006 
 
 
2008 
A. baumannii (5) 
 
A. haemolyticus (2) 
 
 
A. baumannii  (30) 
 
 
 
A. baumannii (28) 
 
 
A. baumannii (105) 
 
 
 
 
 
A. lwoffii (1) 
bronchial secretion  (4); sputum (1) 
 
pus (1); urine (1) 
 
 
pus (3); bronchial secretion  (6); 
catheter (2); blood (4); urine (12); 
sputum (3) 
 
pus (1); bronchial secretion  (13); 
catheter (6); urine (6); other (2) 
 
pus (7); bronchial secretion  (40); 
catheter (2); urine (34); wound (5); 
surgical site (5); blood (4); CRLc (1); 
intraeritoneal fluid (4); ascitic fluid 
(2); other (1) 
 
incubator humidity chamber (1) 
Epidemiological studies; plasmids 
characterization;  
 
 
 
Epidemiological studies; plasmids 
characterization; carbapenem resistance 
mechanisms 
This study, (12) (37) 
 
 
This study 
HPH  2006-2007 A. baumannii (21) NAd 
Epidemiological studies; carbapenem 
resistance mechanisms 
This study 
HST  2006-2008 A. baumannii (16) intraeritoneal fluid (3); pus (3); urine 
(2); catheter (1); bronchial secretion  
(1); other (5) 
CHCB  2007 A. baumannii (5) sputum (2); other (3) 
HA 2007 A. baumannii (21) NAc 
Clinical laboratoriesb 2007 A. baumannii (2) wound (1); urine (1) 
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Table 5 – Characteristics of Acinetobacter spp. isolates included in this thesis (cont.) 
 
 
 
Country 
 
Origin  
 
Period 
 
Species (n) 
 
Sources (n) 
 
Applicability 
 
Reference(s) 
Brazil 
HV 2006 A. baumannii (1) tracheal secretions (1) 
Epidemiological studies This study, (8) 
HGB 2007 A. baumannii (3) anal swab (1); tracheal secretions 
(2) 
HFL NA A. baumannii (1) wound (1) 
HQD 2007 A. baumannii (4) necrotizing fasciitis (1); urine (1); 
bronchoalveolar lavage (2) 
HCD 2007 A. baumannii (5) blood (1); tracheal secretions (1); 
abdominal secretion (1); surgical site 
(1) 
HBD 2006-2007 A. baumannii (2) bronchoalveolar lavage (2) 
HUAP 2007 A. baumannii (1) blood (1) 
Czech 
Republic UHP 2008 A. baumannii (9) 
Sputum (4), wound (2); urine (1); 
bronchoalveolar lavage (1); catheter 
(1) 
Epidemiological studies; carbapenem 
resistance determinants This study 
 
a Indicates representative  isolates selected from a previously published collection, included for a longitudinal analysis of carbapenem-resistant  A. baumannii population and for 
plasmidic characterization; b Isolates from outpatients; c CLR, cephaloraquidian liquid; d NA, information not available 
HPA, Hospital Padre Américo (Penafiel), HUC, Hospitais Universitários de Coimbra (Coimbra), HGSA, Hospital Geral de Santo António (Porto); HPH, Hospital de Pedro 
Hispano (Matosinhos); Hospital de São Teotónio (Viseu);  CHCB, Centro Hospitalar da Cova da Beira (Covilhã), HV, Hospital Vital (Rio de Janeiro), HGB, Hospital Geral de 
Bonsucesso (Rio de Janeiro); HFL, Hospital Federal da Lagoa (Rio de Janeiro); HQD, Hospital Quinta D’Or (Rio de Janeiro); HCD, Hospital Copa D’Or (Rio de Janeiro);  
Hospital Barra D’Or (Rio de Janeiro); HUAP, Hospital Universitário António Pedro (Rio de Janeiro); University Hospital of Pilsen (Pilsen).
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Table 6. Control and recipient strains used in this thesis  
Strain Source Control/Applicability Reference 
Acinetobacter baumannii 65 FFC Laboratory bacterial collection blaIMP-5; In76; Tn402-like transposon (13) 
Acinetobacter baumannii CLA I 
 
Kindly provided by Dr L. Poirel blaOXA-40 (21) 
Acinetobacter baumannii Ab13 
 
Kindly provided by Dr L. Poirel blaOXA-23, Tn2006 (11) 
Acinetobacter baumannii Ab14 
 
Kindly provided by Dr L. Poirel blaOXA-23, Tn2007 (11) 
Acinetobacter baumannii MAD 
 
Kindly provided by Dr L. Poirel blaOXA-58, ISAba3-like (36) 
Acinetobacter baumannii ATCC 
19606 
 
Laboratory bacterial collection Transformation recipient strain;  
qRT-PCR 
 
Acinetobacter baylyi ADP1 Kindly provided by Dr G. Bou Transformation recipient strain (48) 
Escherichia coli ATCC 25922 Laboratory bacterial collection Carbapenemase detection control strain (10) 
Escherichia coli K12 BM21  Laboratory bacterial collection Conjugation recipient strain (20) 
   
 
Escherichia coli V517 
 
Laboratory bacterial collection Plasmid sizing (30) 
Escherichia coli NCTC 50192 Laboratory bacterial collection  
 
Plasmid sizing 
 
Pseudomonas aeruginosa ATCC 
27853 
Laboratory bacterial collection  
 
Antimicrobial susceptibility testing 
control strain 
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Table 7. Oligonucleotides and PCR conditions used for the characterization of Acinetobacter isolates 
Primer Oligonucleotide sequence (5´to 3´) Description Amplicon size 
(bp) 
PCR conditions Reference 
      
Identification of bacterial species 
    
SEQ A 
SEQ B 
AGAGTTTGATCHTGGYTYAGA 
ACGYTACCTTGTTACGACTTC 
16S rRNA gene 1500  94ºC-10min (1 cycle); 
94ºC-1min, 55ºC-1min, 
72ºC-1min (35 cycles); 
72ºC-10min  (1 cycle) 
(21) 
Carbapenem-hydrolyzing class D β-lactamases (CHDLs) 
OXA-23-F 
OXA-23-R 
 
OXA-24-F 
OXA-24-R 
 
OXA-58-F 
OXA-58-R 
 
OXA-143-F 
OXA-143-F 
 
 
OXA-23C 
OXA-23D 
 
OXA-FP2 
OXA-RP1 
 
 
OXA-58A 
OXA-58B 
GATCGGATTGGAGAACCAGA 
ATTTCTGACCGCATTTCCAT 
 
GGTTAGTTGGCCCCCTTAAA 
AGTTGAGCGAAAAGGGGATT 
 
AAGTATTGGGGCTTGTGCTG 
CCCCTCTGCGCTCTACATAC 
 
TGGCACTTTCAGCAGTTCCT 
TAATCTTGAGGGGGCCAACC 
 
 
ATGAATAAATATTTTACTTGC 
TTAAATAATATTCAGCTGTTT 
 
TTCCCCTAACATGAATTTGT 
GTACTAATCAAAGTTGTGAA 
 
 
CGATCAGAATGTTCAAGCGC 
ACGATTCTCCCCTCTGCGC 
blaOXA-23 gene internal fragment 
 
 
blaOXA-24/40 gene internal fragment 
 
 
blaOXA-58 gene internal fragment 
 
 
blaOXA-143 gene internal fragment 
 
 
 
blaOXA-23 complete gene  
 
 
blaOXA-24/40 complete gene  
 
 
 
blaOXA-58 complete gene  
 
501 
 
 
246 
 
 
599 
 
 
149 
 
 
 
820 
 
 
980 
 
 
 
840 
 
 
 
Multiplex PCR 
94ºC-5min (1 cycle); 
94ºC-25s, 52ºC-40s, 
72ºC-50s (30 cycles); 
72ºC-6min  (1 cycle) 
 
 
 
 
 
 
 
 
94ºC-5min (1 cycle); 
94ºC-1min, 52ºC-1min, 
72ºC-2min (30 cycles); 
72ºC-8min  (1 cycle) 
 
 
(49) 
 
 
 
 
 
 
(23) 
This study 
 
 
(5)  
 
(36) 
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Table 7 (cont.) 
Naturally occurring CHDLs  
OXA-51-F 
OXA-51-F 
 
 
 
 
OXA-134F 
OXA-
134_307R2 
TAATGCTTTGATCGGCCTTG 
TGGATTGCACTTCATCTTGG 
 
 
 
 
ACTCAATCSACYCAAGCCA 
 
GTTTCTTGCCATCCCATTTA 
blaOXA-51-like gene internal 
fragment – intrinsic of A. 
baumannii species 
 
 
 
blaOXA-134-like gene internal 
fragment – intrinsic of A. lwoffii 
species 
353 
 
 
 
 
 
223 
94ºC-5min (1 cycle); 
94ºC-25s, 52ºC-40s, 
72ºC-50s (30 cycles); 
72ºC-6min  (1 cycle) 
 
94ºC-3min (1 cycle); 
94ºC-45s, 50ºC-45s, 
72ºC-1 min (35 
cycles); 72ºC-5min  (1 
cycle) 
(49) 
 
 
 
(18) 
Detection of metallo-β-lactamases 
IMP-F 
IMP-R 
 
 
VIP-1 
VIP-2 
CTACCGCAGAGTCTTTG 
AACCAGTTTTGCCTTACCAT 
 
 
ACTCACCCCCATGGAGTTTT 
ACGACTGAGCGATTTGTGTG 
blaIMP genes  
 
 
 
blaVIM genes 
587 
 
 
 
815 
Multiplex PCR 
94ºC-2min (1 cycle); 
94ºC-1min, 55ºC-1min, 
72ºC-3min (35 cycles); 
72ºC-7min  (1 cycle) 
(40) 
(7) 
CHDLs vicinity – Insertion Sequences 
ISAba1A 
ISAba1B 
ISAba2A 
ISAba2B 
ISAba3A 
ISAba3C
  
GTGCTTTGCGCTCATCATG 
CATGTAAACCAATGCTCACC  
AATCCGAGATAGAGCGGTTC  
TGACACATAACCTAGTGCAC 
CAATCAAATGTCCAACCTGC 
AGCAATATCTCGTATACCGC 
tnpA of ISAba1 
 
tnpA of ISAba2 
  
tnpA of ISAba3 
tnpA of ISAba3-like and ISAba3 
Variable 
95ºC-5min (1 cycle); 
95ºC-45s 
54ºC-45s 
72ºC-3min (35 cycles); 
72ºC-5min (1 cycle) 
(36) 
Class 1 integrons 
5´CS 
3´CS 
 
INT-F 
INT-R 
GGCATCCAAGCAGCAAG 
AAGCAGACTTGACCTGA 
 
GCCACTGCGCCGTTACCACC 
GGCCGAGCAGATCCTGCACG 
Class I Integrons 
 
 
Gene intI1 
 
 
 
 
 
Variable,  
94ºC-5min (1 cycle); 
94ºC-1min, 53ºC-1min, 
72ºC-6min (35 cycles); 
72ºC-16min  (1 cycle) 
 
(29) 
 
 
(26) 
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Table 7– cont. 
 
SUL1-F 
SUL1-R 
 
 
 
ORF5-R 
 
 
MITE_Fw_2 
MITE-Rv_2 
 
 
CGGCGTGGGCTACCTGAACG 
GCCGATCGCGTGAAGTTCCG 
 
 
 
AGTTCTAGGCGTTCTGCG 
 
 
GATAACCAATCCATTTATGACA 
TGACTGACCATTAAAGTCTCAA 
 
 
Gene sul1 
 
 
 
 
orf5 
 
 
miniature inverted-repeat 
transposable elements 
 
according with 
integron content 
 
 
 
94ºC-5min (1 cycle); 
94ºC-30s, 69ºC-30s,  
 
72ºC-1min (35 cycles); 
72ºC-8min  (1 cycle) 
 
 
 
 
94ºC-5min (1 cycle); 
94ºC-1min, 53ºC-1min, 
72ºC-6min (35 cycles); 
72ºC-16min  (1 cycle) 
 
(26) 
 
 
 
 
(47) 
 
 
 
This study 
Characterization of gene encoding the heat-modifiable 29-kDa outer membrane protein (carO) 
 
carO_F 
carO_R 
 
CCATGGCTGACGAWGCAGTCGTACATGA 
CCATGGCAAAAGTATTAAAAGTTTTAGCA
GT 
 
Amplification and sequencing of 
carO gene 
 
700 
94ºC-3min (1 cycle); 
94ºC-1min,  
55ºC-1 min, 
72ºC-1min (30 cycles);  
72ºC-10min  (1 cycle) 
(33) 
blaOXA-40 carrying plasmids sequencing 
OXA-40F 
OXA-40R 
OXA_F2 
OXA_R2 
P92_F 
P92_R 
OXAi_40F 
P63_R 
OXABa_F2 
repA_F 
repA_R 
CGCTCAACTTAGAAATGAAAG 
CCCTGTGTTTGAGCTTCATC 
TGTTGCAGCTAGATCATCG 
TGATCAGCTAGATCTATCAG 
TCCCCTAGAGTTGTCGAACG 
TATCACGCTCCCAGTGAT 
CTCTAGGCCAGTCCGTCTTG 
TTATAGAAGCTTCCTATCA 
AATTGTCCATCACTGGGAG 
TATTCCGAAGAGCCAGCCTA 
CGAGAAAGTTGATTGCCAAA 
 
 
 
 
 
Primer walking and PCR 
mapping of blaOXA-40 carrying 
plasmids 
Variable 
 
This study 
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Table 7 ( cont.) 
PCR-based replicon typing of resistance plasmids in Acinetobacter baumannii 
gr1FW 
gr1RV 
 
gr2FW 
gr2RV 
 
gr3FW 
gr3RV 
 
gr4FW 
gr4RV 
 
gr5FW 
 
gr5RV 
 
gr6FW 
gr6RV 
 
gr7FW 
gr7RV 
 
gr8FW 
gr8RV 
 
gr9FW 
gr9RV 
 
CATAGAAATACAGCCTATAAAG 
TTCTTCTAGCTCTACCAAAAT 
 
AGTAGAACAACGTTTAATTTTATTGGC 
CCACTTTTTTTAGGTATGGGTATAG 
 
TAATTAATGCCAGTTATAACCTTG 
GTATCGAGTACACCTATTTTTTGT 
 
GTCCATGCTGAGAGCTATGT 
TACGTCCCTTTTTATGTTGC 
 
AGAATGGGGAACTTTAAAGA 
 
GACGCTGGGCATCTGTTAAC 
 
AGCAAGTACGTGGGACTAAT 
AAGCAATGAAACAGGCTAAT 
 
GAACAGTTTAGTTGTGAAAG 
TCTCTAAATTTTTCAGGCTC 
 
AATTAATCGTAAAGGATAATGC 
GACATAGCGATCAAATAAGC 
 
GCAAGTTATACATTAAGCCT 
AAAAATAAACGCTCTGATGC 
 
replicase p1ABSDF001 
 
 
replicase Aci1 and Aci2 
 
 
replicase Aci3 
 
 
replicase Aci4 
 
 
replicase Aci5 
 
 
 
replicase Aci6 
 
 
replicase p3ABSDF002 
 
 
replicases Aci8 and repM (Aci9) 
 
 
replicase p3ABSDF0009 
 
 
330 
 
 
851 
 
 
505 
 
 
508 
 
 
220 
 
 
 
662 
 
 
885 
 
 
233 
 
 
191 
 
 
94ºC-7min (1 cycle); 
95ºC-30s,  
52ºC-30s, 
 72ºC-1.5min (35 
cycles);  
72ºC-5min  (1 cycle) 
(4) 
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Table 7 (cont.) 
gr10FW 
gr10RV 
 
gr11FW 
gr11RV 
 
gr12FW 
gr12RV 
 
gr13FW 
gr13RV 
 
gr14FW 
gr14RV 
 
gr15FW 
gr15RV 
 
gr16FW 
gr16RV 
 
gr17FW 
gr17RV 
 
gr18FW 
gr18RV 
 
gr19FW 
gr19RV 
 
TTTCACTAGCTACCAACTAA 
ACACGTTGGTTTGGAGTC 
 
GGCTATTCAAAACAAAGTTAC 
GTTTCCTCTCTTACACTTTT 
 
TCATTGGTATTCGTTTTTCAAAACC 
ATTTCACGCTTACCTATTTGTC 
 
CAAGATCGTGAAATTACAGA 
CTGTTTATAATTTGGGTCGT 
 
TTAAATGGGTGCGGTAATTT 
GCTTACCTTTCAAAACTTTG 
 
GGAAATAAAAATGATGAGTCC 
ATAAGTTGTTTTTGTTGTATTCG 
 
CTCGAGTTCAGGCTATTTTT 
GCCATTTCGAAGATCTAAAC 
 
AATAACACTTATAATCCTTGTA 
GCAAATGTGACCTCTAATATA 
 
TCGGGTTATCACAATAACAA 
TAGAACATTGGCAATCCATA 
 
ACGAGATACAAACATGCTCA 
AGCTAGACATTTCAGGCATT 
 
replicase AciX 
 
 
replicase p1ABAYE0001 
 
 
replicase p2ABSDF0001 
 
 
replicase p3ABAYE0002 
 
 
replicase p4ABAYE0001 
 
 
replicase p3ABSDF0018 
 
 
replicase repApAB49 
 
 
replicase A1s_3471 
 
 
replicase p2ABSDF00025 
 
 
replicase rep135040 
 
371 
 
 
852 
 
 
165 
 
 
780 
 
 
622 
 
 
876 
 
 
233 
 
 
380 
 
 
676 
 
 
815 
PCR-based sequence group (SG) identification  
Gr1_ompAF 
Gr1/Gr2_omp
A R 
Gr1csu_EF 
Gr1_csuER 
GATGGCGTAAATCGTGGTA 
CAACTTTAGCGATTTCTGG 
 
CTTTAGCAAACATGACCTACC 
TACACCCGGGTTAATCGT 
ompA gene internal fragment 
from SG1 
 
csuE gene internal fragment from 
SG1 
355 
 
 
702 
 
94ºC-3min (1 cycle); 
94ºC-45s, 
57ºC-45s, 
72ºC-1min (30 cycles); 
72ºC-5min  (1 cycle) 
(45) 
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Table 7 – cont. 
Gr1_OXA66F 
Gr1_OXA66R 
 
Gr2_ompAF 
 
 
Gr2_csuEF 
Gr2_csuER 
 
Gr2_OXA69F 
Gr2_OXA69R 
 
GCGCTTCAAAATCTGATGTA 
GCGTATATTTTGTTTCCATTC 
 
GACCTTTCTTATCACAACGA 
 
 
GGCGAACATGACCTATTT 
CTTCATGGCTCGTTGGTT 
 
CATCAAGGTCAAACTCAA 
TAGCCTTTTTTCCCCATC 
 
blaOXA-51-like internal fragment from 
SG1 
 
ompA gene internal fragment 
from SG2 
 
csuE gene internal fragment from 
SG2 
 
blaOXA-51-like internal fragment from 
SG2 
 
559 
 
 
343 
 
 
580 
 
 
162 
MLST of Acinetobacter baumannii complex, develloped by Bartual et al (2005) (primers from database) 
Citrato F1 
Citrato R12 
 
APRU F 
 
UP1E R 
 
 
M13 [-21] 
M13 F 
 
GDHB 1F 
GDHB 775R 
 
GDH SEC F 
GDH SEC R 
 
RA1 
RA2 
 
CPN 3F2 
CPN R2 
 
 
AATTTACAGTGGCACATTAGGTCCC 
GCAGAGATACCAGCAGAGATACACG 
 
TGTAAAACGACGGCCAGTGCNGGRTCYT
TYTCYTGRCA 
CAGGAAACAGCTATGACCAYGSNGGNGG
NAARTTYRA 
 
TGTAAAACGACGGCCAGT 
CAGGAAACAGCTATGACC 
 
GCTACTTTTATGCAACAGAGCC 
GTTGAGTTGGCGTATGTTGTGC 
 
ACCACATGCTTTGTTATG 
GTTGGCGTATGTTGTGC 
 
CCTGAATCTTCYGGTAAAAC 
GTTTCTGGGCTGCCAAACATTAC 
 
ACTGTACTTGCTCAAGC 
TTCAGCGATGATAAGAAGTGG 
 
amplification and sequencing of 
gltA locus 
 
amplification of gyrB locus 
 
 
 
 
sequencing of gyrB locus 
 
 
amplification of gdhB locus 
 
 
sequencing of gdhB locus 
 
 
amplification and sequencing of 
recA locus 
 
amplification and sequencing of 
cpn60 locus 
 
722 
 
 
909 
 
 
 
 
 
 
 
775 
 
 
 
 
 
425 
 
 
479 
 
 
94ºC-2min (1 cycle); 
94ºC-1min, 
55ºC-1 min, 
72ºC-2min (30 cycles); 
72ºC-2min  (1 cycle) 
(3) 
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Table 7 (cont.) 
GPI F1  
GPI R1 
 
70F RPOD 
 
70R RPOD 
 
 
70FS 
70RS 
 
AATACCGTGGTGCTACGGG 
AACTTGATTTTCAGGAGC 
 
ACGACTGACCCGGTACGCATGTAYAG 
MGNGARATGGGNACNGT 
ATAGAAATAACCAGACGTAAGTTNGCY 
TCNACCATYTCYTTYTT  
 
ACGACTGACCCGGTACGCATGTA 
ATAGAAATAACCAGACGTAAGTT 
 
amplification and sequencing of 
gpi locus 
 
amplification of rpoD locus 
 
 
 
 
sequencing of rpoD locus 
 
508 
 
 
492 
MLST of Acinetobacter baumannii complex, developed by Bartual et al (2005) (primers sequences kindly provided by Dr Mikail Edelstein) 
ABA-gltA-f 
ABA-gltA-r 
 
ABA-gyrB-f 
ABA-gyrB-r 
 
ABA-gdh-f1 
ABA-gdh-r1 
 
ABA-recA-f 
ABA-recA-r 
 
ABA-cpn60-f 
ABA-cpn60-r 
 
ABA-gpi-f 
ABA-gpi-r2 
 
ABA-rpoD-f 
ABA-rpoD-r 
ACAGTGGCACATTAGGTCCC 
GCAGAGATACCAGCAGAGATACA 
 
AACCATCTCAACGAAATCTTCC 
GCTGGGTCTTTTTCCTGACA 
 
CCACATGCTTTGTTATGGGG 
GATTTAAGCGTAATACTTTACCCAT 
 
GGTCCTGAATCTTCTGGTAAAAC 
GAATTTAAGAGCATTACCACCAGT 
 
CAACTGTACTTGCTCAAGC 
CGCTTCACCTTCAACATCTTC 
 
AAAATCCATGCTGGGCAATA 
CAATACAAGACCAAAGAGAATAACG 
 
GTGAAGGTGAAATCAGCATTGC 
GCAATTTGTTCATCTAACCAAGC 
amplification and sequencing of 
gltA locus 
 
amplification and sequencing of 
gyrB locus 
 
amplification and sequencing of 
gdhB locus 
 
amplification and sequencing of 
recA locus 
 
amplification and sequencing of 
cpn60 locus 
 
amplification and sequencing of 
gpi locus 
 
amplification and sequencing of 
rpoD locus 
720 
 
 
500 
 
 
600 
 
 
400 
 
 
450 
 
 
390 
 
 
720 
95ºC-15min (1 cycle); 
94ºC-20s, 
54ºC-30s, 
72ºC-45s (30 cycles); 
72ºC-3min  (1 cycle) 
 
MLST of Acinetobacter baumannii, developed by the Institut Pasteur 
cpn60F 
cpn60R 
 
ACTGTACTTGCTCAAGC 
TTCAGCGATGATAAGAAGTGG 
 
amplification and sequencing of 
cpn60 locus 
 
405 
 
 
94ºC-2min (1 cycle); 
94ºC-30s, 
50ºC-30s, 
(34) 
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Table 7 (cont.) 
fusA7 
fusA8 
 
gltAF 
gltAR 
 
pyrG7 
pyrG8 
 
RA1 
RA2 
 
rplB7 
rplB8 
 
Vic4 
Vic6 
 
ATCGGTATTTCTGCKCACATYGAT 
CCAACATACKYTGWACACCTTTGTT 
 
AATTTACAGTGGCACATTAGGTCCC 
GCAGAGATACCAGCAGAGATACACG 
 
GGTGTTGTTTCATCACTAGGWAAAGG 
ATAAATGGTAAAGAYTCGATRTCACCMA 
 
CCTGAATCTTCYGGTAAAAC 
GTTTCTGGGCTGCCAAACATTAC 
 
GTAGAGCGTATTGAATACGATCCTAACC 
CACCACCACCRTGYGGGTGATC 
 
GGCGAAATGGC(AGT)GA(AG)AACCA 
GA(AG)TC(CT)TCGAAGTTGTAACC 
 
amplification and sequencing of 
fusA locus 
 
amplification and sequencing of 
gltA locus 
 
amplification and sequencing of 
pyrG locus 
 
amplification and sequencing of 
recA locus 
 
amplification and sequencing of 
rplB locus 
 
amplification and sequencing of 
rpoB locus 
 
633 
 
 
483 
 
 
297 
 
 
372 
 
 
330 
 
 
456 
 
72ºC-30s (35 cycles); 
72ºC-5min  (1 cycle) 
Characterization of resistance to aminoglycosides 
armA_F 
armA_R 
 
 
aphA6_F 
aphA6_R 
TGCATCAAATATGGGGGTCT 
GGATTGAAGCCACAACCAAA 
 
 
ATGGAATTGCCCAATATTATTC 
TCAATTCAATTCATCAAGTTTTA 
16S rRNA methylase gene 
 
 
 
aminoglycoside (3') 
phosphotransferase APH(3')-VI 
(aphA6) gene 
770 
 
 
 
770 
95ºC-3min (1 cycle); 
95ºC-30s, 50ºC-1min, 
72ºC-1min (30 cycles); 
72ºC-10min  (1 cycle) 
(25) 
 
(25) 
Characterization of regulator genes for the efflux pump AdeABC 
adeR_F 
adeR_R 
 
 
adeS_F 
adeS_R 
ATGTTTGATCATTCTTTTTCTTTTG 
TTAATTAACATTTGAAATATG 
 
 
ATGAAAAGTAAGTTAGGAATTAGTAAG 
TTAGTTATTCATAGAAATTTTTATG 
Amplification and sequencing of 
the regulator gene adeR 
 
 
Amplification and sequencing of 
the sensor kinase gene adeS 
686 
 
 
 
1060 
95ºC-3min (1 cycle); 
95ºC-30s, 50ºC-1min, 
72ºC-1min (30 cycles); 
72ºC-10min  (1 cycle) 
(25) 
 
(35) 
Quantitative Real-Time-PCR 
q_adeB _F 
 
 
AACGGACGACCATCTTTGAGTATT 
 
quantitation of mRNA transcripts  
 
84 
 
 
Taq activation step:  
 
(35) 
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Table 7 – cont. 
q_adeB_R 
 
q_16S_F 
q_16S_R 
 
CAGTTGTTCCATTTCACGCATT 
 
CAGCTCGTGTCGTGAGATGT 
CGTAAGGGCCATGATGACTT 
 
for adeB gene 
 
quantitation of mRNA transcripts 
for 16S rRNA gene 
 
 
150 
 
95ºC-12 min 
40 cycles: 
95ºC-15s 
60ºC-1min 
 
 
 
 
 
(35) 
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6.2 Sequence submitted to GenBank 
6.2.1 Acinetobacter haemolyticus strain AC63 plasmid pAC63, partial 
sequence.  
GenBank: JN982951.1 
LOCUS       JN982951               5184 bp    DNA     linear   BCT 25-APR-2012 
 
DEFINITION  Acinetobacter haemolyticus strain AC63 plasmid pAC63, partial 
            sequence. 
ACCESSION   JN982951 
VERSION     JN982951.1  GI:384929478 
KEYWORDS    . 
SOURCE      Acinetobacter haemolyticus 
  ORGANISM  Acinetobacter haemolyticus 
            Bacteria; Proteobacteria; Gammaproteobacteria; Pseudomonadales; 
            Moraxellaceae; Acinetobacter. 
REFERENCE   1  (bases 1 to 5184) 
  AUTHORS   Grosso,F., Quinteira,S., Novais,A. and Peixe,L. 
  TITLE     The role of common blaOXA-24/40-carrying platforms and plasmids in 
            the spread of OXA-24/40 among Acinetobacter spp. clinical isolates 
  JOURNAL   Unpublished 
REFERENCE   2  (bases 1 to 5184) 
  AUTHORS   Grosso,F., Quinteira,S., Novais,A. and Peixe,L. 
  TITLE     Direct Submission 
  JOURNAL   Submitted (01-NOV-2011) Laboratory of Microbiology, REQUIMTE - 
            Faculdade de Farmacia da Universidade do Porto, Rua Anibal Cunha, 
            164, Porto 4050-047 Porto, Portugal 
FEATURES             Location/Qualifiers 
     source          1..5184 
                     /organism="Acinetobacter haemolyticus" 
                     /mol_type="genomic DNA" 
                     /strain="AC63" 
                     /db_xref="taxon:29430" 
                     /plasmid="pAC63" 
     gene            complement(<1..768) 
                     /gene="tonB" 
     CDS             complement(<1..768) 
                     /gene="tonB" 
                     /codon_start=1 
                     /transl_table=11 
                     /product="putative TonB-dependent receptor" 
                     /protein_id="AFI32799.1" 
                     /db_xref="GI:384929479" 
                     
/translation="MLNKSKLFLALITLGASKIVLAAEGPVTTLNTIVLTAQSDELGS 
                     
ELLGKSLNVSNQFIDTSKLKQRSTTLGDALGTELGIHSNQYGGGASTPIIRGQEGKRI 
                     
KVLQNNADVLDMSNMSPDHAVTVEPSLAKSIEIIRGASTLLYSSNSAAGVVNVIDYKI 
                     
PTQMPQDGLEGNTTLRFNTGSNEKLTTAGVTVGLSPHVALRAEGLYRNAGNYKTPHYQ 
                     SSSYNSLEDLENQNSIYKNLKYLPESWAESRVGTLGLS" 
     CDS             complement(896..1204) 
                     /codon_start=1 
                     /transl_table=11 
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                     /product="putative cytoplasmic protein" 
                     /protein_id="AFI32800.1" 
                     /db_xref="GI:384929480" 
                     
/translation="MVRYSHKELNEKFGEKQDAEIQRLLAKGTVPDDQLDLSDIPEIT 
                     
DWSNAVRQNQFYRPVKQQTSIRLDADVLAWFKAQGKGYQTRMNEILRDAMLKELKNHQ 
                     " 
     CDS             complement(1197..1493) 
                     /codon_start=1 
                     /transl_table=11 
                     /product="putative inner membrane protein" 
                     /protein_id="AFI32801.1" 
                     /db_xref="GI:384929481" 
                     
/translation="MFFMEQYFEWDEAKNRKNQKKHDISFETASLVFEDPLRISIQDR 
                     HTNGEERWQTIGRVKGVLMLLVAHTIFDEDDCEIIRIISARQVTKAERNKYEHG" 
     misc_recomb     1692..1719 
                     /note="XerC/XerD" 
     gene            1793..2620 
                     /gene="blaOXA-40" 
     CDS             1793..2620 
                     /gene="blaOXA-40" 
                     /codon_start=1 
                     /transl_table=11 
                     /product="carbapenem-hydrolyzing oxacillinase OXA-40" 
                     /protein_id="AFI32802.1" 
                     /db_xref="GI:384929482" 
                     
/translation="MKKFILPIFSISILVSLSACSSIKTKSEDNFHISSQQHEKAIKS 
                     
YFDEAQTQGVIIIKEGKNLSTYGNALARANKEYVPASTFKMLNALIGLENHKATTNEI 
                     
FKWDGKKRTYPMWEKDMTLGEAMALSAVPVYQELARRTGLELMQKEVKRVNFGNTNIG 
                     
TQVDNFWLVGPLKITPVQEVNFADDLAHNRLPFKLETQEEVKKMLLIKEVNGSKIYAK 
                     
SGWGMGVTPQVGWLTGWVEQANGKKIPFSLNLEMKEGMSGSIRNEITYKSLENLGII" 
     misc_recomb     2631..2657 
                     /note="XerD/XerC" 
     CDS             complement(2809..3366) 
                     /codon_start=1 
                     /transl_table=11 
                     /product="hypothetical protein" 
                     /protein_id="AFI32803.1" 
                     /db_xref="GI:384929483" 
                     
/translation="MKSLSVIELSNLYGMTRQAVYKQINKGNLSKNSDGKIDLSEAIR 
                     
VFGEPSKYVNSLQTTETRKLSEVHLLEQQVHMLQKQLEQAHEREKFQRDELKAKNDQL 
                     
HVKDEQIEAMQRLLEAPKTNMTTFADQKPSQDIATDPRPEPEPKHDGLTTPVEIENKR 
                     IPVPEQVELEQPKRGWLSRFFLPNG" 
     gene            complement(3443..4330) 
                     /gene="repA_AB" 
     CDS             complement(3443..4330) 
                     /gene="repA_AB" 
                     /note="similar to repA_AB from pAB02 accession number 
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                     AY228470.1" 
                     /codon_start=1 
                     /transl_table=11 
                     /product="DNA replication protein" 
                     /protein_id="AFI32804.1" 
                     /db_xref="GI:384929484" 
                     
/translation="MDKNQIVKSNQVIEASYQLSAVEQRIVLAAISRIPKSQPITDDE 
                     
LYPVSVNELQLLGVHEKTAYRDLKEGINRLYERSINLSIDDKSIKMRWVQEIQFLDSQ 
                     
SIIGIRFSKPILPFISNLSREFTKYALSDIAGINSGYGIRIYELLVQYRQIGKREISV 
                     
ENLRSMLELGKKYPLFADFKKRVIDTAVDQINECSPLSVSYEQKKTGRKVTHIQFSFK 
                     
EKSKSINHLNEPEKFYKLTDAQVHMFGNQLSRLHELSHLATQGESYDDLAATIKEMLR 
                     DPIQQKQFIPHLRNLGFKG" 
     repeat_region   4375..4471 
                     /note="imperfect 4-repeat iterons; control of DNA 
                     replication" 
     rep_origin      complement(4487..4689) 
                     /note="oriV" 
     CDS             complement(4868..>5184) 
                     /note="involved in plasmid mobilization" 
                     /codon_start=3 
                     /transl_table=11 
                     /product="mobA" 
                     /protein_id="AFI32805.1" 
                     /db_xref="GI:384929485" 
                     
/translation="FSSPEVMHYVNHLIKKASNKKELGHDIDEIIQTQQPILHHEKWD 
                     
IDTINFNLNNARLYPEPDMEFKVRSVQPKPVIEPTSPKSKPEIQPSQPEPKRNDYDGP 
                     GF" 
ORIGIN       
        1 ggataatcca agcgtaccta ctctcgactc tgcccagctt tctggtaaat attttaaatt 
       61 tttataaata ctgttttggt tttcaagatc ttctaaagaa ttataagagc tagactggta 
      121 atgaggagtt ttatagttac cagcattacg atataaccct tctgcccgta aagctacatg 
      181 tgggcttaag ccaactgtta cacctgctgt ggtcaacttc tcattactgc cagtattaaa 
      241 acgtaatgta gtattaccct ctaatccgtc ttgaggcatt tgggttggaa ttttatagtc 
      301 aatgacattg actacccctg ccgcactatt tgaactatac aaaagggtac ttgcaccacg 
      361 tataatttca atagacttag ctaaacttgg ttcaactgtg acagcgtgat ctggggacat 
      421 attagacata tccaacacgt cagcattatt ctgtaaaact ttaatacgtt ttccttcctg 
      481 cccacgaata ataggagtag atgctccacc tccatattga ttagaatgaa ttcctaattc 
      541 cgtacccaag gcatccccta gagttgtcga acgctgttta agtttactag tatcaataaa 
      601 ctgattacta acatttagac ttttgcctaa cagctcagac cctaactcat cagattgtgc 
      661 agttaatact attgtattta aggtagtaac aggcccttca gctgccaata caattttcga 
      721 ggcccctaaa gtaattaaag ctaaaaatag tttactttta tttagcataa aacaaccaaa 
      781 tttaatgtta tattataata taacacttaa aaatttataa aatctactat ttaaattttt 
      841 gaatggtaat cccccctaaa aatgaagtca aaaatgggag cctaagctcc cattcttatt 
      901 gatgattttt taattctttt agcatagcat ctcgtaaaat ttcattcata cgtgtttgat 
      961 aacctttgcc ttgtgctttg aaccaagcaa gtacatcagc atctaaccga attgaagttt 
     1021 gttgctttac tgggcggtaa aattgatttt ggcgtacagc attgctccag tctgtaattt 
     1081 caggaatatc tgatagatct agctgatcat caggaaccgt gcctttagca agcaagcgtt 
     1141 gaatttcagc atcttgcttc tcaccaaatt tctcattcag ctctttgtgt gagtatctaa 
     1201 ccatgctcat atttgtttcg ctccgcttta gtgacttgcc ttgcactaat gattcggatg 
     1261 atttcacagt catcttcatc aaaaatggtg tgagccacca ataacattag tacgccttta 
     1321 actcgtccaa tggtttgcca acgttcttca ccattggtat gtctgtcttg gattgagatc 
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     1381 cgtaatggat cttcaaaaac aaggcttgca gtttcgaaag agatatcatg ctttttctga 
     1441 ttctttcgat tcttagcctc atcccattca aaatactgtt ccataaaaaa cattcaaatt 
     1501 tgtatataca ataatgtatc acatatttgt atcactcaag ctgaaaagcg taatttttag 
     1561 tcaaatttat tggcaagaag tatcaaaact gctcataaaa aagccgactt gtttcaaagt 
     1621 cggctttttg ggcatttttg gatttttcta tttttattaa gtagttgata tttaaattaa 
     1681 tatacaaatg tacttcgtat aatcgccatt atgttaaatt aaaagagttt taactttttt 
     1741 aataaaaata ttatactcta agccccaaaa tttcccctaa catgaatttg taatgaaaaa 
     1801 atttatactt cctatattca gcatttctat tctagtttct ctcagtgcat gttcatctat 
     1861 taaaactaaa tctgaagata attttcatat ttcttctcag caacatgaaa aagctattaa 
     1921 aagctatttt gatgaagctc aaacacaggg tgtaattatt attaaagagg gtaaaaatct 
     1981 tagcacctat ggtaatgctc ttgcacgagc aaataaagaa tatgtccctg catcaacatt 
     2041 taagatgcta aatgctttaa tcgggctaga aaatcataaa gcaacaacaa atgagatttt 
     2101 caaatgggat ggtaaaaaaa gaacttatcc tatgtgggag aaagatatga ctttaggtga 
     2161 ggcaatggca ttgtcagcag ttccagtata tcaagagctt gcaagacgga ctggcctaga 
     2221 gctaatgcag aaagaagtaa agcgggttaa ttttggaaat acaaatattg gaacacaggt 
     2281 cgataatttt tggttagttg gcccccttaa aattacacca gtacaagaag ttaattttgc 
     2341 cgatgacctt gcacataacc gattaccttt taaattagaa actcaagaag aagttaaaaa 
     2401 aatgcttcta attaaagaag taaatggtag taagatttat gcaaaaagtg gatggggaat 
     2461 gggtgttact ccacaggtag gttggttgac tggttgggtg gagcaagcta atggaaaaaa 
     2521 aatccccttt tcgctcaact tagaaatgaa agaaggaatg tctggttcta ttcgtaatga 
     2581 aattacttat aagtcgctag aaaatcttgg aatcatttaa taatttctaa aattaacata 
     2641 atacgcctta tgcgaaatgc ttgaaatttt cttataagca tcaatagttt agtcaaagcc 
     2701 gttctagagt tcagcgcact agaacggctt tttcatgatt attcacgttc cacgcctatt 
     2761 atttgagtaa tgtttcacaa ctttgattag tacacctaaa caagcctttt acccattagg 
     2821 taagaaaaac cggcttaacc accctctttt cggctgctcc agttcaacct gctccggcac 
     2881 tggaatccgc ttattttcta tttcaactgg agtagtcaat ccgtcatgtt tcggctctgg 
     2941 ttctggtcga ggatccgttg ctatatcctg gctaggtttc tgatcggcaa acgtagtcat 
     3001 attggttttt ggggcttcta ataagcgttg catagcctca atttgttcat ccttaacatg 
     3061 taactgatca ttcttagctt ttaattcatc tcgttgaaac ttctcacgct catgagcttg 
     3121 ttcaagctgt ttttgaagca tgtgaacctg ctgttcaagt aagtgaactt ctgacaactt 
     3181 tcgtgtttcg gttgtctgta aactgtttac atatttagat ggctcaccaa agacacgaat 
     3241 ggcctcagaa agatcaattt taccatcact attcttactt aaattacctt tatttatttg 
     3301 tttataaacg gcttgacgag tcattccata gaggtttgaa agctcgataa cagatagtga 
     3361 tttcatgttg taatttaggt tgtctattat gtgaactaag atacatcaag aaacagtcaa 
     3421 ccgctacata cacaatcaaa catcatcctt taaaacctaa attcctaaga tgaggaataa 
     3481 attgcttttg ttgtattgga tctcttagca tttctttgat tgttgcagct agatcatcgt 
     3541 aactttctcc ttgagtcgct aaatgagata gttcatgtag acgagaaagt tgattgccaa 
     3601 acatatggac ttgagcatca gttaatttat aaaacttctc tggctcattg agatgattaa 
     3661 tgcttttgga cttttcttta aatgaaaact gaatatgagt gactttacga ccagtttttt 
     3721 tttgctcata ggaaacgctt aatgggctgc attcatttat ttggtctaca gcagtatcaa 
     3781 ttacccgttt tttgaaatct gcaaatagtg ggtatttttt gccaagctcc aacatgcttc 
     3841 gtaagttctc aacagagatt tcacgcttac ctatttgtct gtattgcacc aataattcat 
     3901 aaatacgaat accatatcca ctattgatcc cagcaatatc tgatagagca tacttagtaa 
     3961 attctctact taaattagat atgaagggca agataggttt tgaaaaacga ataccaatga 
     4021 tactttgact atccaaaaac tggatctctt gtacccacct catttttata gatttatcat 
     4081 caatactaag attaatagat ctttcataaa gtctattaat tccttctttt aagtctctgt 
     4141 atgcggtttt ttcatgtact cctaataact gtagttcatt aacgcttaca gggtataact 
     4201 catcatcagt aataggctgg ctcttcggaa tacgtgaaat agctgccaag acgatacgct 
     4261 gttctacagc acttaattga taggaagctt ctataacttg atttgattta acaatttgat 
     4321 tcttatccaa aataaaacca ttgattttct tttatatatg acaactatat acttgtcata 
     4381 gttagtagtc aatccgtcat agttaagtag tcaatccgtc atagttagta gtcaatccgt 
     4441 catagttagt agtcaatccg tcatagttaa actttgaaag gcttgctcca taagggatac 
     4501 agctcaaaga aaagatttaa aagatataaa aataattaaa aaagacgttt gaaaaaattg 
     4561 cccgtggttt tcgctacgct caaactctat tgaatctcgc tttcgctcga ttcagggggc 
     4621 aatttttctg ttaattcctt cgtgaatttg agaaaaagta aaggcaagag caaaagcaac 
     4681 tcggaattcg cttcgctcat aaagcttttt gctcgcttcg ctcggtctgg aagccagttt 
     4741 tagcatctga tttatgcttt tttaggctat acagccttaa aaagcggttt ttcagaaagt 
     4801 cgaggcgcta attttggtga tgtcgctcgt agacactcgc tttgtacttt ctgatctaga 
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     4861 tccattttta aaaacccgga ccatcataat catttcgttt cggttcaggc tgtgagggtt 
     4921 gtatttcagg ttttgacttc ggtgatgttg gttcaatcac tggttttggt tgtacggatc 
     4981 ggactttaaa ctccatatcc ggttctgggt ataacctggc gttattgaga ttaaaattga 
     5041 tggtatcgat atcccatttt tcgtgatgca ggattggttg ctgagtttga ataatttcgt 
     5101 cgatatcgtg gcccagttct tttttgttac tggctttttt aatgaggtga ttgacgtagt 
     5161 gcatcacttc cggagaactg aagg 
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6.2.2 Acinetobacter baumannii strain AC92 plasmid pAC92, partial 
sequence.  
GenBank: JN982952.1 
  
LOCUS       JN982952               3567 bp    DNA     linear   BCT 25-APR-2012 
 
DEFINITION  Acinetobacter baumannii strain AC92 plasmid pAC92, partial 
            sequence. 
ACCESSION   JN982952 
VERSION     JN982952.1  GI:384929486 
KEYWORDS    . 
SOURCE      Acinetobacter baumannii 
  ORGANISM  Acinetobacter baumannii 
            Bacteria; Proteobacteria; Gammaproteobacteria; Pseudomonadales; 
            Moraxellaceae; Acinetobacter; Acinetobacter 
calcoaceticus/baumannii 
            complex. 
REFERENCE   1  (bases 1 to 3567) 
  AUTHORS   Grosso,F., Quinteira,S., Novais,A. and Peixe,L. 
  TITLE     The role of common blaOXA-24/40-carrying platforms and plasmids in 
            the spread of OXA-24/40 among Acinetobacter spp. clinical isolates 
  JOURNAL   Unpublished 
REFERENCE   2  (bases 1 to 3567) 
  AUTHORS   Grosso,F., Quinteira,S., Novais,A. and Peixe,L. 
  TITLE     Direct Submission 
  JOURNAL   Submitted (02-NOV-2011) Laboratory of Microbiology, REQUIMTE - 
            Faculdade de Farmacia da Universidade do Porto, Rua Anibal Cunha, 
            164, Porto 4050-047 Porto, Portugal 
FEATURES             Location/Qualifiers 
     source          1..3567 
                     /organism="Acinetobacter baumannii" 
                     /mol_type="genomic DNA" 
                     /strain="AC92" 
                     /db_xref="taxon:470" 
                     /plasmid="pAC92" 
     gene            complement(<1..802) 
                     /gene="tonB" 
     CDS             complement(<1..802) 
                     /gene="tonB" 
                     /codon_start=1 
                     /transl_table=11 
                     /product="putative TonB-dependent receptor" 
                     /protein_id="AFI32806.1" 
                     /db_xref="GI:384929487" 
                     
/translation="MLNKSKLFLALITLGASKIVLAAEGPVTTLNTIVLTAQSDELGS 
                     
ELLGKSLNVSNQFIDTSKLKQRSTTLGDALGTELGIHSNQYGGGASTPIIRGQEGKRI 
                     
KVLQNNADVLDMSNMSPDHAVTVEPSLAKSIEIIRGASTLLYSSNSAAGVVNVIDYKI 
                     
PTQMPQDGLEGNTTLRFNTGSNEKLTTAGVTVGLSPHVALRAEGLYRNAGNYKTPHYQ 
                     SSSYNSLEDLENQNSIYKNLKYLPESWAESRVGTLGLSWIDDNTYLGVS" 
     CDS             complement(930..1238) 
                     /codon_start=1 
                     /transl_table=11 
                     /product="putative cytoplasmic protein" 
                     /protein_id="AFI32807.1" 
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                     /db_xref="GI:384929488" 
                     
/translation="MVRYSHKELNEKFGEKQDAEIQRLLAKGTVPDDQLDLSDIPEIT 
                     
DWSNAVRQNQFYRPVKQQTSIRLDADVLAWFKAQGKGYQTRMNEILRDAMLKELKNHQ 
                     " 
     CDS             complement(1231..1527) 
                     /codon_start=1 
                     /transl_table=11 
                     /product="putative inner membrane protein" 
                     /protein_id="AFI32808.1" 
                     /db_xref="GI:384929489" 
                     
/translation="MFFMEQYFEWDEAKNRKNQKKHDISFETASLVFEDPLRISIQDR 
                     HTNGEERWQTIGRVKGVLMLLVAHTIFDEDDCEIIRIISARQVTKAERNKYEHG" 
     misc_recomb     1726..1753 
                     /note="XerC/XerD" 
     gene            1827..2654 
                     /gene="blaOXA-40" 
     CDS             1827..2654 
                     /gene="blaOXA-40" 
                     /codon_start=1 
                     /transl_table=11 
                     /product="carbapenem-hydrolyzing oxacillinase OXA-40" 
                     /protein_id="AFI32809.1" 
                     /db_xref="GI:384929490" 
                     
/translation="MKKFILPIFSISILVSLSACSSIKTKSEDNFHISSQQHEKAIKS 
                     
YFDEAQTQGVIIIKEGKNLSTYGNALARANKEYVPASTFKMLNALIGLENHKATTNEI 
                     
FKWDGKKRTYPMWEKDMTLGEAMALSAVPVYQELARRTGLELMQKEVKRVNFGNTNIG 
                     
TQVDNFWLVGPLKITPVQEVNFADDLAHNRLPFKLETQEEVKKMLLIKEVNGSKIYAK 
                     
SGWGMGVTPQVGWLTGWVEQANGKKIPFSLNLEMKEGMSGSIRNEITYKSLENLGII" 
     misc_recomb     2665..2692 
                     /note="XerD/XerC" 
     CDS             complement(2837..2980) 
                     /codon_start=1 
                     /transl_table=11 
                     /product="hypothetical protein" 
                     /protein_id="AFI32810.1" 
                     /db_xref="GI:384929491" 
                     
/translation="MPKLKDIALGIIVAPLLIPIMLIASYQDKKALKKELDECQKEKD 
                     QAS" 
     gene            complement(2992..>3567) 
                     /gene="rep_aci2" 
     CDS             complement(2992..>3567) 
                     /gene="rep_aci2" 
                     /note="DNA replication protein" 
                     /codon_start=1 
                     /transl_table=11 
                     /product="replicase Aci2" 
                     /protein_id="AFI32811.1" 
                     /db_xref="GI:384929492" 
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/translation="MAKLSLSEVSKKFHVDRSTIYRAVRNGRLSRSSDGQFDLAEVIR 
                     
CFGEPEQTPQKIESSKQEGDESTKKLIAHLENEVKKYQEREERLMQQIDRMQTLIELK 
                     
SVAPATASPQQDATACDTDMQQHATPQQDNDNKKNHELNIAENVAMPQQENTAYHTQT 
                     LQHATLQNVAVPQHKKRGLFGRVLNAVFDND" 
ORIGIN       
        1 aagaaactcc taaataagta ttatcgtcta tccaggataa tccaagcgta cctactctcg 
       61 actctgccca gctttctggt aaatatttta aatttttata aatactgttt tggttttcaa 
      121 gatcttctaa agaattataa gagctagact ggtaatgagg agttttatag ttaccagcat 
      181 tacgatataa cccttctgcc cgtaaagcta catgtgggct taagccaact gttacacctg 
      241 ctgtggtcaa cttctcatta ctgccagtat taaaacgtaa tgtagtatta ccctctaatc 
      301 cgtcttgagg catttgggtt ggaattttat agtcaatgac attgactacc cctgccgcac 
      361 tatttgaact atacaaaagg gtacttgcac cacgtataat ttcaatagac ttagctaaac 
      421 ttggttcaac tgtgacagcg tgatctgggg acatattaga catatccaac acgtcagcat 
      481 tattctgtaa aactttaata cgttttcctt cctgcccacg aataatagga gtagatgctc 
      541 cacctccata ttgattagaa tgaattccta attccgtacc caaggcatcc cctagagttg 
      601 tcgaacgctg tttaagttta ctagtatcaa taaactgatt actaacattt agacttttgc 
      661 ctaacagctc agaccctaac tcatcagatt gtgcagttaa tactattgta tttaaggtag 
      721 taacaggccc ttcagctgcc aatacaattt tcgaggcccc taaagtaatt aaagctaaaa 
      781 atagtttact tttatttagc ataaaacaac caaatttaat gttatattat aatataacac 
      841 ttaaaaattt ataaaatcta ctatttaaat ttttgaatgg taatcccccc taaaaatgaa 
      901 gtcaaaaatg ggagcctaag ctcccattct tattgatgat tttttaattc ttttagcata 
      961 gcatctcgta aaatttcatt catacgtgtt tgataacctt tgccttgtgc tttgaaccaa 
     1021 gcaagtacat cagcatctaa ccgaattgaa gtttgttgct ttactgggcg gtaaaattga 
     1081 ttttggcgta cagcattgct ccagtctgta atttcaggaa tatctgatag atctagctga 
     1141 tcatcaggaa ccgtgccttt agcaagcaag cgttgaattt cagcatcttg cttctcacca 
     1201 aatttctcat tcagctcttt gtgtgagtat ctaaccatgc tcatatttgt ttcgctccgc 
     1261 tttagtgact tgccttgcac taatgattcg gatgatttca cagtcatctt catcaaaaat 
     1321 ggtgtgagcc accaataaca ttagtacgcc tttaactcgt ccaatggttt gccaacgttc 
     1381 ttcaccattg gtatgtctgt cttggattga gatccgtaat ggatcttcaa aaacaaggct 
     1441 tgcagtttcg aaagagatat catgcttttt ctgattcttt cgattcttag cctcatccca 
     1501 ttcaaaatac tgttccataa aaaacattca aatttgtata tacaataatg tatcacatat 
     1561 ttgtatcact caagctgaaa agcgtaattt ttagtcaaat ttattggcaa gaagtatcaa 
     1621 aactgctcat aaaaaagccg acttgtttca aagtcggctt tttgggcatt tttggatttt 
     1681 tctattttta ttaagtagtt gatatttaaa ttaatataca aatgtacttc gtataatcgc 
     1741 cattatgtta aattaaaaga gttttaactt ttttaataaa aatattatac tctaagcccc 
     1801 aaaatttccc ctaacatgaa tttgtaatga aaaaatttat acttcctata ttcagcattt 
     1861 ctattctagt ttctctcagt gcatgttcat ctattaaaac taaatctgaa gataattttc 
     1921 atatttcttc tcagcaacat gaaaaagcta ttaaaagcta ttttgatgaa gctcaaacac 
     1981 agggtgtaat tattattaaa gagggtaaaa atcttagcac ctatggtaat gctcttgcac 
     2041 gagcaaataa agaatatgtc cctgcatcaa catttaagat gctaaatgct ttaatcgggc 
     2101 tagaaaatca taaagcaaca acaaatgaga ttttcaaatg ggatggtaaa aaaagaactt 
     2161 atcctatgtg ggagaaagat atgactttag gtgaggcaat ggcattgtca gcagttccag 
     2221 tatatcaaga gcttgcaaga cggactggcc tagagctaat gcagaaagaa gtaaagcggg 
     2281 ttaattttgg aaatacaaat attggaacac aggtcgataa tttttggtta gttggccccc 
     2341 ttaaaattac accagtacaa gaagttaatt ttgccgatga ccttgcacat aaccgattac 
     2401 cttttaaatt agaaactcaa gaagaagtta aaaaaatgct tctaattaaa gaagtaaatg 
     2461 gtagtaagat ttatgcaaaa agtggatggg gaatgggtgt tactccacag gtaggttggt 
     2521 tgactggttg ggtggagcaa gctaatggaa aaaaaatccc cttttcgctc aacttagaaa 
     2581 tgaaagaagg aatgtctggt tctattcgta atgaaattac ttataagtcg ctagaaaatc 
     2641 ttggaatcat ttaataattt ctaaaattaa cataatacac gttatacgaa atgctgtata 
     2701 attatcctta taattcaacg ctgtagtttc tagtttatag cccgagcatc cctgttcggg 
     2761 ctttttttat gacttttcac gttccacgct attatttcat caatgttcca cacttttgat 
     2821 tagctcaatt gaataatcag gatgcctggt ctttttcttt ttggcattca tccagctctt 
     2881 tcttcagcgc ctttttatcc tggtacgatg caatcagcat gatcgggatc agcagcggag 
     2941 ctacaataat tcccagggca atatctttca gtttcggcat gatcccctcc cttagtcatt 
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     3001 atcaaaaaca gcattcagca cacggccaaa taagccacgt tttttgtgtt gtggcactgc 
     3061 cacattttgc aacgtggcat gctgtagcgt ttgggtgtgg tatgccgtat tttcttgctg 
     3121 tggcattgcc acattttctg caatatttaa ttcatgattc tttttattat cattgtcttg 
     3181 ttgtggtgtc gcatgctgtt gcatgtcagt gtcgcatgcc gtagcatctt gttgtggtga 
     3241 tgctgtggca ggtgcaacac ttttcagctc aatgagtgtt tgcatacggt caatttgttg 
     3301 cattaaccgt tcttcacgtt cttggtattt tttgacttca ttttctaaat gggcaataag 
     3361 tttttttgta gattcatcac cttcttgctt agatgattca attttttggg gtgtttgctc 
     3421 aggttctcca aagcatcgga tgacctctgc tagatcgaat tgtccatcac tggagcgtga 
     3481 taaacgtcca ttacgtacag ctctgtaaat ggttgatcta tccacatgga attttttaga 
     3541 tacttcactt agtgataact tagccat 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
